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Ever since scientists were first able to read a DNA sequence, techniques to do so have 
developed explosively. The transcription of DNA to mRNA and subsequent translation 
into protein determines to what extent a gene plays a role in the functioning of the cell. 
For this reason, techniques to measure gene expression (i.e. the abundance of the 
mRNA of a certain gene in a sample) were developed. The first description of a 
microarray approach to measure gene expression on a genome wide level, rather than 
in individual genes, was described in -''[ (Schena et al. -''[). From this point onwards, 
progress was rapid and with more data available, ever more correlations between gene 
expression and disease progress could be discovered. A research area in which the 




Broadly defined, cancer is the malignant proliferation of cells. In other words, cancer 
arises when cells start dividing when they should not. A fully developed human body 
consists of an estimated \(.. trillion cells (Bianconi et al. ./-\). From the moment the 
ovum is fertilized and starts dividing to form a foetus, the division of each cell is tightly 
regulated. Whether a cell divides or not is influenced by many factors, arising from both 
within the cell as well as its environment. A host of mechanisms are involved in this 
complicated process: mechanical factors, hormones, signalling molecules and nutrient 
receptors, among other things.  
 
When all signals align and a cell starts to divide to form a new cell, the roughly \ billion 
DNA bases in our genome need to be copied in order to provide the new cell with an 
identical copy of the genetic material. This process is not error free. It has been 
estimated that per -//,/// bases one error occurs (Arana and Kunkel ./-/). If these 
errors would persist and be passed on to the new cell (and then to subsequent progeny), 
they could lead to dysregulated activity within these cells and eventually disease. There 
are therefore many safeguards against passing on aberrant DNA; fidelity of the copy is 
checked both during transcription and before the final cell division. When errors are 
detected that cannot be corrected a cell can induce apoptosis, a controlled cell death.  
 
Nevertheless, with \(.. trillion cells and \ billion bases per cell, sometimes errors will 
slip through and be passed on to the next generation of cells. However, most often, in 











order to disturb the function of a certain gene, both alleles of the genes need to contain 
an error. This is known as Knudsons “two hit-hypothesis” (Knudson -'(-). Even if this 
happens and leads to a cancerous cell it will not necessarily cause disease; the cell can 
be destroyed by the immune system before proliferating and forming a tumor.  
 
Then what does need to happen before cancer develops, given all the safeguards? In 
./// Hanahan and Weinberg defined , hallmarks of cancer that can be used to 
understand and categorize the steps that are required for carcinogenesis to be initiated 
(Hanahan and Weinberg .///). Two hallmarks are about taking the brakes off 
proliferation: resisting cell death and evading growth suppressors. This for example 
means disrupting the checks for accurate DNA replication before cell division. Two 
more hallmarks are about accelerating proliferation: enabling replicative immortality 
and sustaining proliferative signalling. A normal, healthy cell has a finite number of 
divisions it is able to perform, while a cancer cell needs to be able to divide indefinitely. 
Moreover, a cell is usually dependent on signals from its environment to kickstart the 
division; a cancer cell needs to sustain its own signals to achieve ongoing proliferation. 
Lastly, cancer is characterized by its ability to leave the site of origin and spread through 
the body. It therefore needs to activate invasion and metastasis. To have access to 
nutrients and oxygen a cancer cell needs to activate angiogenesis in order to form new 
blood vessels. The follow up paper in ./-- introduced four other hallmarks and also 
described the need for cancer cells to evade the immune system (Hanahan and 
Weinberg ./--). 
 
According to the hallmarks of cancer each cancer cell needs to exhibit all of these 
hallmarks to develop into disease. However, there are many different ways a cell can 
acquire one or more hallmarks since dysregulating different parts of the control system 
can have the same downstream effect. This dysregulation is usually caused by changes 
in the DNA of key genes regulating the cell behavior. Some genes controlling the cell 
cycle need to be under-expressed, i.e less present than in a healthy cell. On the other 
hand, cells driving cell division can be over-expressed. The fact that there are different 
roads a cell can take to become a cancer cell, means that the same type of cancer can 














When reading out the DNA sequence and measuring mRNA became easier and cheaper, 
tumors that were always considered to be the same disease, started to be subtyped and 
were shown to have a vastly different genetic architecture. Breast cancer was the first 
type of cancer where this was extensively shown. Perou et al. already described , 
different intrinsic subtypes in ./// based on gene expression measurements (Perou et 
al. .///).  
 
Not long after Perou et al., Van ‘t Veer et al. took the next step and described how gene 
expression measurements could be used to predict survival in breast cancer at the 
moment of diagnosis (Veer et al. .//.). This (/-gene model could predict if a breast 
cancer patient had a high or low risk of experiencing a metastasis of the primary tumor 
within [ years. This proved that the different genetic background of tumour influences 
the progression of disease. Many different gene expression signatures in many different 
cancer types would follow (Raponi et al. .//,; Barrier et al. .//,; Bullinger and Valk 
.//[; Kuiper et al. ./-.).  
 
Machine learning  
 
These growing datasets also called for new analysis methods and machine learning 
started to play a bigger part in biological and medical research. The term “machine 
learning” was coined by computer scientist Arthur Samuel. His -'[' paper on an 
algorithm that can play checkers starts with describing his studies on machine learning 
as “concerned with the programming of a digital computer to behave in a way which, if 
done by human beings or animals, would be described as involving the process of 
learning” (Samuel -'[').  
Samuels checker-playing program is seen as the first machine learning program 
(Schaeffer .//,). It clearly demonstrates an aspect of machine learning that is often 
explicitly included in later definitions: they can build models based on available data to 
perform a certain task on new data - without being explicitly programmed to do so. That 
is, the algorithm is told what its ultimate goal is (winning at checkers, in the case of 
Samuel) and the boundaries of the problem (the rules of checkers). However, how it 
should behave within these boundaries to achieve its goals is something it has to learn, 
as this behaviour is not explicitly programmed. Moreover, the program has to learn this 
in a way that makes its solutions applicable to situations on the board it has never seen 











before. What goes for checkers, goes for all machine learning problems. A model that 
learns to predict cancer progression in an available dataset is useless if it cannot also 
predict this in a newly diagnosed patient with gene expression patterns it has never seen 
before.  
 
Machine learning approaches can generally be divided into three categories: supervised 
learning, unsupervised learning and reinforcement learning. Unsupervised learning 
aims to learn a structure in the data, without being guided by labels or classifications. 
Clustering algorithms are a good example in this category; they attempt to group data 
points that are similar to each other within a cluster and separate data points that are 
very dissimilar into different clusters. The different subtypes that were discovered in 
breast cancer are an example of unsupervised learning. Figure -a shows a gene 
expression matrix, figure -b shows the same gene expression matrix when clustered 
through unsupervised learning. As can be seen in the clusters marked by the two blue 
rectangles, clusters can be formed through finding genes that are all highly expressed, 
but also through a combination of under-expression (green) and over-expression (red). 
In reinforcement learning, the algorithm takes a sequence of decisions and gets 
rewarded (or punished) for the outcome of this decision. It learns by updating its model 
and amending its decision in response to this reward. Samuels checker player is an 
example of reinforcement learning; certain moves (decisions) lead to better game 
outcomes (rewards) than others. Unsupervised and reinforcement learning will not be 
considered further here; most approaches to predict survival or progression in cancer 
and all algorithms presented in this thesis use supervised learning.  
 
Supervised learning uses labelled data as input and learns a model that can accurately 
predict something about this label on unseen data; we use labels to define what the 
model should learn. The (/-gene breast cancer signature, for instance, labels patients 
as ‘poor prognosis’ if their survival was shorter than [ years and ‘good prognosis’ 
otherwise. Labels that indicate class membership (like poor or good prognosis) are 
categorical, but labels can also be continuous; for example, reduction in tumor size. 
Approaches differ for both types of labels, but in all supervised methods the model 
combines certain features (i.e. what was measured) to predict the label of interest (i.e. 
what we cannot measure and want to know). Figure -c shows supervised learning with 













gene expression for a certain gene and the tumor size. This model can be extended to 
incorporate many variables. Often, we have measured more about the sample than is 
relevant. For example, we have measured expression for all genes, but the majority is 
not informative for survival time. Most approaches therefore include a feature selection 
step, to select the most relevant features. Feature selection can precede training or be 
incorporated in the training procedure.  
 
High dimensional data and overtraining 
 
An important challenge in machine learning, which is particularly salient in the analysis 
of gene expression data, is the curse of dimensionality. This challenge stems from the 
fact that we, in general, have many more features (genes) than samples (patients). When 
considering high dimensional datasets, it is likely to find untrue correlations: when you 
consider thousands of features, some will by chance correlate with the label even if no 
true signal is present in the data. It is important to take this into account when selecting 
features and training the model. In a high dimensional setting a machine learning model 
can easily overtrain, which means the model is not fitting an actual relationship 
between the gene expression patterns and the outcome, but starts to accommodate 
noise in the data. As a result, overtrained classifiers will not work on new and unseen 
data. Figure -d shows how this can happen with categorical labels; the grey line 
represents an overtrained classifier. Instead of learning a general distinction between 
good and poor prognosis (the red line), it has fitted the specific datapoints present in 
this dataset. To assess whether a true pattern is found (i.e. a pattern that generalized to 
new and unseen data) an important concept is the separation of training and test data, 
where one dataset is used to fit a model and other, unseen data is used to assess the 
performance of the model. Of course, we usually do not have unlimited data available. 
To guard against overtraining we can use cross-validation. In cross-validation we split 
the training data in equal parts, for example three, also called folds (Figure -e). We then 
train a model on the first two folds and test the model on the remaining third to obtain 
a better estimate of the expected performance on external data. We repeat this until all 
three folds have been used as test data once. When we do multiple repeats of this, the 
variables or models that perform well over all folds are most likely to be true and can be 
tested on true external data.  
 











Figure 1. a. Unclustered gene expression. b. Unsupervised learning: clustering of gene 
expression. c. Supervised learning with continuous label: regression. d. Supervised 
learning with categorical label: classification. The grey line represents an overtrained 














One can also try to directly prevent overtraining in the training of the model itself; one 
way is regularization. When applying regularization, the model contains parameters 
that penalize complicated models. If a model is allowed to incorporate enough features, 
it can fit any pattern. Imagine the model would incorporate each feature that was 
measured; it could describe the training data perfectly, while not learning general 
patterns. While regularization may lead to choosing simpler models with a slightly 
worse fit, such models are more likely to generalize to external data.  
 
Another way of preventing overtraining is using ensemble classifiers and bootstrapping. 
In an ensemble classifier many weak classifiers are trained: classifiers of which the 
performance by  
itself will not be satisfactory. The idea here is that a weak classifier will make many 
mistakes in assigning a sample to a class, but when we combine many weak classifiers 
that all make a different mistake, together they can still distinguish better between 
classes than any classifier on its own. We can make it more likely that these classifiers 
fit different effects in the data by bootstrapping. In bootstrapping we sample randomly 
from the data (typically with replacement) to generate a training dataset which 
encompasses a random subset of the variables and samples of the full dataset. Because 
we do this for each classifier separately, all classifiers have access to a slightly different 
part of the data. This simultaneously assures they cannot overfit on the dataset as a 
whole and that each classifier will make different mistakes. Which approach to prevent 
overtraining is best depends on the type of data and classification problem, though 
many successful approaches use a combination of all mentioned techniques.  
 
Personalized medicine  
 
If tumors behave differently based on the differences in mutations and gene expression 
patterns, a logical next step is to investigate whether these differences can be used to 
inform treatment. In .//-, it was estimated that for treatment across cancer types only 
one in four patients sees a beneficial effect (Spear, Heath-Chiozzi, and Huff .//-). 
While these numbers have improved somewhat with the rise of targeted therapies, it is 
clear that even today we treat patients with drugs that will not benefit them.  
 











The practice to tailor treatment to the individual patients is known as personalized 
medicine. Broadly, we can differentiate between two approaches in personalized 
medicine. The first approach entails looking for specific mutations or aberrations 
present in the tumor that can be targeted with drugs. One of the first examples of such 
an approach was applied in chronic myelogenous leukemia, a type of blood cancer. A 
common aberration in CML creates a so-called fusion gene between the BCR gene and 
the ABL gene. This fusion gene encodes a protein that drives the rapid division of 
leukocytes. In the late '/’s a drug was developed - imatinib - that specifically inhibited 
this fusion gene and enormously improved survival for patients whose tumor harbors 
this particular fusion gene (Druker et al. .//-). By now more drugs that target cancer 
specific mutations have been introduced, like vemurafenib for BRAF mutations and 
crizotinib targeting ALK positive tumors (Chapman et al. ./--; Shaw et al ./-\). While 
this has led to great advances in cancer survival, there are many cancer patients for 
whom the tumor is not characterized by a cancer-specific, targetable mutation 
(Priestley et al. ./-') and that therefore do not benefit from this strategy.  
 
The second approach in personalized medicine is based on the presence of patient or 
tumor characteristics that can predict whether they will benefit from generic treatment, 
i.e. treatment not targeted to a cancer-specific aberration. Sometimes this can be 
achieved by simply associating known prognostic markers with treatment benefit. For 
example, it was shown that patients identified as low-risk by the (/-gene breast cancer 
signature could safely forego chemotherapy (Cardoso et al. ./-,). There have also been 
more specific machine learning approaches to predict a patient's response to a 
treatment, both using mutational data and gene expression (Le et al. ./-(; Tanoue ./-.; 
O'Connell et al. ./-/). Response to treatment can also be determined by non-tumor 
characteristics, like how the body metabolizes the drug before it reaches the tumor. The 
field of pharmacogenomics has identified many germline variants - common DNA 
variants inherited from your parents - that have an influence on how a drug is 
metabolized. Certain variants known to influence treatment are already routinely used 
to determine for example effective dose (van der Wouden et al. ./-'). Of course, even 
targeted treatments do not benefit every patient that receives them; here the two 















Survival analysis  
 
To investigate whether one treatment leads to a better patient outcome than another 
treatment, survival analysis is often employed. This enables an assessment of whether a 
patient is statistically significantly less likely to die from the disease when for example 
being treated with a certain treatment. To perform survival analysis we need to define 
an endpoint: this is the outcome we are interested in. This can be death, but also, for 
example, metastasis of the cancer. A big challenge in analyzing survival data is the fact 
that some patients will be censored. When patients are enrolled in a trial and follow up 
is performed for -/ years some patients will die during this period and some will be 
known to be alive at the end of trial. However, there will also be a group for whom no 
information is available: they have left the trial or contact was lost for some reason. The 
patients for whom we have not recorded a date of death will be censored; we record the 
last date on which they were known to be alive. The challenge is using the data from 
censored patients; even if follow-up was not completed, there is useful information in 
the fact that a patient was still alive after a certain time. The most commonly used model 
is Cox proportional hazard model (Cox -'(.). Here the partial log likelihood is 




Optimizing the likelihood means the model finds the 𝛽 that is most likely to give rise to 
the observed data. The i indicates the censoring status; if this is - a date of death was 
recorded, if it is a / this was not the case. Simply put, the Cox model describes which 𝛽 
best explains the observed sequence of deaths. This enables us to take censored patients 
into account up to the point of censoring; if a patient is censored at [ years, we know 
for sure everyone with an event before [ years died before them. The X in the formula 
represents the variable under consideration; when evaluating treatment effect this is 
the treatment variable. If a treatment had no effect at all, the 𝛽 will be (near) zero.  
 
When we use the Cox model to estimate treatment effect this is often captured in the 
hazard ratio. The hazard ratio is the exponent of the 𝛽; when a treatment has no effect, 
C ∑∑β θ= −
≥=
Xi j( ) ( log )
j Yj Yii Ci :: 1











the HR is - (i.e. the exponent of /). Survival data is often visualized in Kaplan Meier 
plots, an example of which is shown in Figure .a. The 𝛽 describes the difference between 
the two treatment groups, here with treatment A as reference. The 𝛽 is this example is 
--, which means that when a patient receives the treatment their hazard of dying is 
lower. A 𝛽 above / would signify the patient has a higher hazard when treated with 
treatment A. Censored patients are represented with a vertical mark. The Cox model 
makes several assumptions about the data, the most important of which are that a) the 
hazards between the different groups are proportional over time and that b) the 
censoring is uninformative. Proportional hazards mean that the difference in risk 
between groups is the same at any point in time - i.e. if treatment A reduces risk two-
fold this should be true in year - but also in year [, etc. When the lines in a Kaplan Meier 
plot cross, this assumption is violated. Uninformative censoring means that the variable 
under consideration should not influence whether a patient is censored. If one 
treatment group has much more censoring and this is somehow due to the treatment 
itself, this cannot be modelled accurately within the Cox model and it will bias the 
estimate of treatment effect.  
 
In this thesis we mostly employ Cox proportional hazards modeling to estimate 
treatment effect, but it is not confined to treatment estimates. It can for example also 
be used to estimate the effect of gene expression on survival; it can incorporate multiple 
variables at once and a fitted Cox model can then also be used to predict outcome for a 
new patient. Survival analysis has been combined with machine learning, where the 
survival data functions as a label. For example, regularized cox models (i.e. models with 
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Figure 2. a. An example Kaplan Meier plot of a treatment A that confers a survival 














high dimensional data sets like gene expression data (Simon et al. ./--). Another 
popular approach for high dimensional data is training a Random Survival Forest. A 
random forest is a machine learning approach that can be used on both discrete and 
continuous labels and trains an ensemble of decision trees (Breiman .//-). It is 
particularly suitable for high dimensional datasets as it prevents overtraining both by 
bootstrapping and forming an ensemble classifier (discussed in the Machine Learning 
section). As the name suggests, Random Survival Forests extend this approach to 
survival data with censoring present. Rather than predict a particular label, Random 
Survival Forests aims to divide the samples in subsets with a maximum survival 
difference (Ishwaran and Lu ./-').  
 
The difficulties of treatment benefit  
 
Due to the rapid developments in cancer treatment, there is an increasing number of 
cancer treatments available to choose from and often it is not clear which will be the 
best choice. The classifiers previously discussed either predicted prognosis (regardless 
of treatment) or predicted response to a single treatment. Figure .b shows a Kaplan 
Meier plot for a prognostic classifier. While this classifier identifies patients with a 
better survival, the benefit from treatment A is present in both classes. Had this 
classifier been trained and validated on a population with solely patients who were 
treated with treatment A it would be impossible to distinguish between a predictive 
effect for treatment A specifically or a general prognostic effect. In this example the poor 
prognosis group still survives better than the good prognosis group when treated with 
treatment B; all patients should receive treatment B. When multiple treatments are 
available and a choice has to be made between them, the current classifiers are not 
sufficient. Arguably the most clinically relevant question is which treatment will benefit 
a patient most; i.e. which treatment would lead to the longest survival. However, 
patients who benefitted from a certain treatment cannot be identified straightforwardly, 
since we can only observe the response to the treatment the patient actually received. 
Even if a good response was achieved, it does not mean the patient benefited specifically 
from this treatment. Possibly any other treatment would have achieved the same 
results. Conversely, even if a patient had a short survival time, the given treatment could 
still have been the best choice - maybe the response would have been even worse on 
any other treatment. We can thus not label a patient as benefiting or not from the 











observed survival. Traditional supervised machine learning approaches cannot be 
employed; these approaches rely on predefined labels.  
 
We thus need to employ other approaches to predict treatment benefit. In all following 
work we define treatment benefit as a patient surviving longer on the treatment of 
interest than they would have done on a comparator treatment. Figure .c visualizes 
treatment benefit in a Kaplan Meier plot: we identify a ‘benefit’ class with a larger 
benefit than the population as a whole and a ‘no benefit’ class where treatment A does 
not lead to a better survival.  
 
One approach is to investigate if known prognostic markers are also linked to treatment 
benefit, as was done in the case of the (/-gene breast cancer signature. However, these 
associations can only be investigated after the genes or markers were identified using 
survival information only (or possibly an unsupervised approach). It is to be expected 
that methods taking treatment specific survival into account in the discovery will be 
superior to after the fact analysis.  
 
Another approach is to model on two treatments separately, but to only retain variables 
that have an opposite effect in both treatment arms. The drawback here is that the 
model does not get an opportunity to specifically look for a combination of variables 
that achieve this. It is not necessarily expected that there will be one single marker that 
can separate these groups. Of course, a good response to one treatment would not 
automatically mean a bad response to another treatment and markers would be difficult 
to find in separate analyses.  
  
We show in Chapter * that we cannot successfully train a model on labels derived 
directly from survival and treatment information. In this thesis we will present multiple 
approaches to predict treatment benefit using survival outcome and treatment 




When we talk about treatment benefit, we are trying to answer the question “what 













answer to this type of what-if question is known as a counterfactual. Counterfactual 
reasoning has mostly been used in establishing causality, i.e. which variable is causal for 
the difference in events when the “if” is changed. It should be noted that establishing 
causality is not necessarily the goal of machine learning; accurate prediction is. These 
two things can and perhaps ideally do occur together, but it is not necessary.  
 
Counterfactual approaches can explain models or important variables by investigating 
what would have changed the prediction of an already existing model (Mothilal, 
Sharma, and Tan ././). This is visualized in Figure \a; would a different treatment have 
led to the same poor outcome? The problem with these approaches is that a model 
needs to exist already or that at the very least candidate variables need to be known. 
With a defined model it can be investigated what the change in predicted outcome is 
when the value of a variable (like the treatment variable) is changed. In a gene 
expression setting tens of thousands of variables are available and it is likely only a small 
part of those are relevant to benefit from the treatment under investigation.  
We thus need a method to answer the what-if question without already having a model. 
An example of attempting this is an approach using so-called ‘virtual twins’ (Foster, 
Taylor, and Ruberg ./--). In the context of a clinical trial a ‘virtual twin’ can be modelled 
for each clinical trial participant, where the twin undergoes the counterfactual 
Figure 3. a. Example of a counterfactual model. We have observed a poor outcome when 
a patient with a certain gene expression profile (GEP) was exposed to drug A. The model 
now needs to predict whether drug B would have led to the same outcome. b. Example of 
how matched patients can be used; patient 2 has a similar gene expression profile as patient 
1, but was exposed to a different drug and experienced a longer survival. This represent the 
potential benefit for patient 1, had they been treated with drug B. 











condition of the real participant (Vittinghoff et al. ./-/). Here again, the assumption is 
that the estimation of both responses arises from the same (linear) model and that the 
measured variables are independent of the alternative option you are modelling. Figure 
\b shows this matching of patients based on gene expression profiling, where patient - 
and . are very similar, but received a different treatment. However, the virtual twin 
approach was proposed in a setting of low dimensionality, considering less than -// 
variables. It has been shown since that the assumptions made in this approach do not 
hold in high dimensional settings (Lu et al. ./-)). Other imputation-like approaches, 
where the outcome on the treatment not received is regarded as a missing data point, 
have mostly been applied in a setting with a limited number of variables that are all 
likely to be of influence. In a high dimensional setting like gene expression - or even 
more difficult, germline variation - we are dealing with many irrelevant variables, but 
no way of determining which are irrelevant before building the model. We do not know 
which genes should be used to identify matched patients. We thus need new methods 
to be able to apply counterfactual reasoning in high dimensional datasets.  
 
Multiple Myeloma  
 
Chapter * and Chapter + deal with predicting treatment benefit in multiple myeloma. 
Multiple myeloma is a cancer of the plasma cells that develops in the bone marrow 
(Rajkumar ./-)). Plasma cells are a fully differentiated white blood cell and play an 
important role in the immune defense by producing immunoglobulins, i.e. the 
antibodies that enable the immune system to recognize pathogens. Multiple myeloma 
can develop slowly, sometimes being present as smouldering multiple myeloma over 
the course of decades, to suddenly spike and cause symptoms (Kyle et al. .//(). 
Multiple myeloma is also a very heterogeneous disease. A few chromosomal aberrations 
are often found in multiple myeloma, but most only occur in a minority of the patients 
(Nahi et al. ./--). Mutations in DNA are also sparse and there is no clear mutational 
event to define multiple myeloma (Walker et al. ./-)). A lot of effort has gone into 
distinguishing patients with high or low risk variants of the disease and most of these 
are defined by gene expression (Szalat, Avet-Loiseau, and Munshi ./-,). It is still an 
incurable disease, though survival expectancy at the moment of diagnosis has increased 
significantly in the past two decades due to novel treatment being introduced in the 













Two major treatment classes now used in the clinic are proteasome inhibitors (PI) and 
immunomodulatory drugs (IMIDs) and in this thesis we focus on predicting benefit to 
PIs. The rationale behind PIs is that MM cells overproduce immunoglobulins, which are 
proteins. The proteasome is the main way a cell has to get rid of unwanted proteins and 
this system is overburdened in MM cells. When the proteasome is inhibited, proteins 
start to accumulate in the cell, eventually triggering apoptosis when this situation 
cannot be resolved. MM cells are more reliant on the proteasome than other, healthy 
cells, providing a therapeutic window for PI treatment (Moreau et al. ./-.).  
 
An open problem is whether the risk profiles and different gene expression patterns 
across MM patients can also be informative for which treatment is ideal. Currently these 
markers are not used to decide on an ideal treatment and we thus have to look beyond 
the known markers. Multiple myeloma represents a good test case for the prediction of 
alternative treatment response from gene expression data; clinical trials are available 
and it is known gene expression is of influence on disease trajectory and there is an 
unmet need for tools to aid in treatment decisions. A clinical trial setting is ideal for 
training a model like this, since treatment assignment is random. As discussed, in 
counterfactual reasoning it is assumed that the variables in the model are independent 
of the condition to be modelled; this can be safely assumed in a clinical trial.  
 
Understanding treatment benefit  
 
Predicting treatment specific survival is one part of the challenge and very important in 
clinical decision making. The next question that inevitably presents itself is why certain 
patients respond better than others to a certain treatment. Could a well-performing 
model shed some light on this?  
A usual step to gain insight in the mechanism behind the predicted benefit is to 
investigate the genes included in the model that can predict treatment response, but 
more often than not these do not present a clear picture of mechanisms of treatment 
response. Classifiers trained for the same purpose, with similar performances, show very 
little overlap in genes used (Tang et al. ./-(). For the (/-gene breast cancer classifier 
mentioned earlier, it was shown that a similar classifier can be built when these (/ genes 
are excluded from the analysis (Ein-Dor et al. .//[). The fact that a good prediction 
performance can be achieved by many different genes is at least partly caused by the 











great redundancy in gene expression information. This in turn is due to the fact genes 
act in pathways and regulate each other giving rise to highly (inversely) correlated gene 
expression patterns. For classification purposes, it can be irrelevant which of these genes 
are included in the model, since they provide the same information - as shown by Ein-
Dor et al. Substituting one for the other will not change the model performance. 
However, for the biological interpretation and understanding the role of these genes in 
determining patient benefit to treatment these genes are not equal.  
 
Some classification approaches take this aspect into account, and include pathways and 
known relationships between genes in the model. However, it has been shown these 
methods can achieve similar performances when using random networks as when true 
biological networks are used (Staiger et al. ./-.), rendering the importance of the 
biological links doubtful. These networks can also be biased towards well-studied genes; 
if a gene is known to be important in cancer development, more research will study it 
and more relationships will be discovered. Thus there are a few well known genes, that 
are annotated in many different contexts, while other genes are not annotated at all 
(Haynes, Tomczak, and Khatri ./-)). This limits the new mechanisms that can be 
discovered to what is already known. Moreover, disease can also change how genes 
interact with each other; interactions in healthy tissue can be very different to 
interactions in cancerous tissue and interactions can differ between cancer types. A 
possible approach is to learn new gene networks that are specific to the disease or even 
the treatment. This can be done in a data-driven manner, so it is not biased by gene 
annotation of pathways in health cells. In this thesis we use both known biological 
annotation (Chapter * and Chapter ,) and present a method to learn new networks, 
specific to treatment benefit (Chapter +).  
 
Contribution of this thesis  
 
There is a gap between the machine learning approaches available to predict treatment 
response and the clinical reality, where we are interested in answering the question: 
which drug is the best choice for this patient? There have been several approaches 
developed in the field of counterfactual reasoning, but none that can handle the high 
dimensional nature of gene expression data. In this thesis we present several different 













a different treatment. With these we can predict treatment benefit in a clinically 
relevant way. Much of the work rests on our concept Simulated Treatment Learning, 
which uses the idea that genetically similar patients who received a different treatment 
can be used to model response to the alternative treatment. In Chapter * we present 
GESTURE (Gene Expression-based Simulated Treatment Using similaRity between 
patiEnts), an algorithm that evaluates which gene sets (here formed by Gene Ontology 
annotation) are most relevant to treatment benefit and combines them in an ensemble 
classifier to predict treatment benefit for new patients. We show its performance in a 
multiple myeloma dataset, predicting benefit to both bortezomib (a PI) and 
lenalidomide (an IMID), representing two major treatment classes in multiple 
myeloma. In Chapter + we present STLsig, which uses Simulated Treatment Learning 
to form disease and treatment specific gene networks that can predict treatment 
benefit. We demonstrate its utility in predicting treatment benefit to PI treatment in 
multiple myeloma and moreover showing that the genes in the signature are unique 
(i.e. a new, similar performing signature cannot be found with the same method when 
the genes are removed). This offers perspective for biological interpretation. In Chapter 
, we adapt GESTURE to predict chemotherapy benefit in breast cancer. This offers 
additional challenges, as we do not have access to randomized trial data and the event 
rate is much lower. Here we also find the limitations of such a setting, as we can build 
a classifier that validates in cross validation, but not in external data. In Chapters * - , 
we use tumour gene expression data to predict treatment benefit, but in Chapter / we 
use SNP data (i.e. germline variation) to predict treatment benefit. We introduce 
RAINFOREST (tReAtment benefIt prediction using raNdom FOREST) and use it to 
predict benefit to cetuximab in metastatic colorectal cancer. This method is based on 
random forests, but does not need predefined labels and can identify a subset of patients 
who benefit from the addition of cetuximab, while the population as a whole.  
 
Together, we provide an array of tools that can be used to predict treatment benefit in 
high dimensional settings and we show their utility in a variety of settings. This can help 
make personalized medicine a reality in cancer treatment. 
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Many cancer treatments are associated with serious side effects, while they often 
only benefit a subset of the patients. Therefore, there is an urgent clinical need for 
tools that can aid in selecting the right treatment at diagnosis. Here we introduce 
Simulated Treatment Learning (STL), which enables prediction of a patient's 
treatment benefit. STL uses the idea that patients who received different 
treatments, but have similar genetic tumor profiles, can be used to model their 
response to the alternative treatment.  
  
We applied STL to two Multiple Myeloma gene expression datasets, containing 
different treatments (bortezomib and lenalidomide). We find that STL can predict 
treatment benefit for both; a two-fold progression free survival (PFS) benefit was 
observed for bortezomib for -'.)% and a three-fold PFS benefit for lenalidomide for 
\-.-% of the patients. This demonstrates that STL can derive clinically actionable 
gene expression signatures that enable a more personalized approach to treatment. 
  













The successful treatment of cancer is hampered by genetic heterogeneity of the disease. 
Differences in the genetic makeup between tumors can result in a different response to 
treatment (Burrell et al. ./-\). As a result, despite the existence of a wide range of 
efficient cancer treatments, many therapies only benefit a minority of the patients that 
receive them (Block et al. ./-[). Because many therapies may be associated with serious 
adverse effects, there is a great clinical need for tools to predict - at the moment of 
diagnosis - which patient will benefit most from a certain treatment. 
  
To address this, substantial efforts have been made to identify clinical and molecular 
markers, such as gene expression signatures, that can predict a favorable or adverse 
prognosis (Santos et al. ./-[). Traditionally, this is achieved by defining subtypes (e.g. 
through unsupervised learning approaches) based on molecular markers such as 
genotype or gene expression. For many of these subtypes an association has been 
determined to survival or drug response (Lièvre et al. .//,; Bernard et al. .//'; 
Walther .//'). 
  
More direct approaches use supervised learning, such as (logistic) regression, to identify 
markers associated with survival. In this setting, a class label is defined for each patient 
based on their survival or some other outcome measure, such as the risk of experiencing 
a relapse. The training procedure then focuses on predicting these labels as accurately 
as possible to ultimately produce a classifier that can predict outcome for a new patient. 
One of the first successful examples of such approach resulted in a (/-gene prognostic 
expression signature for breast cancer (Van ‘t Veer et al. .//.). A phase III clinical trial 
recently revealed that patients predicted to have good survival based on this signature 
can safely forego chemotherapy without compromising outcome (Cardoso et al. ./-,), 
thus preventing overtreatment of these patients. These examples demonstrate that 
prognostic predictors can have value in predicting benefit to treatment. 
  
Despite these successes, prognostic signatures are fundamentally limited in their ability 
to predict treatment benefit. This is because prognostic signatures are determined 
without taking treatment into account, i.e. they are not trained to distinguish patients 













'long survival' class may in fact survive just as long on any treatment available. 
Conversely, patients in the 'short survival' class could actually have benefit from 
treatment because they would have had an even shorter survival on another treatment. 
In Figure 4a and 4b we illustrate this in the setting of a randomized trial with two 
treatment arms. Figure -a shows the result for a prognostic classifier which results in a 
survival difference between the two classes that is similar in both treatment arms. 
However, to achieve treatment benefit prediction we should identify a subset of patients 
that specifically benefit from one of the two treatments, that is, where the difference in 
survival between the two treatments is larger than in the population as a whole (Figure 
4b). It should be noted that it is possible that a prognostic classifier happens to identify 
a difference between treatment arms as well, but this is not an aim in the training 
procedure. We hypothesized that a method that is specifically geared towards 
Figure 1. Illustration of the difference between prognostic and predictive classifiers 
and an overview of the approach a. Example of the Kaplan Meier curve for a 
prognostic classifier. b. Example of the Kaplan Meier curve for a predictive classifier. 
c. Division of dataset into training and test sets. D1, D2 and D3 are all used once to 
validate the classifier trained on the remaining two thirds of data. d. Flow of the 
GESTURE algorithm. In step 1 the prototypes with a longer than expected survival 
difference are identified on fold A. In step 2 the number of prototypes and 
corresponding decision boundary used in the classifier are optimized on fold B. In 
step 3 the performance of the classifier on fold C across all repeats is used to select 
the combination of gene sets to be used in the final classifier. In step 4 a classifier 
for these gene sets is defined on all training data. This classifier will be validated on 





































































optimizing the identification of a subset of patients with a greater treatment benefit will 
achieve better results. 
  
Treatment benefit is commonly measured by the Hazard Ratio (HR), which describes a 
patient’s hazard to experience an event, for example death or progression of disease, 
relative to another set of patients who received a different treatment. Some recently 
published predictive classifiers have only shown to find a difference in response or 
survival between two groups of patients who all received the same treatment (Bhutani 
et al. ./-(; Vansted et al. ./-); Ting et al. ./-(). These signatures are not constructed 
to be predictive, since they do not necessarily provide a treatment decision; the 
prognosis may well be the same in every treatment group. To be truly predictive, a  
subgroup with a difference in survival between two treatment arms needs to be 
identified. 
  
Constructing classifiers that can achieve true treatment benefit prediction thus poses a 
unique challenge, as it is impossible to know how a patient would have responded to 
the alternative treatment. As a result, class labels based which can be used to train a 
classifier are not available and existing classification schemes are not applicable (as 
demonstrated in the Results and discussion section). 
 
To address the lack of suitable training labels, we introduce the concept of Simulated 
Treatment Learning (STL), a method to derive classifiers that can predict treatment 
benefit. STL can be applied to gene expression datasets with two treatment arms and 
survival data. STL uses genetic similarity, defined based on gene expression in the 
tumor, between patients from different treatment groups to model how a particular 
patient would have responded to the alternative treatment.  
 
In this work we focus on predicting treatment benefit for Multiple Myeloma (MM), a 
clonal B-cell malignancy that is characterized by abnormal proliferation of plasma cells 
in the bone marrow. Median survival of MM patients is [ years (Howlader et al. ./-,). 
In the last two decades many novel therapies have been introduced for MM, resulting 
in an improved survival (Kumar et al. .//); Munshi and Anderson ./-\). Bortezomib 
and lenalidomide were crucial in achieving these improved survival rates. However, 













insufficient tools to predict treatment response or survival. Between MM patients 
heterogeneity in gene expression profiles is observed (Lohr et al ./-+; Keats et al. ./-.). 
For these reasons, genetic signatures that can predict treatment benefit for MM patients 
are of high clinical value, making it an ideal test case for STL. 
 
There are some preliminary indications that predictive signatures may exist for MM. 
Some of the various prognostic factors known in MM were later found to be predictive 
as well. For instance, it was shown that patients with the chromosomal aberration 
del-(p, known to be prognostic, benefitted more from the proteasome inhibitor 
bortezomib than patients without del-(p (Neben et al. ./-.). Furthermore, expression 
levels of tumor suppressor RPL[, located on chromosome -, were also found to correlate 
with bortezomib response (Hofman et al. ./-(). Both these abnormalities have been 
found to be recurrently present in MM plasma cells and were later found to be 
prognostic and predictive. STL enables us to directly discover predictive markers, 
without relying on previously discovered (prognostic) markers. 
 
We implement the STL concept in the algorithm GESTURE (Gene Expression-based 
Simulated Treatment Using similaRity between patiEnts), which makes it possible to 
derive a gene expression signature that is able to distinguish a subset of patients with 
improved treatment outcome from the treatment of interest, but not from the 
comparator treatment.  
We show that GESTURE can predict treatment benefit for two major treatments in 
multiple myeloma, bortezomib and lenalidomide. The final classifier finds a subgroup 
containing -'.)% of the patients that have a two-fold progression free survival (PFS) 
benefit when treated with bortezomib and a three-fold PFS benefit for lenalidomide for 
\-.-% of the patients. Our results demonstrate that GESTURE can be used to robustly 
derive clinically actionable gene expression signatures that enable a more personalized 




Definition of treatment benefit class 
We combined data from three randomized phase III clinical trials comprising of '-/ 
patients with MM (see methods), who either received the proteasome inhibitor 











bortezomib (n = +/() or not (n = [/\). For each patient gene expression profiles were 
generated from purified myeloma plasma cells at diagnosis. An overall HR of /.(+ ('[% 
CI /.,- – /.'/, p = /.//.', n = '-/) is observed between the two treatment arms, in 
favor of the bortezomib arm. While this HR indicates significant treatment benefit for 
bortezomib, we asked whether this was driven by a small benefit for all patients, or if a 
subgroup of patients can be identified showing a large benefit from treatment with 
bortezomib, while the remainder of patients show a smaller or no benefit from 
bortezomib. With this research we aim to identify a subset of patients, the ‘benefit’ class, 
who benefit from the treatment of interest (bortezomib) relative to a comparator 
treatment arm which does not contain bortezomib. The patients not included in the 
‘benefit’ class belong to the class ‘no benefit’ and would not benefit from receiving 
bortezomib. The classifier identifying this ‘benefit’ class could serve as a valuable 
diagnostic to determine which newly diagnosed patients would benefit from 
bortezomib (based) treatment. 
  
Regular classifiers cannot predict treatment benefit  
We first aimed to evaluate how well a regular (prognostic) classification approach is 
able to reach treatment benefit prediction. According to our definition of treatment 
benefit, a classifier should identify a subset of patients (class ‘benefit’) with a 
significantly better survival on the treatment of interest than the population as a whole. 
In a regular binary classification setting, training such classifier requires a labeled 
dataset, where the label indicates if the patient will or will not benefit from treatment. 
As discussed in the introduction, such labels are not available, since we cannot know 
how a patient would have responded to a different treatment. However, one reasonable 
assumption could be that patients who survive long in the treatment arm of interest do 
so because they benefited from the treatment, and, conversely, patients who survive 
short in the other treatment arm do so because they should have received the treatment 
of interest. Following this line of reasoning, we define the ‘benefit’ class as the .[% 
longest surviving patients in the bortezomib arm and the .[% shortest surviving non-
bortezomib patients. Together, these two groups form the class ‘benefit’ (.[% of all 
patients). All other patients from the two arms (([%) are labeled as class ‘no benefit’. 
  
Table 4 demonstrates that with some classifiers class ‘benefit’ can be predicted from the 













/.[) for the random forest classifier to /.)- for the support vector machine classifier. 
However, using an independent validation fold, we find that prediction of treatment 
benefit fails as no improvement in HR is found over the whole population. A similar 
absence of performance is observed when other percentages than .[% were chosen to 
define the class ‘benefit’ (Supplementary Table *, + and ,). 
 
The approach to derive labels directly from survival information is essentially similar to 
prognostic classification, and our results thus cast doubt on the utility of prognostic 
approaches in a predictive setting. However, this lack of performance may not be 
surprising, since the training labels already lead to unrealistically large HRs (</.-), 
indicating that the labels are often wrong. Classifiers trained on such noisy labels are 
indeed unlikely to have predictive performance in independent validation data. It 
should moreover be noted that this approach does not take censoring of the patients 
into account. 
As an alternative approach, we therefore also generated a large number (-///) of 
random labelings and evaluated the HR in the ‘benefit’ class of these randomly labeled 
datasets. Those labelings that resulted in a significant (p</./[) HR below /.[ were 
subsequently used to train a classifier. This greedy random search procedure enables 
taking into account censoring of patients (through the calculation of the HR) and leads 
to less extreme HRs in the training data. However, this approach also did not yield 
classifiers with a significant HR when applied to the validation fold (Table *). This 
demonstrates that it is not straightforward to derive labels for treatment benefit that 
can be accurately predicted from the gene expression dataset. 
 
Overview of simulated treatment learning 
The key idea of STL is that a patient’s treatment benefit can be estimated by comparing 
its survival to a set of genetically similar patients that received the comparator 
treatment (Figure 4d, step -). Patients with a large survival difference compared to 
genetically similar patients can then act as prototype patients; new patients with a 
similar gene expression profile are expected to also benefit from receiving the treatment 
of interest. Since similarity in gene expression profile is greatly influenced by the choice 
of input genes, we define this similarity according to a large number of gene sets. 
Training the prototype-based classifier requires optimizing two parameters per gene 
set: the number of prototypes to use and the decision boundary, defined in terms of the 













Table 1. Classification accuracy in cross validation and HR in independent validation 
for the classifiers trained on labels based on the top 25% surviving bortezomib patients 
and the bottom 25% non-bortezomib patients. 
  
  Classification 
accuracy 
Validation HR p-value 
Nearest mean /.[) (sd: /./() /.', ('[% CI: /.[( - 
-.,/) 
/.), 
Random forest /.,) (sd: /./\) /.'[ ('[% CI: /.[+ – 
-.,)) 
/.)( 






Table 2. Classification accuracy in cross validation and HR in independent validation 
for the classifiers trained on labels selected from randomly generated classifications 
with a significant HR under 0.5 
  Classification 
accuracy 
Validation HR p-value 
Nearest mean /.[/ (sd: /./.) /.)- ('[% CI: /.+' – 
-.\[) 
/.+. 
Random forest /.,, (sd: /./.) /.)- ('[% CI: /.[/ – 
-.+-) 
/.[- 

















Euclidean distance to the prototype (Figure 4d, step .). The STL classifier also needs to 
select the optimal gene sets to ultimately classify a patient. Importantly, the labels are 
now defined using the prototypes identified for the various gene sets, which means that 
in the STL approach there is no need to define labels before training the classifier. To 
train the classifier and select the best performing gene sets, the training data are split 
in three folds (A, B and C). Fold A is used to identify prototypes, fold B to optimize the 
decision boundary and fold C to estimate classifier performance. 
  
To obtain unbiased estimates of the overall prediction performance, the entire dataset 
is divided in three equal folds, D-, D. and D\, ensuring a similar HR between the 
treatment arms in all three folds. Training is performed on two folds, while the 
remaining fold is kept separate to serve as an independent validation set. This is rotated 
to obtain an unbiased prediction for each fold. The division of the data in D-, D. and 
D\, and subsequently in folds A, B and C is shown in Figure 4c. 
 
It is a priori unknown which genes will be relevant to defining patient similarity and 
predicting treatment response. We used -/,[)- functionally coherent gene sets based 
on Gene Ontology annotation. Each gene set is used to train a separate classifier. The 
top-performing classifiers are subsequently combined into an ensemble classifier to 
determine the optimal number of gene sets to be used in the final classifier (Figure 4d, 
step \, for details see Methods). For the gene sets included in this optimal number a 
single classifier is trained using all the training data. These classifiers are combined into 
the final ensemble classifier that is used to classify the patients in the validation set 
(Figure 4d, step +). 
 
STL finds a predictive classifier for bortezomib benefit 
Figure *a shows the cumulative progression free survival curves for two treatment 
arms, with an HR of /.(+ ('[% CI /.,- – /.'/, p = /.//.', n = '-/) between the 
treatment arms. Figure *b shows the treatment arms and classes as identified by the 
STL classifier, when combining the class ‘benefit’ from the three validation folds. These 
three validation folds together comprise the whole dataset; the classification of each 
validation fold is predicted by separately trained classifiers. This enables us to show a 
validation performance for the whole dataset. The validation HRs for the ‘benefit’ and 
‘no benefit’ class are /.[/ ('[% CI /.\. – /.(,, p = /.//-., n = -)/) and /.() ('[% CI 











/.,\ – /.'), p = /./\, n = (\/), respectively. In the entire population an HR of /.(+ (p 
= /.//.', n = '-/) is observed. These results show that a subgroup, comprising -'.)% 
of the population (n=-)/ out of '-/), is identified by our method that benefits 
substantially more from bortezomib treatment than the population as a whole.  
 
More importantly, the STL approach is able to discover and predict this subgroup using 
the gene expression data at diagnosis. In the bortezomib arm, the ‘benefit’ and ‘no 
benefit’ class exhibit similar survival curves. This is expected, since our classifier is 
trained to predict benefit with respect to the patient group not receiving bortezomib. 
As the Kaplan Meier in Figure *b shows, the other treatment arm in the ‘no benefit’ 
class also has a similar survival, which means we expect these patients would have had 
a similar survival had they not received bortezomib. The ability to determine that a 
patient would not benefit from bortezomib is of equal importance as predicting benefit; 
preventing unnecessary treatment is an important aim of personalized medicine. 
 
The HRs observed within each of the individual validation folds are similar to the HR 
obtained when combining all folds (/.[- ('[% CI /..) – /.'., p = /./\, n = )',), /.\' 
('[% CI /.-+ – -./), p = /./(, n = \/,) and /.+, ('[% CI /..- – -./., p = /./,, n = ,-) in 
folds D-, D. and D\ respectively). We note that the HR is comparable in all folds, 
demonstrating a stable performance, although not statistically significant for fold D. 
and D\ at p < /./[ due to the fact that in D. '.'% of patients and in D\ ./.-% are 
included in the ‘benefit’ class and versus .'.+% in D-. 
 
Traditionally, the performance of a classifier is assessed by computing its accuracy, 
which is done by comparing the labels predicted by the classifier with ground truth 
labels. Ground truth labels are labels that are known to be accurate because they can be 
directly observed, e.g. if a patient survives longer than [ years or not. Since we do not 
know beforehand which patients benefited from bortezomib, we have no ground truth 
labels available and cannot compute the accuracy of our classifier. However, we can 
compare the class labels obtained with the three separate classifiers when applied to all 
'-/ patients. We find that these three class assignments agree between the classifiers 
significantly more than expected by chance (i.e. //\ classifiers or \/\ classifiers predict 
benefit; Supplementary Figure 4). A similar conclusion is reached by comparing the 














HR = 0.74, p = 0.0029 HR 'benefit' class = 0.50, p = 0.0012
















































Figure 2. Overview of the bortezomib classifier results and comparison to known markers. a. 
Kaplan Meier of the entire bortezomib dataset, showing a HR of 0.74 (95% CI 0.61 – 0.90, p 
= 0.0029, n = 910,) between the treatment arms. b. Kaplan Meier of the combined 
classifications into a ‘benefit’ and ‘no benefit’ class of D1, D2 and D3. A HR of 0.50 (95% CI 
0.32 – 0.76, p = 0.0012, n = 180,) is found between the treatment arms in the ‘benefit’ class 
and a HR of 0.78 (95% CI 0.63 – 0.98, p = 0.03, n = 730) in the ‘no benefit’ class. These results 
show that a subgroup, comprising 19.8% of the population (n=180 out of 910 total), is identified 
by our method that benefits substantially more from bortezomib treatment than the population 
as a whole; in the entire population an HR of 0.74 (95% CI 0.61 – 0.90, p = 0.0029, n = 910) 
is found. c. The HR found in the ‘benefit’ class (y-axis) when different operating points (x-axis) 
are used, compared with known predictive and prognostic markers. The gray dotted line 
indicated the HR found in the entire dataset, without classification. d. Relationships between 
the 31 genes in common between the D1, D2 and D3 classifiers. Node size corresponds to 
how much more a gene was observed in the selected gene sets than expected. Green nodes 
indicate that the gene is associated with a p-value < 0.05. Relationships are inferred from 
literature with the GeneMANIA algorithm (Warde-Farley et al. 2010). A purple edge indicates 
the genes are co-expressed, a green edge indicates a genetic interaction, a red edge a 
physical interaction, an orange edge a shared protein domain, a dark blue edge indicates co-
localization and a light blue edge shows that both genes are annotated to the same pathway. 
 











When considering the cases for which the three classifiers agree, we find that [/\ 
patients are consistently classified as ‘no benefit’ and [( patients as ‘benefit’. Together, 
this demonstrates that, even though the classifiers do not agree on the class assignment 
for all patients (which is expected in practice for classifiers with less than -//% 
accuracy), they capture the same gene expression patterns. 
  
The decision boundary of the classifiers are defined by the parameters k and gamma 
and a threshold T. We optimize the combination of k and gamma by an exhaustive grid 
search. We verified that the performance of our classifier is robust to small changes in 
these parameters (Supplementary Note 4). The operating point of the classier is 
determined by the number of individual classifiers in the ensemble that agree on the 
class label, and is thus directly related to the confidence of the ensemble classifier about 
the label ‘benefit’. To ensure sufficient power and provide a treatment decision for a 
substantial group of patients, the operating point of the classifier was set to ./% in 
training (see methods). At this operating point, -'.)% of patients in the validation folds 
were actually assigned to the ‘benefit’ class. Figure *c depicts the HR as a function of 
the confidence level of the classifier. We observe that, for higher confidence levels 
(yielding smaller sizes of the ‘benefit’ class) more extreme validation HRs are observed, 
demonstrating that there is a direct relation between classifier score and treatment 
benefit. This is consistent with the fact that the highest HR and largest class ‘benefit’ 
are found in fold D- in validation, while the lowest HR and the smallest class ‘benefit’ 
are found in D.. 
  
As a control experiment, we also ran the algorithm with shuffled treatment labels, 
destroying the relationship between the gene expression and the treatment specific 
survival. As expected, the classifier trained on this data shows no performance in the 
validation data, achieving an HR of -./' ('[% CI /.(- – -.,(, p = /.,', n = -,() in the 
class ‘benefit’ and an HR of /.'[ ('[% CI /.(( – -.-), p = /.,[, n = (+\) in the class ‘no 
benefit’ (Supplementary Figure +). This reinforces our observation that STL identifies 
a true effect, since the classifier shows no performance in random data. 
  
STL classifier outperforms known markers 
We compared the HRs found using the STL classifier with several known prognostic 













classifier has a superior performance for operating points that result in assignment of 
up to \/% of the patients to the class ‘benefit’. The markers that slightly outperform the 
STL classifier do so only for operating points that results in much larger sizes of the class 
‘benefit’ and lead to smaller effect sizes. The grey line indicates the baseline HR found 
in the entire dataset. A clinically actionable classifier should reach a substantially larger 
benefit than this baseline, which is only attained by the STL classifier and the MF cluster 
for operating points <\/%, where the STL classifier outperforms the MF biomarker. 
  
Biological information is important for performance 
To investigate if the biological knowledge contained in the Gene Ontology, used to 
define gene sets, truly aids classification performance, we also tested random gene sets 
with the same set size distribution. Using the random gene sets, final classification 
results in a significant HR of /.[, ('[% CI /.\+ – /.'/, p = /./., n = -+)) when all three 
validation folds are combined (Supplementary Figure *). This is not unexpected as 
combining random feature sets in an ensemble classifier is known to achieve good 
classification performance (Breiman .//-). Moreover, it has been shown previously that 
random gene signatures can perform on par in a prognostic setting (Venet et al. ./--). 
Nonetheless, the STL classifier trained using the GO gene sets outperforms the random 
gene set approach in both HR and p-value. Moreover, in contrast to the relatively stable 
performance across validation folds when using the GO gene sets, the performance of 
the random set approach varies greatly between the folds, ranging from an HR of /.(, 
('[% CI /.\. – -.)[, p = /.[[, n = +-) in D- to an HR of /.++ ('[% CI /..- – /.'\, p = 
/./\, n = ,() in D\. 
Together, this demonstrates that the biological information contained in the Gene 
Ontology gene sets is important to the performance of the STL classifier. 
  
Genes used to predict treatment benefit bortezomib 
The classifiers built for D-, D. and D\ use respectively --\, .-) and --- GO gene sets to 
predict bortezomib benefit, encompassing a total of -'-\ unique genes. There are \- 
genes used in all three classifiers (Figure *d). There are GO categories that include a 
large subset of these \- genes, including “positive regulation of transcription from RNA 
polymerase II promoter”, “cellular response to hypoxia” and “negative regulation of the 
apoptotic process”. All these GO categories are associated with the pathogenesis of 
cancer. Both increased proliferation and the ability to evade apoptosis are hallmarks of 











cancer (Hanahan and Weinberg ./--). It has also been established that cancer cells can 
adapt their metabolism to thrive in hypoxic conditions (Eales et al. ./-,). For the \- 
genes, we calculated they are selected more than expected by chance. GO sets are 
hierarchical (i.e. there is a larger parent category that can include several children 
categories) and genes can be annotated to multiple GO categories. Therefore, we have 
taken into account how many GO categories include a certain gene to establish if we 
observe a gene more often than expected in our classifiers. The expected count for a 
gene is based on the number of GO categories that include that gene, e.g. PTEN is 
included in -.\ of the -/,[)- gene sets, so in the ++. gene sets used across D-, D. and 
D\ we would expect to observe PTEN approximately [ times if it would occur at the 
same frequency as within our selected gene sets. Most genes in common between the 
three classifiers are observed more often than expected (degree of overrepresentation 
indicated by node size in Figure *d), with -- of \- significantly overrepresented (p < 
/./[). The most overrepresented genes are TMODG, PHKAG, SPTCLK and SPTCLG. None 
of these genes are known to be associated with MM or response to bortezomib. 
However, investigation of the proteome of a cell line carrying a SPTCLK mutation 
showed an increased presence of Ig kappa chain C (Stimpson et al. ./-[). 
Immunoglobulin light chain presence is used as a biomarker for MM and has been 
identified as a risk factor for progression (Dispenzieri et al .//)). PTEN is also found to 
be significantly overrepresented. PTEN is a known tumor suppressor and was found to 
be mutated in a various cancers (Yamada and Araki .//-). In MM, PTEN mutations are 
relatively uncommon and associated with advanced disease (Chang et al. .//,). 
  
Impact of dataset of origin on validation performance 
Our training dataset is a combination of three different datasets: Total Therapy ., Total 
Therapy \ (together forming the TT dataset) and HOVON,[/GMMG-HD+ (H,[). Both 
the bortezomib and the no bortezomib arm contain more than one treatment regimen 
(Supplementary Table 4). We trained and validated on a combination of the datasets 
(see Methods). To investigate the contribution of the different datasets to the final 
validation performance, we calculated the HR in class ‘benefit’ for the TT and H,[ 
patients separately. Reassuringly, we observe a similar effect in class ‘benefit’ in both 
datasets, albeit not significant due to small sample size in the H,[ dataset (HR = /.,' 
('[% CI /.\, – -.\.) , p = /..,, n = +', for H,[ and HR = /.\) ('[% CI /..- – /.,'), p = 













smaller in the TT dataset. This may be expected, since the HR in the overall population 
is also smaller in TT than in H,[ (the overall HR in TT is /.,. ('[% CI = /.+, – /.)+), 
p = /.//., n = [)\ vs. an HR of /.), ('[% CI = /.,, – -.-\), p = /..), n = \.( in H,[). 
We hypothesized that heterogeneity helps to prevent overfitting to one specific dataset 
or treatment regimen. To test this, we also performed a cross validation within the two 
TT datasets only (the H,[ dataset is too small for this with n = \.(). Subsequently, we 
trained a classifier on the entire TT dataset (combining Total Therapy . and Total 
Therapy \) and validated on H,[. Cross validation within the TT dataset leads to an HR 
of /..) ('[% CI /.-\ – /.,/, p = /.///'), n = ),) in class ‘benefit’ and an HR of /.(- 
('[% CI /.[- – /.'), p = /./\), n = +'() in class ‘no benefit’ (Supplementary Figure 
I), which is a substantial improvement over the classifier trained on the combined 
dataset. In contrast, when the classifier is trained on the entire TT dataset, no 
performance is observed in the H,[ dataset (an HR of -.-\ ('[% CI /.,\ – ../+), p = 
/.,), n = ,, in class ‘benefit’ and /.)- ('[% CI /.,/ – -.-), p = /.-), n = .,- in class ‘no 
benefit’), indicating that some dataset specific fitting has occurred. Importantly, dataset 
specific fitting does not necessarily indicate overtraining; the classifiers still validate on 
the completely independent hold out validation fold. These results do suggest that it is 
very important to match the training population with the population one intends to use 
the classifier in. If the population in which the classifier is intended to be applied is 
heterogeneous, the training dataset also needs to reflect this heterogeneity. 
In the MM dataset under study here, one possible explanation for the lack of validation 
of the TT- based classifier on the H,[ data is that the TT trials were conducted in the 
USA and included more additional treatment than the European H,[ trial (see 
Supplementary Table 4 for treatment details). When the STL classifier is trained 
exclusively on the TT datasets, it could become specifically predictive for the TT 
regimen, rather than bortezomib, explaining why this classifier does not show a 
satisfactory performance in H,[. When trained on the mixed dataset, the classifier does 
show performance in the H,[ dataset, but still performs better within the TT dataset, 
which makes up a bigger part of the training data. 
  
STL finds a predictive classifier for lenalidomide benefit 
The STL method was developed based on the bortezomib dataset. Even though a strict 
separation of training and validation has been made, we cannot exclude the possibility 
of ‘experimenter bias’ (Holman et al. ./-[), which is the result of making experimental  












choices based on the results on the training dataset and which can lead to a classifier 
that will only perform well on the specific dataset at hand. 
  
To demonstrate that the STL method is not biased to just one dataset we applied it to a 
completely independent dataset obtained from the CoMMpass database 
(https://research.themmrf.org/). CoMMpass contains data from an observational MM 
study, meaning the trial did not interfere with the treating physician’s choice of 
treatment. This is a good model for the setting in which an eventual predictive 
biomarker would be applied. Moreover, instead of microarrays, RNA-seq was used to 
obtain gene expression measurements, thus providing an additional axis of variation 
compared to microarray data. Overall, gene expression data and annotation was 
available for ,,. patients, ++( of which received lenalidomide in the first line and .-[ 
did not. An overall HR of /.[' (p = /.//+) in favor of lenalidomide was observed, as 
seen in the Kaplan Meier in Figure +a. 
  
Similar as before, the dataset was divided into three equal folds and STL obtains 
classifiers that successfully predict benefit in all folds. Since the CoMMpass dataset is 
a. b.
HR = 0.59, p = 0.0042 HR 'benefit' class = 0.36, p = 0.0031  
HR 'no benefit' class = 0.71, p = 0.13
Figure 3. Overview of the lenalidomide classifier results a. Kaplan Meier curves for 
the entire lenalidomide dataset, showing an HR of 0.59 (95% CI 0.41 – 0.84, p = 
0.0042, n = 662) between the treatment arms. b. Kaplan Meier curve of the combined 
classifications into a ‘benefit’ and ‘no benefit’ class of D1, D2 and D3. An HR of 0.36 
(95% CI 0.18 – 0.71, p = 0.0031, n = 206) is found between the treatment arms in the 















smaller than the bortezomib dataset used before, we required the ‘benefit’ class to 
contain at least \/% of the patients, to ensure sufficient power. This results in a 
combined HR of /.\, ('[% CI /.-) – /.(-, p = /.//\-, n = ./,) over the entire dataset, 
as shown in Figure +b. In total \-.-% of patients were classified as class ‘benefit’. Again, 
the STL classifier was able to distinguish a subset of patients with significant treatment 
benefit in each fold with HRs of /..( ('[% CI /./( – -./,, p = /./,, n = (.), /.\' ('[% 
CI /.-- – -.+-, p = /.-[, n = ,,) and /.+/ (/.-+ – -.-[, p = /./', n = ,)) in D-, D. and D\, 
respectively. This demonstrates that STL also successfully identified a predictor for 
lenalidomide benefit. 
 
Genes used to predict treatment benefit lenalidomide 
The predictive classifiers for lenalidomide use +(, [ and --' gene sets in D-, D. and D\ 
respectively, encompassing \(.\ unique genes. Out of these, [ genes are used in all three 
classifiers: CYPKKBG, SHH, HGNC, CAVK and SMO, all of which are observed more 
frequently than expected. SHH and CYPKKBG are significantly overrepresented (p < 
/./[). SHH is a crucial part of the hedgehog signaling pathway, which has been 
previously found to play an important role in the pathogenesis of MM (Blotta et al. 
./-.). Neither of these genes has previously been associated with lenalidomide 
response, possibly representing an undiscovered mechanism influencing lenalidomide 




Simulated Treatment Learning addresses an urgent clinical need because response rates 
to current cancer therapies are often poor and moreover frequently accompanied with 
serious side effects. STL offers an important step towards realistic personalization of 
cancer medicine administration by identifying gene expression markers that can be 
used to determine the most effective treatment for a cancer patient at the moment of 
diagnosis. 
  
The STL classifier was successfully tested across different gene expression platforms, 
different treatments and different study types, demonstrating that STL is more 
generically applicable than one particular dataset. Since our work has focused on MM, 
an important next step is to investigate if STL is also successful in unraveling treatment 











benefit for other diseases. If so, STL can play an important role in rescuing treatments 
that do not achieve a significant effect in the entire patient population but may still 
benefit a subset of the patients. For instance, STL can be an important post-hoc analysis 
for phase III clinical trials of novel treatments that have missed their endpoint, such as, 
for instance, nivolumab in the CheckMate-/., trial (Socinki et al. ./-,). We do note 
that STL requires a relatively large number of samples to build the classifier, which may 
not always be available when a novel treatment first enters clinical trials. The generic 
concept of STL can be readily extended to include patient similarity definitions based 
on e.g. germline or somatic genomic profiles and other types of outcome measure such 




Data and processing 
We pooled gene expression and survival data from three phase III trials: Total Therapy 
. (TT., GSE.,[)) Total Therapy \ (TT\, GSE.,[)) and HOVON-,[/GMMG-HD+ (H,[, 
GSE-'()+). The TT. dataset included \+[ newly diagnosed multiple myeloma (NDMM) 
samples, treated either with thalidomide and melphalan (n = -(\) or melphalan alone 
(n = -(.). Average age is [,.\ (range: .+ - (,) and [(.-% of the patients is male. The TT\ 
dataset included .\) NDMM samples treated with bortezomib, thalidomide, 
dexamethasone, cyclophosphamide, cisplatin and etoposide (VTDPACE). Average age 
is [).( (range: \. - ([) and ,(.,% is male. The H,[ dataset included \.( NDMM 
samples, treated either with vincristine, doxorubicin and dexamethasone (VAD, n = -[)) 
or bortezomib, doxorubicin and dexamethasone (PAD, n = -,'). Average age is [+.( 
(range: .( - ,[) and [,.+% percent is male. In our analyses of the pooled data two 
treatment arms were considered: a bortezomib arm, which comprises the PAD arm from 
H,[ and TT\, and a non-bortezomib arm, which comprises the VAD arm from H,[ and 
TT.. Combined, these datasets include '-/ patients, of which +/( received bortezomib 
and [/\ did not.  
  
All samples were profiled with the Affymetrix Human Genome U-\\ plus ../ array. Gene 
expression was MAS[ and log. normalized. Batch effects resulting from pooling 













to mean / and variance - per probeset. Probesets with a variance of < - before scaling 
were discarded. 
 
The data was split in fold D- (\/\ samples), fold D. (\/\ samples) and fold D\ (\/+ 
samples), stratifying for treatment arm and survival. Fold D- is not used at any point in 
the training and serves as validation data, while Fold D. and fold D\ are combined to 
serve as training data. After the STL classifier is successfully validated on fold D-, the 
folds are rotated to serve as additional validation folds to assess robustness. The training 
data for fold D. consists of D- and D\ and the training data for D\ consists of D- and 
D. (specification of which samples were used in which folds is available with the code 
in the GitHub repository). 
  
After developing the STL method on the microarray dataset, we also applied it to the 
CoMMpass trial (NCT/-+[+.') dataset generated by the Multiple Myeloma Research 
Foundation (MMRF). For ,,. patients both RNAseq, survival data, and treatment 
information was available. Sequencing data is processed with the Cufflinks pipeline 
(researcher.themmrf.org). The dataset was split into a treatment arm where patients 
received lenalidomide as first line treatment (n = ++() and an arm where patients did 
not (n = .-[). This data was also split into folds D- (../ samples), D. (..- samples) and 
D\ (..- samples), specification of which samples were used in which folds is available 
with the code in the GitHub repository.  
  
Endpoint and survival analysis 
Progression Free Survival (PFS) was used as endpoint, as this is the most direct readout 
of first line treatment related survival and therefore considered to be more relevant 
compared to overall survival. PFS times in the TT. and H,[ datasets were truncated to 
[..[\ months, corresponding to the longest follow-up time in the TT\ dataset. 
  
Survival analyses were done using the Cox Proportional Hazards model (survival 
package, version ..\).+)(Therneau ./-[). For the microarray data, the survival analysis 
included a stratification for dataset of origin. This means the base hazard was estimated 
separately for the TT./TT\ dataset and the H,[ dataset. This is necessary to correct for 
the significant survival difference found between these datasets. Hazard Ratios (HR) 
and associated .-sided p-values were calculated. P-values below /./[ were considered 











statistically significant. All HRs are computed as bortezomib vs no bortezomib and 
lenalidomide vs no lenalidomide, which means an HR below - signifies a benefit when 




For the bortezomib classifier we tested all Gene Ontology (GO) categories, as defined 
by the R Bioconductor package hgu-\\plus..db (Carlson ./-,)(accessed: .( October 
./-[), with two or more probesets associated to them. This resulted in -/,[)- gene sets. 
To test whether the biological information, contained in the GO annotation, aids the 
performance of the algorithm, -/,[)- random gene sets matching the size of the actual 
selected GO categories were also tested. 
For the lenalidomide classifier we tested all the GO categories with two or more genes 
associated to them, as defined by Bioconductor package biomaRt (Durinck et al 
.//')(accessed: -' June ./-(). This resulted in ',-.- gene sets. 
  
Algorithm 
The STL classifier aims to predict if a patient does or does not benefit from a certain 
treatment of interest based on the gene expression profile of the patient. In order to 
train this classifier, a gene expression dataset is required that consists of two treatment 
arms and a continuous outcome measure. These data are first split into training and 
validation folds. The training data comprises of two thirds of the data, while one third 
(fold D) is kept apart to function as validation data. We define three separate folds D 
(D-, D. and D\), such that each patient is included in the validation set once. The 
training data is subsequently split further into folds A, B and C for training. 
  
We first define a ranked list of prototype patients on fold A (Step -) that exhibit a better 
than expected prognosis on the treatment of interest compared to a set of genetically 
similar patients that received an alternative treatment. In Step ., a decision boundary 
around a selection of prototype patients is determined on fold B. Patients that lie within 
this decision boundary are expected to show a favorable outcome when receiving the 
treatment of interest and are classified as benefitting (class ‘benefit’). All other patients 
are considered class ‘no benefit’ and are not expected to benefit from receiving the 













similarity should be defined, step - and . are performed for a large number of 
functionally coherent gene sets obtained from the Gene Ontology annotation, yielding 
one classifier per gene set. Step - and . are repeated -. times to obtain a robust estimate 
of the performance per gene set. In each repeat, the training data is split into a different 
fold A, B and C. The performance is defined as the Hazard Ratio (HR) between 
treatments in class ‘benefit’, found in a fold C, which contains samples that were not 
used in step - and .. All gene sets are ranked by their mean performance in fold C across 
repeats. In Step \ we determine the optimal number of gene sets to combine into a final 
classifier. We found that defining performance and selecting the optimal number of 
gene sets on the same folds C leads to overtraining. Therefore, we run the entire 
algorithm a second time (Run .), using -. new repeats with different splits into fold A, 
B and C. The first run of -. repeats is used to rank the gene sets. The combined 
performance of these ranked gene sets on the folds C from Run . is used to determine 
the optimal number s of gene sets. Similar to the boosting principle (Schapire -'''), the 
individual classifiers are combined into an ensemble to construct a more robust final 
classifier. The performance of this combined classifier is measured on fold C of Run .. 
The gene sets are added to the classifier in order of their ranking, until an optimal 
performance is reached across all the repeats from Run .. Since there are -. repeats, 
each combination results in -. HRs as measured on the folds C from run -.. To 
determine the optimal number of gene sets, we fit a local polynomial regression line on 
the median HRs for each combination of gene sets. The optimal number of gene sets s 
is reached when adding a gene set does not result in a lower HR. We then rank the gene 
sets based on their individual performance across the folds C of Run . and select the 
top s for inclusion in the final ensemble classifier. Finally, in Step +, one final classifier 
is trained using the entire training dataset for these selected gene sets. 
These steps are visualized in Figure 4d and are described in more detail below. 
  
In Step -, we perform prototype ranking on Fold A. For each patient receiving the 
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where O is the set of the n most similar patients (based on Euclidean distance) that did 
not receive the treatment of interest. We use n = -/. In an approach similar to Harrell’s 
C-statistic (Harrell et al. -'',), ΔPFS is only calculated for neighbor pairs where it is 
clear which patient experienced an event first; if both are censored or one patient is 
censored before the neighbor experienced an event, ΔPFS is not computed. When n = 
-/ is used, this on average leads to ( neighbours being used in the calculation of ΔPFS. 
To correct for the fact that a patient with a long survival time will, on average, have a 
large ΔPFS irrespective of its relative treatment benefit compared to genetically similar 
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where RPFS is a distribution of -/// random ΔPFS scores, obtained by calculating ΔPFS 
for randomly chosen sets O, i.e. determining treatment benefit with respect to random 
patients instead of genetically similar patients. Based on the zPFS score all patients in 
fold A that were given the treatment of interest can be ranked. 
  
In Step ., we define the classifier on fold B. The classifier is defined by a subset of k top-
ranked prototypes along with a decision boundary defined in terms of the Euclidean 
distance γ around a prototype. A patient is classified as class ‘benefit’ when it lies within 
γ of any of the top k prototypes. The optimal values for k and γ are those resulting in 
the lowest Hazard Ratio (HR) in class ‘benefit’ (the patient group in which the treatment 
of interest should have a better survival). We set an operating point that additionally 
constrains k and γ, such that class ‘benefit’ comprises at least a certain percentage of the 
dataset. This ensures sufficient statistical power to compute the significance of the HR 
in the ‘benefit’ class. The number of prototypes was restricted to -/ to prevent defining 
an extremely complicated classifier. The search grid for parameter γ was made 
dependent on the local density of the neighbors, and consisted of the sorted list of 
Euclidean distances between the prototype and its neighbors. The optimal k and γ 
combination is chosen so that the HR in class ‘benefit’ is minimal, while still associated 
with a p-value below /./[. If no combination results in a p-value below /./[, the 














In step \, we rank and select the gene sets. First, the gene sets are ranked by their mean 
performance in fold C over all repeats from Run -. After ranking, we run the algorithm 
a second time, with different divisions into fold A, B and C. We add gene sets to an 
ensemble classifier one by one based on this ranking. The performance of the combined 
gene sets is measured on each fold C of this second run. We find that defining the 
ranking on different folds than we use to measure combined performance prevents 
overtraining, although some bias is still expected to occur. Since the found HR can 
fluctuate between folds and gene set numbers, a regression line is fit through the 
median HRs found on folds C in the second run and the optimal number of gene sets is 
determined: the first combination of gene sets for which adding another gene set does 
not lead to an improvement of the HR larger than -*-/". 
  
After the optimal number of gene sets is determined in Step \, the final classifier is 
defined in Step +. The gene sets are ranked based on their mean performance in fold C 
in the second run. The top scoring gene sets are selected and for these gene sets a final 
classifier is trained. To this end, the complete training dataset is split into only two folds, 
since the third fold is no longer required. The classifiers defined by different gene sets 
are combined into an ensemble classifier by an equally weighted voting procedure, 
which means each classifier has an equal influence on the final classification. For an 
ensemble classifier containing s gene sets, this defines a classification score between / 
and s per patient. This score is thresholded by threshold T, which determines whether 
a patient is to benefit from the treatment of interest, where a patient with a score below 
the threshold is classified as not benefitting from treatment (‘no benefit’ class). The 
optimal threshold T is the one for which the HR between treatments is minimal in class 
‘benefit’. This combination of classifiers and threshold can be used to classify new and 
unseen patients and is validated on fold D. 
 
Calculating overrepresentation of genes in the classifier 
The same gene can be used multiple times in a single classifier and/or multiple times 
across the classifiers obtained for fold D-, D. and D\. Both cases provide evidence of 
the importance of the gene for the treatment benefit prediction. To assess whether 
genes are selected more frequently than expected by chance across all three classifiers, 
we determine the degree of overrepresentation by dividing the observed count by the 
expected count. The expected count is calculated by 𝑝 ∗ 𝑊 where 𝑝 is the fraction of the 











gene sets containing the gene and 𝑊 the total number of gene sets selected across all 
three classifiers. A p-value is determined using the binomial test. 
  
Training regular classifiers 
We defined the labels that were used to train the regular classifiers in two ways. First, 
labels were defined by assigning the .[% longest surviving bortezomib patients and the 
.[% shortest surviving non-bortezomib patients to the ‘benefit’ class and all others to 
the ‘no benefit’ class. A classifier was trained using folds A-C to predict these labels, 
using the HR in validation fold D- as performance measure of the predictive power. For 
the nearest mean classifier, a double-loop cross-validation was used to optimize the 
number of genes (ranked based on t-score), using balanced accuracy as the performance 
measure. 
 
A random forest classifier (R package randomForest, version +.,.-.)(Liaw and Wiener 
.//.) and a support vector machine (R package e-/(-, version -.,.()(Meyer et al. ./-[) 
were also trained. For both these classifiers, the number of genes was optimized in cross 
validation. For the random forest classifier ./// trees were trained per classifier and 
the bootstrap sample was sampled equally from both classes, to prevent the classifier 
being affected by the class imbalance. For the support vector machine, C-values from - 
to -// were tested, in steps of -. The gamma used is -/P, where P is the number of input 
variables, i.e. the number of genes. 
For all classifiers, the accuracy reported is the mean accuracy in cross validation for the 
optimal number of input genes. 
 
 
Comparison with known prognostic markers 
To the best of our knowledge, RPL[ is the only published gene expression based marker 
that predicts bortezomib benefit by comparing to another treatment group (Hofman et 
al. ./-(). We tested RPL[ on the data from the Total Therapy studies, since it was 
trained on the HOVON-,[ data. Since some predictive markers are discovered by 
testing markers previously known to be prognostic, we also compare with prognostic 
markers. FISH markers were called on the gene expression data, using previously 
developed classifiers (Van Vliet et al. ./-\), since FISH data was not available for all 













tested if any predictive information was available in previously defined molecular 
subtypes in MM (Zhan et al. .//,) and in the prognostic gene signature EMC-'. 
(Kuiper et al. ./-.). 
 
Data availability 
 All survival and treatment data included in the bortezomib dataset are supplied in 
Supplement -. The gene expression data from the Total Therapy II and Total Therapy 
III studies are accessible in the GEO database, accession number GSE.,[). The gene 
expression data from the HOVON-,[/GMMG-HD+ study is accessible in the GEO 
database, accession number GSE-'()+. 
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Supplementary Figure 1. We computed for how many patients the three classifiers 
trained in the different folds of the cross validation agree on class assignment. The 
values on the x-axis represent the number of classifiers that classified a patient as 
benefitting from treatment. A value of 0 means that all three classifiers classified a 
patient as ‘no benefit’ and the value of 3 (which is the maximum) means all 
classifiers agreed on the assignment to class ‘benefit’. These are the red dots in the 
plot. We also generated 10 000 random labelings per training fold, with the same 
proportion of patients labeled ‘benefit’ and ‘no benefit’ as in the labelings found by 
STL to obtain a background distribution of the expected overlap by random chance 
(boxplot). Since the number of patients for which all three STL classifier agree (i.e. 
the patients with either a value of 0 or 3) is larger than expected by random chance, 
the concordance between the STL classifiers is significant. 

















Supplementary Figure 3. Kaplan Meier showing the survival curves in validation 
when the treatment labels are shuffled, i.e. patients are in silico randomly assigned 
to the either the bortezomib or no bortezomib arm. An HR of 1.09 (95% CI 0.71 – 
1.67, p = 0.69, n = 167) in the class ‘benefit’ and an HR of 0.95 (95% CI 0.77 – 1.18, 
p = 0.65, n = 743) in the class ‘no benefit’ is observed. It is expected that no 
performance is observed, since the relationship between the gene expression data 
and the treatment specific survival is destroyed. 
HR ‘benefit’ class = 1.09, p = 0.69 
HR ‘no benefit’ class = 0.95, p = 0.65 
HR ‘benefit’ class = 0.56, p = 0.02 
HR ‘no benefit’ class = 0.77, p = 0.02 
Supplementary Figure 2. Kaplan Meier of the classification of the bortezomib 
dataset using random gene sets. In the class ‘benefit’ an HR of 0.56 (95% CI 0.34 
– 0.90, p = 0.02, n = 148) is found and in the class ‘no benefit’ an HR of 0.77 (95% 














Supplementary Figure 4. Validation performance of the STL classifier in the H65 
dataset when the classifier is trained on the combined TT/H65 dataset. An HR of 
0.69 (95% CI 0.36 – 1.32, p = 0.26, n = 49) is observed in class ‘benefit’ and an HR 
of 0.85 (95% CI 0.63 – 1.14, p = 0.27, n = 278). 
HR ‘benefit’ class = 0.69, p = 0.26 
HR ‘no benefit’ class = 0.85, p = 0.27 
HR ‘benefit’ class = 0.38, p = 0.002 
HR ‘no benefit’ class = 0.71, p = 0.05 
Supplementary Figure 5. Validation performance of the STL classifier in the Total 
Therapy dataset when the classifier is trained on the combined TT/H65 dataset. An 
HR of 0.38 (95% CI 0.21 – 0.69, p = 0.002, n = 131) is observed in class ‘benefit’ 
and an HR of 0.71 (95% CI 0.50 – 1.00, p = 0.05, n = 452) in class ‘no benefit’. 
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TT.  X X X X X X X 
HR ‘benefit’ class = 0.28, p = 0.00098 
HR ‘no benefit’ class = 0.71, p = 0.038 
Supplementary Figure 6. Kaplan Meier showing the survival curves when the STL 
classifier is trained within the Total Therapy (TT) datasets, excluding the data from 
the HOVON65 (H65) trial. An HR of 0.28 (95% CI 0.13 – 0.60, p = 0.00098, n = 86) 
is observed in class ‘benefit’ and an HR of 0.71 (95% CI 0.51 – 0.98, p = 0.038, n = 
497) is class ‘no benefit’. The HR found in class ‘benefit’ is far lower than the HR 
found in validation when TT and H65 are combined. 
Supplementary Table 1. An X indicates a patient included in the study (rows) 

















 [% -/% -[% ./% .[% \/% \[% +/% +[% [/% 
HR -./[ -./. /.(. /.)[ /.', /.,[ /.,+ /.(+ /.([ /.,[ 
p-value /.)[ /.', /.., /.[\ /.), /./) /./' /..\ /..\ /./) 
Size class 
'benefit' 
/.\/ /../ /..( /.\[ /.\, /.+- /.+. /.++ /.+, /.+' 
Mean 
accuracy 
/.+- /.[/ /.+' /.+' /.[) /.[, /.[, /.[[ /.[[ /.[, 
 [% -/% -[% ./% .[% \/% \[% +/% +[% [/% 
HR /.,- /.[, /.'/ /.'- /.'- /.([ /.)+ /.(+ /.)/ /.([ 
p-value /.+- /..\ /.(\ /.)/ /.(\ /..' /.[- /..\ /.\, /..+ 
size class 
'benefit' 
/.-- /.-\ /../ /.-, /..[ /.\/ /.\( /.+- /.++ /.[/ 
accuracy /.(/ /.,' /.(/ /.,' /.,' /.,) /.,) /.,) /.,( /.,[ 
Supplementary Table 2. Performance of nearest mean classifier when different 
percentages are used to define class ‘benefit’ 
Supplementary Table 3. Performance of random forest classifier when different 
percentages are used to define class ‘benefit’ 














Supplementary Note 1 
The parameters k and g determine the classification boundary. For this reason, they are 
optimized using an exhaustive grid search which chooses the optimal combination. To 
investigate how sensitive this optimization is, we investigated how small changes to the 
parameters affect the HR found in validation. In essence, a smaller g leads to a smaller 
class benefit. We show the effect of changing the g parameter in two scenarios: leaving 
all other parameters as is (Supplementary Figure () and when also retraining the 
threshold T which determines how many classifiers need to agree on the ‘benefit’ 
classification (Supplementary figure )). The classifier is robust to (small) changes in 
these parameters, which is a desirable feature of a robust classifier. As can be seen in 
Supplementary Figure (, when g decreases, the HR also decreases since a smaller class 
benefit is identified. This is consistent with our observation that a smaller class benefit 
leads to a lower HR (Figure .c). When threshold T is also reoptimized, the HR stays 
relatively constant when g is changed, since the threshold T is chosen so at least ./% of 
the patients are classified as class ‘benefit’. Supplementary Figure ' shows the number 
of patients who receive a different class assignment when g is changed, again without 
reoptimizing threshold T (black line) and with reoptimization (red line). When 
 [% -/% -[% ./% .[% \/% \[% +/% +[% [/% 
HR NA '.+(E 
+/) 
/.+- /.', /.)- -./- /.)[ -.-\ /.)\ /.(/ 
p-value NA -./// /.[\ /.'[ /.,( /.'( /.[( /.,, /.+, /.-, 
size class 
'benefit' 
NA /./-\ /./. /./[ /.-/ /..\ /.\/ /.\+ /.+/ /.[/ 
accuracy /.') /.',\ /.'\ /.'. /.)- /.() /.(. /.(- /.(' /.(- 
Supplementary Table 4. Performance of support vector machine when different 
percentages are used to define class ‘benefit’. When using 5% no patients were 













threshold T is reoptimized, few patients change classification, showing different 
settings for g would identify the same patients as benefitting from bortezomib. We also 
investigated how sensitive the classifier is to changing the number of genesets in the 
classifier (with reoptimization of threshold T, Supplementary figure -/). The red line 
indicates the validation HR we originally found. As can be seen, there are many settings 
which achieve a similar or better validation performance, indicating the classifier is also 
not very sensitive to the exact number of gene sets included.  
 
We also investigated the training HR found for all k and g combinations of three of our 
top- performing genesets (Supplementary Figures -- - -\). Note that these gene sets were 
the best performing in one of the folds and are not necessarily overrepresented in the 
final classifier. The y-axis show the different settings for k and the x-axis the different 
settings for g. A yellow color indicates a low HR, a blue color a high HR and white 
indicates too few or too many patients were included in class ‘benefit’ when this 
combination was used. What can be seen is that a low setting for k (meaning few 
prototypes) leads to the most favorable HRs. Also here can be seen that small changes 
in k and g do not lead to large changes in HR.











Supplementary Figure 7. The effect of changing g on the HR when threshold T is 
not re-optimized. The y-axis shows the validation HR and the x-axis the change in 
g. 
Supplementary Figure 8. The effect of changing g on the HR when threshold T is 













Supplementary Figure 9. The number of patients who change from class ‘benefit’ 
to class ‘no benefit’ or vice versa when g is changed. The red line shows the 
difference when we re-optimize the threshold T, the black line when we do not. 
Supplementary Figure 10. The validation HR found when a different number of 
genesets is included in the final classifier. The red line indicates the validation HR 
found with the original classifier. 











Supplementary Figure 11. Training performance for different combination of k and 
g, using GO category olfactory bulb axon guidance. The y-axis show the different 
settings for k and the x-axis the different settings for g. A yellow color indicates a low 
HR, a blue color a high HR and white indicates too few or too many patients were 
included in class ‘benefit’ when this combination was used. 
Supplementary Figure 12. Training performance for different combination of k and 
g, using GO category peptidoglycan receptor activity. The y-axis show the different 
settings for k and the x-axis the different settings for g. A yellow color indicates a low 
HR, a blue color a high HR and white indicates too few or too many patients were 













Supplementary Figure 13. Training performance for different combination of k and 
g, using GO category IgG binding. The y-axis show the different settings for k and 
the x-axis the different settings for g. A yellow color indicates a low HR, a blue color 
a high HR and white indicates too few or too many patients were included. 
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Proteasome inhibitors are widely used in treating Multiple Myeloma, but can cause 
serious side effects and response varies between patients. It is therefore important to 
gain more insight into which patients will benefit from proteasome inhibitors. 
 
We introduce Simulated Treatment Learned signatures (STLsig), a machine learning 
method to identify predictive gene expression signatures. STLsig uses genetically similar 
patients who received an alternative treatment to model which patients will benefit 
more from proteasome inhibitors than from an alternative. STLsig constructs gene 
networks by linking genes that are synergistic in their ability to predict benefit. 
 
In a dataset of '-/ MM patients STLsig identifies two gene networks that together can 
predict benefit to the proteasome inhibitor bortezomib. In class ‘benefit’ we find a 
hazard ratio of /.+( (p = /./+) in favor of bortezomib, while in class ‘no benefit’ the 
hazard ratio is /.'- (p = /.,)). Importantly, we observe a similar performance (HR class 
benefit = /.+,, p = /./+) in an independent patient cohort. Moreover, this signature 
also predicts benefit for the proteasome inhibitor carfilzomib, indicating it is not 
specific to bortezomib. No equivalent signature can be found when the genes in the 
signature are excluded from the analysis, indicating they are essential. Multiple genes 
in the signature are linked to working mechanisms of proteasome inhibitors or MM 
disease progression. 
STLsig can identify gene signatures that could aid in treatment decisions for MM 
patients and provide insight into the biological mechanism behind treatment benefit. 
  













For many anti-cancer drugs the response varies widely across patients. As many of these 
drugs are associated with serious side effects, it is essential to identify which drug will 
maximally benefit the patient. Tools that aid in such decisions, e.g. based on patient-
derived genetic or transcriptomic profiles have only been developed for a few 
treatments and diseases. Most efforts in this direction focus on detecting specific 
mutations for which it is known that a targeted therapy exists (Syn et al. ./-,). However, 
many patients do not carry any mutations that are known to be actionable and in 
practice only (% of patients can be matched to a targeted therapy with the highest level 
of evidence (Zehir et al. ./-(). Moreover, a range of efficacious therapies exist that are 
non-targeted. Consequently, there is a clear clinical utility for methods that can more 
generically predict - at the time of diagnosis - if a patient will benefit from a certain 
treatment or not. 
  
Multiple myeloma (MM) is characterized by a malignant proliferation of plasma cells, 
both in the bone marrow and extramedullary sites. MM is considered incurable with a 
median survival of approximately , years (Rajkumar and Vincent Rajkumar ./-)). 
Several driver mutations have been identified in MM (Walker et al. ./-)), but in most 
patients no actionable mutations are observed and targeted therapies are therefore not 
commonly used in MM. Currently, proteasome inhibitors (PIs) are one of the most 
important components of treatment in MM and since their introduction in the clinic 
survival has significantly improved (Moreau et al. ./-.). Due to higher immunoglobulin 
production, MM cells are thought to be more reliant on proteasomal degradation of 
proteins, making them vulnerable to proteasome inhibition (Laubach, Richardson, and 
Anderson ./--). After bortezomib, which was the first PI to be introduced in the clinic 
for MM, second generation proteasome inhibitors like carfilzomib and ixazomib have 
recently been approved. 
  
Despite the success of PIs, there is still wide variability in response across patients. 
Substantial efforts have been made to discover what distinguishes responders from non-
responders. For instance, several studies have implicated differential expression of 
genes involved in the unfolded protein response (Dong et al. .//'). Other studies 














factor (Soriano et al. ./-,). Several chromosomal aberrations have also been found to 
influence bortezomib response, although this effect is not fully understood (Smetana et 
al. ./-\; Avet-Loiseau et al. ./-/). Despite all efforts, there is currently no biomarker 
capable of determining which patients will benefit most from receiving a PI. 
  
Most studies investigating PI response compare gene expression patterns of patients 
responding well or poor to a certain treatment (Laubach, Richardson, and Anderson 
./--; Hofman et al. ./-(; Yoshida et al. ./-); Narita et al. ./-[). The identified genes 
can then be combined in a classifier to predict good or poor response in new patients. 
However, a clinically more interesting question is whether a patient will benefit more 
from a PI than from another treatment. This is a markedly different question than 
identifying good and poor responders within one homogeneous treatment group. After 
all, even patients with poor survival may have benefited from their treatment; their 
outcome could have been even worse on another treatment. Conversely, a patient with 
a good survival outcome could have experienced an equivalently good or better 
response on another treatment. It is therefore impossible to assign patients to class 
‘benefit’ or ‘no benefit’ a priori, since response to another treatment cannot be observed. 
Standard methods. which rely on the existence of such class labels, are thus unsuitable 
for predicting treatment benefit. 
  
Here we propose a novel method, Simulated Treatment Learning signatures (STLsig), 
to infer gene signatures that can predict treatment benefit for patients at the moment 
of diagnosis. We apply STLsig to find a gene expression signature capable of identifying 
patients for whom treatment with PIs results in better survival than an alternative 
treatment. Firstly, the gene signature should be capable of predicting PI benefit in an 
independent patient cohort, which has been shown challenging for prognostic 
classifiers (Bernau et al. ./-+). A second important objective of STLsig is to identify a 
simple, interpretable model which contains genes that have biological relevance to the 
molecular mechanism underlying PI efficacy. To enable this, we leverage the core 
concept of Simulated Treatment Learning (STL), which we proposed previously (Ubels 
et al. ./-)), that allows training classifiers without having a predefined labelling of 
patients. While our previous method was successful in identifying a model that can 
predict treatment benefit, these models rely on large numbers of Gene Ontology sets, 
making interpretation complex. 












We propose a different approach which identifies small gene networks that can be used 
to predict PI benefit. To obtain a signature for treatment benefit, we form networks of 
genes that are complementary in their ability to predict benefit. STLsig is fully data 
driven and does not rely on any biological knowledge or predefined gene networks as 
input. 
  
We demonstrate the utility of STLsig on a '-/ sample dataset combining three different 
Phase III clinical trials with MM patients receiving either a treatment with or without 
the PI bortezomib (the HTT cohort). STLsig enables discovery of a -+-gene signature 
that can accurately identify a subset of patients benefiting from bortezomib. We 
validate this gene expression signature in independent data (the CoMMpass cohort) 
where we predict benefit for bortezomib or an alternative PI, carfilzomib, 
demonstrating that the signature is robust and generalizes to other data. Moreover, we 
show that no gene expression signature with a similar performance can be found when 
the signature genes are removed from the dataset. The genes included in the signature 
are thus essential for predicting PI benefit. Several of the genes in the signature are 
related to MM or the working mechanisms of PIs. To our knowledge, this is the first 






To develop the gene network and train the bortezomib benefit signature, we pool gene 
expression and survival data from three phase III trials (referred to as the HTT cohort): 
Total Therapy . (TT., GSE.,[)), Total Therapy \ (TT\, GSE.,[)) and HOVON-
,[/GMMG-HD+ (H,[, GSE-'()+). The TT. dataset includes \+[ newly diagnosed 
multiple myeloma (NDMM) samples, treated either with thalidomide and melphalan (n 
= -(\) or melphalan alone (n = -(.). The TT\ dataset includes .\) NDMM samples 
treated with bortezomib, thalidomide, dexamethasone, cyclophosphamide, cisplatin 
and etoposide (VTDPACE). The H,[ dataset includes \.( NDMM samples, treated 
either with vincristine, doxorubicin and dexamethasone (VAD, n = -[)) or bortezomib, 














bortezomib arm (n = +/(), which comprises the PAD arm from H,[ and TT\, and a 
non-bortezomib arm (n = [/\), which comprises the VAD arm from H,[ and TT.. We 
divide the HTT cohort in a train set (n = ,/,) and a test set (n = \/+). We ensured the 
two treatment arms were distributed evenly between training and test data and that the 
HR between the treatments was similar. 
  
All samples have been profiled with the Affymetrix Human Genome U-\\ plus ../ array. 
Gene expression is MAS[ and log. normalized. Batch effects resulting from pooling 
different datasets are corrected with ComBat(Johnson, Li, and Rabinovic .//(). Data is 
scaled to mean / and variance - per probeset. 
  
For validation of both the bortezomib model and carfilzomib model, we use the 
CoMMpass trial (NCT/-+[+.') dataset generated by the Multiple Myeloma Research 
Foundation (MMRF). For (+( patients both RNAseq, survival data, and treatment 
information is available (CoMMpass Interim Analysis -\). Of these patients, ,- did not 
receive any PI in first line treatment, [\/ received bortezomib and -[, received 
carfilzomib. Sequencing data is processed with the Cufflinks pipeline (for details see 
researcher.themmrf.org). For validation we combine the log. normalized values from 
the HTT data and the FPKM values from CoMMpass. We scale the combined data to 
mean / and variance - and then perform ComBat batch correction, as performing mean-
variance scaling before ComBat leads to better overlap between the datasets in the tSNE. 
In ComBat batch correction H,[, TT., TT\ and CoMMpass are defined as four separate 
batches. 
  
For training the signature, we use Progression Free Survival (PFS) as an endpoint as we 
consider PFS a more direct measurement of treatment effect than overall survival. Cox 
proportional hazard models were fitted using the R package ‘survival’ (version ..++). 
  
Constructing and evaluating gene pairs 
We select only probe sets that meet the following requirements: (i) variance across the 
samples > . in the training dataset before mean variance scaling, (ii) unambiguous 
mapping to one gene and (iii) matching gene in the CoMMpass dataset. This yields n = 
\\-' genes. We then construct all possible gene pairs from these \\-' genes, resulting 
in [,[/,,..- gene pairs. 












To train the gene signature we divide the HTT cohort (n = '-/) into four folds, Fold A 
(n = ./.), Fold B (n = ./.), Fold C (n = ./.) and Fold D (n = \/+), fold assignment is 
provided in the supplementary information. Fold A, B and C are used to train the 
signature as described below, while fold D acts as hold out data to validate the signature 
and optimize a threshold to use in independent validation data. 
  
To determine treatment benefit, we follow the core concept of STL laid out in our 
previous work (Ubels et al. ./-)), where for each patient a score zPFS is defined that 
measures whether the patient survived longer than expected compared to patients with 
similar gene expression that received another treatment. More specifically, for genepair 









where PFSj is the progression free survival time of patient j, I =- if patient j received the 
target treatment (a PI in this work) and I =--, otherwise. Moreover, Π! is the set of K 
nearest neighbors to patient j defined in terms of euclidean distance in the expression 
space spanned by genes n and m and only considering patients that received another 
treatment than patient j. Throughout this manuscript K=-/. In the set Π!, we discard 
patients for whom we cannot be sure whether they survived longer or not (i.e. if both 
patients are censored). This leads to an average of ( patients being used in the 
calculation of μPFSj. Subsequently, zPFS is normalized to a z-score by comparing PFS 
to a background distribution resulting from repeating this procedure M=-/// times 
with a random Π!. The zPFS score describes how much smaller (or larger) the survival 
of patient j is compared to patients with similar gene expression but opposite treatment 
than expected by random chance. 
  
To score gene pairs, a .-fold cross validation is employed using fold A (n = ./.) and fold 
B (n = ./.). Within each fold, a kNN-regression model (k = -/) is trained, which is used 
to predict zPFS on the other fold. The gene pair score is defined as the Spearman 














patients. The score for each gene pair is the mean correlation of the . folds. We repeat 
this procedure [ times with a different split in folds. 
  
Gene network construction 
We construct gene networks separately for all [ repeats and then construct a consensus 
network, which only contains the genes and edges found in all [ repeats. To construct 
the gene networks, for each gene, we rank all gene pairs containing that gene on the 
mean Spearman correlation coefficient found. We then connect genes that are mutually 
synergistic. We achieve this by requiring that AB is among the top [% of pairs including 
A and among the top [% of pairs including B. However, if a single gene is informative 
for treatment benefit, gene pairs containing this gene could be highly ranked even if the 
second gene is uninformative. Including these gene pairs in our network and 
subsequent signature would introduce noise, which would both harm biological 
interpretation of the signature and potentially decrease the predictive performance in 
independent data. Therefore, we also require the mean correlation of the gene pair to 
be above the median correlation of all selected gene pairs. We evaluate all gene 
networks in the consensus network on their ability to predict benefit and select the best 
performing combination to construct the signature. 
  
Gene network selection and gene signature construction 
After gene network construction, gene networks are selected using forward feature 
selection. To rank gene networks, we determine the predictive performance for each 
gene network. To this end, we calculate zPFS for each patient and each gene network 
separately on fold A and B together (n = +/+). The top .[% of patients (in terms of 
zPFS) are assigned to class ‘benefit’, while the remaining patients are assigned to class 
‘no benefit’. Subsequently, a Cox proportional hazards regression on the treatment 
variable is performed within the ‘benefit’ patient group as well as in the ‘no benefit’ 
patients. The performance of a gene network is defined by the difference between the 
Cox’ regression β’s in class ‘benefit’ and class ‘no benefit’. 
To select gene networks to use in the final model we perform forward feature selection 
using fold C, which comprises ./. patients not used in fold A and B. Gene networks are 
added sequentially based on their performance on fold A and B. Ranking of patients 
across more than one gene network is done based on the sum of the zPFS scores of the 
individual gene networks. 











Validation of gene networks 
To validate the signature in independent data, we use all training data (n = ,/,) as a 
reference set where zPFS is known. For each patient in the validation set we compute 
the euclidean distance to all patients in the reference set per gene network. We then 
use inverse distance weighting to calculate the estimated zPFS of a validation patient j 
by 
where T comprises all patients in the reference dataset. Given a certain gene expression 










Overview of the algorithm 
STLsig relies on the idea that patients exhibiting similar gene expression profiles who 
received different treatments, can be used to model response to the treatment they did 
not receive. Similarity between patients should be defined by genes relevant to 
treatment benefit. STLsig therefore derives treatment specific gene networks, to form a 
gene expression signature capable of predicting treatment benefit. To train this 
signature we divide the HTT cohort in a test set (Fold D, n = \/+) and a training set (n 
= ,/,), which is further subdivided into three equal parts, fold A, B and C. We then 
assess the ability to predict bortezomib benefit for all [,[/,,..- gene pairs arising from 
the high variance genes (n = \\-') in the HTT training set. 
For each patient i in fold A, we determine a z-score (zPFS) per gene pair describing the 
normalized mean survival difference of patient i with its genetically similar neighbours 
that received a different treatment than patient i. We then test the ability of the 
genepair to predict the zPFS score for patients in fold B. We also assess the performance 
of each gene pair when calculation of zPFS is performed on Fold B and predicted on 
Fold A. Performance of each gene pair is defined as the mean Spearman rank correlation 














retained if it is synergistic, i.e. if the genes in the pair predict zPFS better together than 
when they are paired with other genes. 
We form a consensus network by repeating the two-fold cross validation five times. 
Only gene pairs that are found to be synergistic in all repeats and that exceed the 
median correlation across all gene pairs and all repeats are retained. From this 
consensus network we extract gene networks, i.e. all connected components. 
  
To evaluate each gene network, we recalculate zPFS for each patient using all genes in 
the network and classify the top .[% of the patients as class ‘benefit’ and the rest as 
class ‘no benefit’. Subsequently, gene networks are ranked based on the difference 
between the Cox regression β’s found in class ‘benefit’ and class ‘no benefit’. To build 
the signature, we sequentially add each network based on this ranking and evaluate the 
performance of the combined networks on fold C. The steps of the algorithm are 
summarized in Figure 4. 
  
Gene networks yield a 14-gene signature that can predict bortezomib benefit  
The consensus network formed as described above contains ,-( genes connected by +[- 
edges and consists of -,( gene networks, which includes -/+ individual gene pairs. The 
largest gene network contains +. genes; the mean number of genes per network is \.(. 
The optimal signature is formed by combining the top two ranked gene networks, which 
are shown in Figure *. With this signature we find a hazard ratio (HR) of /.+' (p = 
/./', '[% CI /... - -.--) in class ‘benefit’ (n = [/) and an HR of /.'- (p = /.(+, '[% CI 
/.[+ - -.[[) in class ‘no benefit’ (n = -[.), on fold C of the HTT cohort. In order to assign 
a zPFS score to a new and unseen patient, for whom survival is unknown, we calculate 
the distance in gene expression space between this patient and every patient in the 
training data (the reference set). The predicted zPFS score of the new patient is the 
weighted sum of the zPFS scores of the patients in the reference set. Weights are 
determined by the inverse distance, i.e. the most similar patients in the reference set 
contribute most to the predicted zPFS (see ‘Methods’). In this manner, we assess the 
ability of the -+-gene signature to predict benefit for the \/+ patients from the HTT 
cohort not included in training (Fold D). The HR in favour of bortezomib found in fold 
D is /.([ (p = /.--, '[% CI /.[\ - -./,). Figure +a shows the HR in class benefit found 











with different zPFS thresholds. A range of thresholds result in an HR below the HR  with 
Figure 1. Overview of the construction and selection of the gene networks. First 
each gene pair is scored on the correlation between predicted and calculated zPFS. 
Gene networks are then formed by connecting synergistic genes, i.e. genes that are 
amongst the top 5% partners for each other based on correlation coefficient. The 
gene networks are then ranked based on difference between Cox regression β in 
class ‘benefit’ and ‘no benefit’. The signature consists of the combination of gene 
networks that results in the largest difference in Cox’ regression β between class 
‘benefit’ and ‘no benefit’. 
 
  
Figure 2. The constructed network with all gene networks. The highlighted networks are 



























































































ATAD2FILNC1 EPHA4 THRAP3PYHIN1 SSX3PTPN14 LINC00922ADAM28RNF180BANK1 BTF3EPB41L5 ZBTB45RAI2PLN NXPE1













































































































































































































































































































































































FAM49A SLC4A4COPG2 GREM1EFEMP1SDC3 SVIL MYBL2
LIMD2 HIVEP3TTC7A IRF4TACC2PSG3 PDLIM5 NUDC
BACE2C1orf21 GADD45GFZD1 ANKRD22 GALK1 BEX5 PRAME
OR52K3P CCDC136MAMDC2LVRNCCAR1MIR17HGCDKL3WNT7BJADE2




TAS2R14 TBC1D8BRNGTTGLIS3 PPM1H IGLJ3




























with different zPFS thresholds.  A range of thresholds result in an HR below the HR 
observed in the total dataset, indicating that the predicted zPFS is associated with  
bortezomib benefit. The optimal class ‘benefit’, i.e. the class ‘benefit’ associated with the 
lowest HR, comprises \/.,% of the patients which corresponds to a zPFS threshold of 
/.\.,). With this threshold we find an HR of /.+( (p = /./+, '[% CI /..\ - /.',) in 
class ‘benefit’ and an HR of /.'- (p = /.,), '[% CI /.,/ - -.\') in class ‘no benefit’ 
(Figure +b). This establishes that our signature can predict bortezomib benefit in 
unseen data from the same patient cohort, demonstrating that the signature can be used 
prospectively to inform treatment choice. Our results indicate that, despite the fact that 
nearly all MM patients receive a treatment regimen that includes a PI (Moreau et al. 
./-.), approximately (/% of patients do not see benefit. 
 
The 14-gene signature achieves robust prediction performance in an independent 
patient cohort 
Gene expression signatures often suffer from cohort-specific fitting and cross-validation 
within one dataset can thus lead to an overestimation of performance(Castaldi, 
Dahabreh, and Ioannidis ./--). To obtain a more robust estimate of performance it is 
essential to perform validation on an external and completely independent cohort. 
Therefore, we validate its performance in the CoMMpass trial, which represents an 
independent patient cohort which was profiled on a different platform (RNAseq). In 
contrast to the HTT dataset, which is a randomized clinical trial, the CoMMpass dataset 
is an observational study and thus represents clinical reality more closely. To bring the 
CoMMpass RNAseq data in the same space as the microarray reference dataset, we 
employ a ComBat batch correction (Supplementary Figure 4 and Methods). We 
define a PI treatment arm (n = ,),) and a no PI treatment arm (n = ,-). The PI treatment 
arm contains both bortezomib and carfilzomib. Using the threshold optimized on fold 
D of the HTT cohort, we find an HR of /.+, (p = /./+, '[% CI /... - /.'() in class 
‘benefit’ (n = -[/) (Figure +c). We also see a good performance when we use overall 
survival (OS) as an endpoint (Table 4). Our signature is thus capable of predicting 
benefit in a completely independent cohort and across platforms, indicating the signal 
picked up by our classifier is robust and generalizes to the broader MM patient 
population. We next assess the performance for each of the two PIs separately. When 
we evaluate benefit for the bortezomib patients (excluding carfilzomib patients from  
 












the analysis), we find an HR of /.+' (p = /./,, '[% CI /..\ - -./\) in class ‘benefit’ (n = 
-.+). 
 
When predicting benefit for the carfilzomib patients we find an HR of /.\- (p = /./,, 
'[% CI /./' - -./.) in class ‘benefit’ (n = \)). It should be noted the carfilzomib ‘no 
benefit’ group should be considered a ‘less benefit’ group, as there is still a significant 
HR in favor of carfilzomib in class ‘no benefit’, likely due to the low overall HR (/.+., p 
= /.///+, '[% CI /.., - /.,)). Nevertheless, the fact that our signature can identify a 
patient group with substantially reduced HRs for carfilzomib treated patients indicates 
that it is more broadly applicable to PIs in general and not only bortezomib. All HRs for 
PFS and OS are shown in Table 4. 
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PI, benefit (n = 138)
PI, no benefit (n = 548)
Other, benefit (n = 12)
Other, no benefit (n = 49)

































Bortezomib, benefit (n = 34)
Bortezomib, no benefit (n = 102)
Other, benefit (n = 59)
Other, no benefit (n = 109)
a. b. c.
d. e.





































Figure 3. a. HR found in class ‘benefit’ using different zPFS thresholds on the hold 
out data. b. KM of bortezomib benefit prediction in the hold out data using the 
optimal zPFS threshold. c. KM of PI benefit prediction on CoMMpass using the 
optimal zPFS threshold from the hold out data. d. HR found in class ‘benefit’ for 
bortezomib in CoMMpass, using different zPFS thresholds. e. HR found in class 
‘benefit’ for carfilzomib in CoMMpass, using different zPFS thresholds. f. the 















Table 1. Summary of HRs found in all analyses using PFS and OS as an endpoint 
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- H.CI) 
p = C.HH 












n = LHH 
C.EH (C.KF -
H.HH) 
p = C.HG 




p = C.HG 






n = LHH 
PI C.EC (C.FH 
– C.ME) 
p = C.CK 















p = C.CCE 

















p = C.CM 
















p = C.CL 

















p = C.CCCK 












n = HNC 
C.LK (C.HH – 
C.FG) 
p = C.CCCK 






n = HNC 
Lenalidomide C.EL (C.FN 
– C.NN) 
p = C.CCH 
















p = C.CCCH 

















p = C.CG 
















p = C.CCI 










p = C.HF 
n = KCI 















p = C.IC 












n = GHI 
C.NL (C.FH 
– H.GL) 
p = C.KL 












n = GHI 
Bortezomib (APEX) C.EK (C.FK 
– H.CG) 
p = C.CE 












n = LHE 
H.LK (C.NL 
– H.NL) 
p = C.LN 

















p = C.CCCL 












n = KHN 
C.KI (C.GL 
- C.II) 
p = H*HC-" 












n = KHN 
 * No events in carfilzomib arm 
  
The percentage of patients classified as ‘benefit’ in the CoMMpass dataset is lower than 
on the HTT dataset. When we calculate the HR on the CoMMpass dataset using 
different zPFS thresholds to define class ‘benefit’, we find that for both bortezomib and 
carfilzomib the class ‘benefit’ associated with the lowest HR contains approximately 
\/% of the patients (Figure +d,e), similar to what we observed in the HTT data. This 
shows that also in CoMMpass, different zPFS thresholds are associated with benefit and 
suggests approximately \/% of MM patients experience more benefit from PI treatment 
than the population as a whole. 
  
Finally, we confirm that our model is specific for PI treatment by testing it on the 
immunomodulatory drug lenalidomide. We find an HR of /.(' ('[% CI /.[/ - -..[) in 
class ‘benefit’ (n = -+'), clearly showing the signature is specific for PI treatment. 
  
The predictive performance of the 14-gene signature holds in single agent PI treatment 
 In clinical practice, the majority of patients receive a combination of treatments. To 
ensure the signal captured in our signature is PI specific, and not dependent on a 
specific treatment combination, we test the performance of our signature on data from 














treatment was tested against high-dose dexamethasone in a relapse setting. 
Unfortunately, two of the genes in our signature (CFAP[\ and linc//+)[) were not 
measured in this study, but we can apply the signature with the remaining -. genes. 
With these genes, -/.\% of the patients are classified as benefit and we find an HR of 
/.\- ('[% CI /.---/.)(, p = /./\) in favor of bortezomib in class ‘benefit’, while in class 
‘no benefit’ we find an HR of /.() ('[% CI /.[[ - -.-/, p = /.-[)(Supplementary Figure 
*). Secondly, while there are no single agent treated patients in CoMMpass, we find that 
we can still predict benefit when we remove patients who received both a PI and 
lenalidomide, albeit with a non-significant HR due to lower sample size (Table 4). The 
signal of our signature is thus not dependent on a combination of treatments.  
 
The predictive performance of the 14-gene signature is relevant in current clinical 
practice 
Chemotherapy is not regularly used to treat MM in the clinic anymore, but is present in 
the CoMMpass dataset. To test the performance of our model in a more clinically 
representative setting and show the performance generalizes to a more modern  
treatment regimen, we exclude all patients who received any type of chemotherapy 
(vincristine, doxorubicin, cyclophosphamide or melphalan, n = .\., patient numbers 
per treatment in Supplementary table .). We find that, in this chemotherapy free 
cohort, we can still predict benefit to PI treatment with a similar effect size (HR = /.[/ 
('[% CI /..\ - -.-\, p = /.-/)), as found in the whole dataset (Supplementary Figure 
+). However, due to the smaller sample size this HR is not significant at p = 
/./[. Bortezomib and lenalidomide are two of the most used drugs and are often given 
together. In the CoMMpass data many patients in the PI arm also received lenalidomide 
(see Table * for patient numbers per treatment). The combination of bortezomib and 
lenalidomide is superior to both lenalidomide alone and to bortezomib alone. However, 
in class ‘benefit’ this combination is not superior to bortezomib alone (HR = /.'[, '[% 
CI /.[) – -.[[, p = /.)+), suggesting the addition of lenalidomide is not beneficial if the 
patient already benefits from bortezomib treatment. This shows our signature is also 
relevant in treatment combinations and could guide when bortezomib alone is 















Table 2. Overview of the distribution of the combination of PI and lenalidomide 
treatment in the CoMMpass dataset 
  
  Class ‘benefit’ Class ‘no 
benefit’ 
Total 
Bor without Len [\ (\[.,%) .-' (\,.,%) .(. (\,.+%) 
Car without Len ) ([.+%) [- ().[%) [' ((.'%) 
Len without Car/Bor -/ (,.(%) +, ((.(%) [, ((.[%) 
BorLen [' (\'.,%) -'' (\\.\%) .[) (\+.[%) 
CarLen -( (--.+%) )/ (-\.+%) '((-\./%) 
No Car/Bor/Len . (-.\%) \ (/.[%) [ (/.(%) 
  -+' [') (+( 
 Bor= bortezomib (PI arm), Car = carfilzomib (PI arm), Len = lenalidomide 
 
Class ‘benefit’ cannot be characterized by known markers or models 
Next we assess whether class ‘benefit’ can be characterized by known markers. To this 
end we first performed enrichment analysis of the routinely measured chromosomal 
aberrations (FISH markers), ECOG performance status or revised International Staging 
System (ISS) score in both classes. None of these were overrepresented in either class 
‘benefit’ or ‘no benefit’ (Figure +f).  
 
Moreover, none of the markers have a predictive performance for PI benefit in the 
CoMMpass study that outperforms our signature (Supplementary figure ,). There 
have been extensive efforts to predict prognosis in MM using gene expression, for 
example with the GEP(/ signature (Chapman et al. ./-); Shaughnessy et al. .//(). We 
find no correlation between our score and the GEP(/ model (Supplementary figure 
/). While we observe that the GEP(/ low risk group in CoMMpass has more benefit 
form PI treatment (HR = /.[,, '[% CI /.\) - /.)+, p = /.//[), we do not see this effect 














signature can also still distinguish a benefit group (n = ),) within this low risk group in 
CoMMpass (HR benefit is /.\\, '[%CI /.-+ - /.(,, p = /.//'). 
Recently, a (-gene signature was published to distinguish standard and good response 
to bortezomib in the PADIMAC study (Chapman et al. ./-)); none of these genes 
overlap with our signature genes. When we assess the ability of our signature to predict 
bortezomib response in the PADIMAC study, we find an AUC of /.), (Supplementary 
Figure I), indicating that our signature is also capable of predicting response. 
Moreover, the (-gene signature is reported to only be applicable in a non-transplant 
setting, while our signature does not have this limitation.  
  
Selected genes and links between them are essential for performance 
In prognostic classification it is known that many different signatures with similar 
performance can be found (Ein-Dor et al. .//[). This casts doubt on the usefulness of 
biologically interpreting the genes within a signature. We thus first investigate whether 
the genes in our signature are essential for performance.  
  
We first permute the expression vector for each gene in the signature -// times (while 
the other -\ genes remain unchanged) and apply this signature to fold D of the HTT 
cohort. The largest effect is observed for DABGIP, with a mean difference in validation 
HR of /..' (se = /./,). Correlation between genes influence the decrease in 
performance: for instance, shuffling SHTNK has the smallest impact on validation 
performance and its expression is significantly correlated with more genes than any 
other gene (with TPDUGLK, NES and STVGALG, Supplementary figure J). Therefore, 
losing its information has less impact. Nevertheless, we demonstrate all individual 
genes are important for the validation performance, as none can be shuffled without 
decreasing performance (Figure ,a). 
  
Next, we assess the importance of the relationship between the genes by shuffling the 
edges between all genes included in the network ten times, while ensuring every gene 
remains linked to at least one other gene. We then infer a signature with STLsig, 
meaning a new combination of gene networks is selected to form the predictive 
signature. The mean HR found in the hold out data in class ‘benefit’ is /.(+ (se = /./[), 
which is approximately equal to the HR found in the dataset without classification. The 
connection between genes is thus essential for the performance of the signature. Lastly, 











we remove all -+ signature genes from the dataset and rerun STLsig. The new signature, 
which contains \-. genes from )[ gene networks, results in an HR of /.[, (p = /..\,  
 
'[% CI = /..\ - -.+-) in the training data, which is worse than the original signature. The 
performance on the patients in fold D, which requires optimizing a new zPFS threshold, 
also yields a worse performance (HR of /.['; p = /./,, '[% CI /.\+ - -./-; n=-\/ in the  
 
‘benefit’ class). Moreover, changing this threshold to yield a differently sized class 
‘benefit’ does not yield performances that approach that of the original -+-gene 
signature (Supplementary Figure K). Together, these results establish that the -+ 
identified genes are essential to the performance of the model. 
  
Multiple signature genes are associated with MM or proteasome inhibition 
Having established the genes in the signature are essential to the performance, we 
investigate how the genes in the signature may be involved in determining PI benefit. 
Interestingly, in addition to having the largest impact when its information is lost, 
DABGIP is also the only gene that is significantly differentially expressed between class 

























































































































































Figure 4. a. The decrease in performance (difference in HR) for i) shuffling of each 
gene separately, ii) shuffling links in the network and iii) when the 14 signature genes 
are excluded from the analysis. Error bars indicate standard error. b. Genes with a 
significant change in expression before and 48 hours after bortezomib treatment in 
only either class ‘benefit’ or ‘no benefit’. Bold genes have a significant difference in 
response between class ‘benefit’ and ‘no benefit’, determined empirically by testing 















mediated ER stress response and inducing apoptosis via the JNK pathway (Luo et al. 
.//)). Apoptosis induced by ER-stress is one of the main working mechanisms of 
proteasome inhibitors (Moreau et al. ./-.). 
  
While none of the other signature genes are differentially expressed between class 
benefit and no benefit, several genes do have a clear link to cancer or MM specifically. 
For instance, NES is a stem cell marker that is not found in healthy plasma cells, but is 
found specifically in MM (Svachova et al. ./-+). Moreover, NES has been associated 
with treatment response in MM. CLIP- is involved in microtubule-kinetochore 
attachment and plays a role in proper chromosome alignment during mitosis (Amin et 
al. ./-+) and has been associated with cancer progression and chemotherapy resistance 
(Sun et al. ./-.), though not in relation to MM. SNX' is described to play an important 
role in trafficking ADAM' to the cell surface (Mygind et al. ./-)). ADAMX is expressed 
in MM cells and induces IL, production by osteoblasts, potentially creating a more 
permissive bone marrow environment for MM cell proliferation (Karadag, Zhou, and 
Croucher .//,). One of the described working mechanisms of bortezomib is the 
downregulation of the production of IL-, in the bone marrow environment (Karadag, 
Zhou, and Croucher .//,; Roccaro et al. .//,). The gene TPDUGLK is a negative 
regulator of ATM (Chen et al. ./-\), which is involved in the DNA damage response and 
activated by bortezomib treatment (Hideshima et al. .//\). STVGALG has been 
described before to be significantly downregulated in carfilzomib-resistant cell lines 
(Zheng et al. ./-(). 
  
Together, this indicates that our signature is not only capable of predicting benefit but 
could also aid in understanding differential response to PI treatment. 
  
Different cellular response to bortezomib in class benefit 
For -+. patients in the HTT cohort tumor gene expression was measured again +) hours 
after receiving bortezomib. To investigate whether the cellular response to bortezomib 
is different for patients classified as ‘benefit’, we performed a differential expression 
analysis before and after treatment separately in class ‘benefit’ and class ‘no benefit’ 
using SAM (Tusher, Tibshirani, and Chu .//-). Because of the low number of patients 
in class ‘benefit’ for whom a second measurement is available, we relax our definition of 
benefit and classify patients as ‘benefit’ if the calculated zPFS>/ (n = (-). We find -. 











genes that are significantly differentially expressed before and after treatment in class 
‘benefit’ but not in class ‘no benefit’. We also find two genes that are significantly 
differentially expressed only in class ‘no benefit’ (Figure ,b). To identify the genes that 
truly represent a different cellular response in class ‘benefit’ and ‘no benefit’, we 
compute the difference in fold change between both classes. To ensure that this is not 
a random difference, we also compute this difference for all genes using -/// random 
class labellings. We find four genes - TNSY, PXN, CGCDZA and PSPCK - where the 
difference between ‘benefit’ and ‘no benefit’ is larger than expected by random chance 
(p </./[ after Bonferroni correction for multiple testing). None of these genes have 
been linked to MM, though all have been connected to disease progression in other 
cancer types (Carter et al. ./-\; Wu et al. ./-/; Yao et al. ./-[; Yeh et al. ./-)). 
Interestingly, TNSY, PXN and PSPCK are all described to play a role in cell adhesion and 
a migratory phenotype (Yeh et al. ./-); Mouneimne and Brugge .//(). Cell adhesion 
mediated drug resistance (CAM-DR) has been described extensively in MM (Damiano 
et al. -'''; Landowski et al. .//\; Damiano and Dalton .///). Moreover, it has been 
suggested that bortezomib can overcome CAM-DR (Hatano et al. .//'; Yanamandra 
.//,). A different regulation of cell adhesion in class ‘benefit’ could play a role in the 




In this work we propose STLsig, a method to identify interpretable signatures that 
robustly predict patient benefit to PIs from a gene expression measurement at time of 
diagnosis. The -+ gene signature, derived with our method, validates on an independent 
patient cohort which was moreover measured on a different platform, confirming the 
robust nature of the signature. 
  
A clinical trial setting is most suitable for training the STLsig model. Here treatment is 
randomized and each treatment arm contains roughly the same number of patients. 
This is important for calculating zPFS and training the signature, as it ensures each 
patient has sufficiently similar neighbours in the gene expression space. Once the 
signature is trained, it can be validated on a less balanced dataset. We therefore used 
the HTT cohort as training data, rather than the newer CoMMpass dataset. It should be 














representative of clinical practice; since sufficiently long follow up is needed to train a 
model, we necessarily train on older data. Recently, it was shown that daratumumab, 
combined with bortezomib, thalidomide and dexamethasone (VTd), is superior to VTd 
(Moreau et al. ./-'). This will arguably be the new standard, but since daratumumab is 
relatively new, suitable gene expression datasets are not available. It is clear that PIs 
continue to play an important role in MM treatment. In the CoMMpass dataset, we 
show that the performance of our signature remains stable in different treatment 
combinations and that - while it was trained on bortezomib - also can predict benefit to 
carfilzomib. Moreover, we show that the addition of lenalidomide to bortezomib based 
treatment only leads to better survival in the ‘no benefit’ group. This establishes our 
model is also relevant in a more modern, chemotherapy free setting. We also 
demonstrate our signature can be applied to patients for which the expression profiling 
was performed using RNAseq, demonstrating cross-platform robustness. 
  
We have only considered gene expression patterns in this research since it has been 
shown that for classifiers aimed at predicting cancer survival, gene expression captures 
the majority of the signal (Aben et al., ./-)). More specific to MM, Chapman et al found 
bortezomib response could not be reliably predicted from mutation events (Chapman 
et al. ./-)). The mutational landscape in MM is quite sparse and we find no difference 
in mutation burden or in the specific genes that are mutated between class ‘benefit’ and 
‘no benefit’ (Supplementary Figure L). We also do not see a difference between class 
‘benefit’ and ‘no benefit’ in the ,\ driver genes that were recently identified (Walker et 
al. ./-)) (Supplementary Figure 4M). While MM is a very complex disease and this 
complexity can most likely not be captured in only two groups differentiated by gene 
expression patterns, the signature identified can aid in optimal treatment selection and 
thus has direct clinical applicability. 
  
Several of the genes in the signature are already described to be involved in the 
proteasome system or disease progression in MM and we show these genes are essential 
for the predictive performance, as no equivalent signature can be found without them. 
These findings reinforce the importance of the selected genes and indicate the power of 
STLsig to further elucidate proteasome inhibitor specific mechanisms. 
  











STLsig can readily be applied to other diseases and drugs. A very potent application 
could be to perform post-hoc analysis of clinical trial data for drugs which missed their 
endpoint. Such analysis could reveal a subset of patients who would still benefit from 
the drug, thus potentially extracting valuable information from failed clinical trials. 
  
Taken together, we provide a powerful machine learning approach to aid in treatment 
decisions in the clinic, ensuring a more optimal treatment choice and ultimately 
improve patient outcomes. 
  
Availability of data and material 
The datasets supporting the conclusions of this article are available on GEO. Gene 
expression data from the HOVON-,[/GMMG-HD+ study is available at GSE-'()+ 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE-'()+). Gene expression 
data from both Total Therapy . and Total Therapy \ are available at GSE.,[) 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE.,[)) . \/ patients from 
the Total Therapy \ study used in the manuscript are not included in the GSE.,[) 
dataset, these can be found in ArrayExpress dataset E-TABM---\) 
(https://www.ebi.ac.uk/arrayexpress/experiments/E-TABM---\)/). The PFS survival 
data for all three studies are available at https://github.com/jubels/GESTURE, linked to 
the GEO and ArrayExpress IDs. All gene expression and survival data for the CoMMpass 
study is available at research.themmrf.org 
  
All code needed to discover and validate the signature is available at 
https://github.com/jubels/STLsig. All code requires R and is platform independent.  
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 Supplementary table 1 Log2 fold difference of signature genes between class 
‘benefit’ and ‘no benefit’ in fold D of the HTT cohort 
  
  
Mean log* fold 
difference p-value 
NEXN /..( /.-, 
DAB*IP -/.,[ /.//. 
CFAP/+ -/./, /.(. 
TPD/*L4 /../ /.\+ 
SHTN4 /.\) /./[ 
ZNF,L+ -/./-[ /.'[ 
NES /.-/ /.(( 
CLIP4 /..\ /.., 
LINCMM,K/ /.-[ /.+' 
STIGAL* /.., /.-+ 
EBF* -/.-+ /.++ 
LINCMMLL* /.-[ /.++ 
FA*H /./[ /.(+ 

















Supplementary table 2. Overview of the number of patients who received a form of 
chemotherapy 
  
  Class benefit Class no benefit Total 
Doxorubicin / (/%) + (/.(%) + (/.[%) 
Cyclophosphamide .) (-).)%) -,) (.).-%) -', (.,..%) 
Melphalan -. ().-%) ./ (-.(%) \. (+..%) 
Vincristine / / / 
 
  
Supplementary figure 1. tSNE of the datasets before and after batch correction 




















Supplementary figure 3. Kaplan Meier plot of the performance of the signature 
when patients who received chemotherapy are removed from the CoMMpass 
validation set.  

































PI, benefit (n = 98)
PI, no benefit (n = 360)
Other, benefit (n = 11)
Other, no benefit (n = 46)
HR class no benefit = 0.75, p = 0.15
HR class benefit = 0.5, p = 0.1

































Bortezomib, benefit (n = 18)
Bortezomib, no benefit (n = 155)
Dexamethasone, benefit (n = 7)
Dexamethasone, no benefit (n = 62)
HR class no benefit = 0.78, p = 0.15
HR class benefit = 0.31, p = 0.03
Supplementary figure 2. Kaplan Meier plot of the performance of the signature in 
the APEX study. 















Supplementary figure 4. Performance of several known markers in predicting 
benefit to PI treatment. The blue line represents the performance of our signature 
at different size class ‘benefit’, the red dotted line represents the HR as found in the 
dataset as a whole.  







































































Supplementary figure 6. ROC curve of the performance of our signature in the 
PADIMAC dataset and boxplot of the benefit score for good and standard 
responders. The red dotted line represents the cutoff for class ‘benefit’.  
Supplementary figure 7 The HR found in class ‘benefit’ using different cutoffs for 
zPFS, as predicted by the signature found when excluding the original 14 genes 
from the analysis. 























































































































































































































Supplementary figure 8. Correlation matrix of the Pearson correlation between the 
gene expression of the genes included in the signature, per gene network included 
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Predicting treatment benefit in data with low event rates and 


















Selecting the best treatment for each patient remains a challenge in cancer. We have 
previously developed the GESTURE algorithm, which is designed to predict whether a 
patient will benefit more from a treatment than an alternative using tumor gene 
expression. We here adapt it to deal with survival data with few events, to predict 
chemotherapy benefit in breast cancer. We show it can successfully identify a subgroup 
of patients who benefit more from chemotherapy than the population as a whole. 
Importantly we also identify a group who does not see a significant benefit from 
chemotherapy and can thus be spared the side effects. The classifier does not validate 
in other external data with a different patient composition and treatment regimen, 
highlighting the importance of matching the patient population included in the training 
and validation set, and by extension the intended use population.  
  













Personalized medicine has received increasing attention in cancer. However, selecting 
the best treatment for each patient remains a challenge in almost all cancer types, 
especially when treatments targeting a specific mutation are not available.  
We have previously developed GESTURE (Gene Expression-based Simulated Treatment 
Using similaRity between patiEnts), an algorithm that can predict treatment benefit 
using gene expression and survival data as input (Ubels et al. ./-)). We define 
treatment benefit as having a superior survival on the treatment of interest to the 
survival had this patient been given an alternative treatment. This is a challenging 
problem, as we can only observe the response to the treatment a patient actually 
received. Even when a patient did not experience a good outcome on a certain 
treatment, they may still have benefited, as their outcome may have been even worse 
on another treatment. In GESTURE we therefore implement the concept of Simulated 
Treatment Learning (STL). STL relies on the idea that a genetically similar patient who 
received a different treatment can be used to model the response to a treatment the 
patient did not receive. We need to define this similarity between patients with genes 
that are relevant to treatment benefit. In GESTURE we use many different gene sets 
based on Gene Ontology (GO) annotation to define similarity; we then build a classifier 
out of the gene sets that are most successful at identifying so-called prototype patients. 
These are patients who experience more benefit from the treatment than similar 
patients who did not receive the treatment; new patients who are similar to such a 
prototype are also expected to benefit from the treatment.  
 
We developed GESTURE and demonstrated its performance in Multiple Myeloma 
(MM), a type of plasma cell cancer. However, GESTURE is not specific to MM and can 
be applied to any dataset where gene expression, survival data and two treatment 
groups are available.  
 
With roughly -.( new million cases per year, breast cancer is the most common cancer 
for women and one of the leading causes of death in women worldwide (Sharma ./-'). 
Breast cancer was one of the first cancer types where gene expression was used to 
predict disease progression (Veer et al. .//.). Moreover, it was later shown in a 














which women can safely forego chemotherapy (Audeh et al. ./-'; Cardoso et al. ./-,). 
Breast cancer represents a good test case for applying GESTURE in a new disease, as it 
is known that information relevant to treatment choice is captured in the gene 
expression. While the MammaPrint was developed to predict [-year survival and was 
later found to be relevant to treatment benefit, GESTURE can train classifiers that are 
optimized to predict treatment benefit.  
 
While GESTURE is not specific to MM, the algorithm as is does not achieve a satisfactory 
performance on the breast cancer data. This may be expected, as there are certain key 
differences between the clinical reality of both diseases. MM is an incurable disease, 
with a median survival of [-, years (Rajkumar and Vincent Rajkumar ./-)). For breast 
cancer, the average [-year survival rate is '/% (SEER statistic). Because of this higher 
survival rate and thus lower number of events, we have to adapt the optimization 
criterion GESTURE uses for training classifiers. For clarity, from here on we call the 
adapted version GESTURE-BC. GESTURE defines the best classifier as the one that can 
identify a subset of patients - class ‘benefit’ - with the largest difference in survival 
between the two treatment arms, as defined by the hazard ratio (HR). However, in 
breast cancer a subset without any events in the treated arm can easily be identified. A 
better HR cannot be achieved, even if the other treatment arm also has very good 
survival. Applying GESTURE to breast cancer thus leads to a class ‘benefit’ where 
patients in both treatment arms survived well, and a class ‘no benefit’ (i.e. all patients 
not in class ‘benefit’) where we also find a significant HR in favor of the treatment 
(Supplementary figure -). Such a classifier cannot be used to aid in clinical decisions. 
We thus adjust the optimization criterion in GESTURE-BC to take both class ‘benefit’ 
and ‘no benefit’ into account, to arrive at a classifier that is clinically useful. 
 
Another consideration is that STL hinges on the idea that similar patients are present 
in both treatment arms. The ideal setting for training a treatment benefit classifier is 
thus a clinical trial, where treatment is randomized and similar patients are by 
definition included in both treatment arms. However, in practice suitable clinical trials 
data is rarely available and data from clinical practice has to be used. Breast cancer has 
been well characterized both by gene expression and receptors present on the cell 
surface. An important consideration in treating breast cancer is the presence or absence 
of estrogen receptors (ER), progesterone receptor (PR) and human epidermal growth 











factor receptor . (HER.). There are specific treatments targeting these and triple 
negative breast cancer (absence of all three receptors) carries the worst prognosis 
(Kaplan and Malmgren .//)). There are also treatment guidelines taking tumor size, 
lymph node status (i.e. whether cancer cells have infiltrated the lymph nodes) and cell 
differentiation into account (Waks and Winer ./-'). In breast cancer it is thus most 
likely not true both treatment arms contain similar patients. When we train in such a 
cohort, it is likely the signal captured in the classifier is then specific to the setting where 
the data was gathered. For example, if only node positive patients received 
chemotherapy, the classifier cannot train on chemotherapy benefit for node negative 
patients. This classifier will then probably not generalize to a wider breast cancer patient 
population, where patients with other characteristics did receive chemotherapy.  
 
When clinical trials are impossible or simply not (yet) available, one could potentially 
still leverage datasets with non-random treatment groups by computationally matching 
the patients characteristics between the two groups. A possible approach is the 
matching of patients to break the link between certain patient characteristics and the 
treatment variable, so the model fitted is not influenced by these correlations (Ho et al. 
.//(). In this approach we use the relevant patient characteristics (i.e. age, tumor size 
and node status) to calculate the probability a patient received chemo. We then match 
patients from both treatment arms that have a similar probability. With perfect 
matching, there is then no longer a correlation between these variables and the 
treatment, so they will not bias the classifier. While perfect matching is often not 
possible, this approach can still reduce the bias.  
 
We here show GESTURE can be successfully adapted to fit the clinical reality of breast 
cancer and find a classifier that can predict chemotherapy benefit in cross-validation. 
We show its performance in ..(\ ER positive and ER treated patients from the Sweden 
Cancerome Analysis Network - Breast cancer cohort. Our classification cannot 
characterized by factors currently in the treatment guidelines and we thus identify a 
new group of patients with chemotherapy benefit. We also show that training a classifier 
on matched data improves performance on unmatched data from the same population. 
However, neither a classifier trained on unmatched nor on matched data could show 
performance in an unrelated, older cohort, highlighting the importance of matching 

















GESTURE relies on the idea that patients who received different treatments, but have 
similar tumor gene expression profiles, can be used to model the expected response to 
an alternative treatment than the one received. Patients with a larger than expected 
survival difference with similar patients who received a different treatment, can be used 
as prototype patients. New patients who have a similar gene expression profile to a 
prototype patient can then be expected to also benefit from that particular treatment. 
The process of defining similarity and identifying prototype patients has been described 
in detail before (Ubels et al. ./-)). Briefly, to identify prototype patients we first need 
to define similarity between all patients. Because it is unknown a priori which genes are 
relevant to treatment benefit and thus should be used to define this similarity, we use 
gene sets based on Gene Ontology (GO) annotation. We can then build a classifier based 
on each GO set separately and assess which gene set leads to the best performance. To 
build a classifier we divide the training data in three equal parts: fold A, fold B and fold 







where Si is the overall survival for the treated patient and O the set of the n nearest 
patients (based on Euclidean distance) who did not receive the treatment of interest. 
For all training we set the n to \/. We normalize this survival difference by also sampling 
n random neighbours a -/// times and calculating 𝛥𝑆%	, to select patients with a larger 
survival difference with their neighbours than expected randomly.  
The classifier then optimizes two variables on fold B: how many prototypes are used (k) 
and how close to a prototype a new patient should be to be considered class ‘benefit’ 
(𝜸).  
 
Previously, for the algorithm developed on MM data, the best classifier (representing 
one gene set) was defined as the classifier that resulted in the largest hazard ratio (HR) 
between the two treatment arms within class benefit. The HR in the class ‘no benefit’ 
(i.e. all patients not close to a prototype) was not taken into account. However, there 
are far fewer patients who experienced an event in the breast cancer dataset ('./% 











versus +)..%). Furthermore, there is already a large HR between the chemotherapy and 
no chemotherapy arm (HR = /.+[, p = [., * -/-,). When GESTURE only takes the HR 
in class ‘benefit’ into account when choosing the optimal values for k and 𝜸, it tends to 
define a class benefit with no events at all in the chemotherapy arm in the training 
procedure, since this leads to the best possible performance. However, this classifier is 
not useful in clinical practice, as we also find a large, significant HR in favor of 
chemotherapy in class ‘no benefit’ (Supplementary Figure 4 shows the cross-validated 
performance of this classifier).  
 
Therefore, we here define the best performance in GESTURE-BC as the minimum of 
𝛽)*"*+%,	 −	𝛽"-	)*"*+%,where the β is the coefficient for the treatment variable in each 
class as calculated by Cox regression. We then test the optimal classifier on fold C. The 
β’s found in fold C define the performance of this gene set in this repeat.  
Since there can be large differences in performance of a gene set when a different 
division in folds is used, we repeat the procedure +) times. We take the median 
performance over , repeats at a time and rank the gene sets, resulting in ) separate 
rankings (+)/,). The final ranking of the geneset is determined by its mean rank over 
these ) rankings. We found that this method leads to a more robust ranking than either 
taking the mean of the +) separate rankings or calculating the median performance over 
all repeats. Averaging the rankings, rather than the performance directly, reduces the 
impact of having a few extremely low HRs, while not disregarding them entirely. The 
whole algorithm is summarized in Figure 4.  
 
This final ranking of gene sets is used to perform forward feature selection; gene sets 
are added sequentially to form an ensemble classifier. For each repeat we evaluate the 
performance of this ensemble classifier on fold C; the combination leading to the largest 
median difference between class ‘benefit’ and ‘no benefit’ is selected. For these gene sets 
a final classifier is trained on all training data to validate on hold-out data.  
 
Data 
We train GESTURE-BC on data from the Sweden Cancerome Analysis Network - Breast 
cancer (SCAN-B) initiative (Saal et al. ./-[) (GEO accession: GSE',/[)). This study 
included women with breast cancer from centers around Sweden between ./-/ and 














randomized trial and this cohort thus represents current clinical practice. The publicly 
available data includes RNAseq for .',' patients, patient characteristics are 
summarized in Table 4. The majority of patients are ER positive. Since survival and 
treatment strategies differ significantly between these two groups, we exclude all ER 
negative patients and ER positive patients who did not receive ER treatment from the 
analysis, which results in ..(\ patients.  
 
The only other dataset available which includes the necessary patient information is 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) (Curtis 
et al. ./-.). This dataset includes -')- patients from the UK and Canada, diagnosed 
between -'(( and .//[, for whom gene expression was measured with Illumina array.  
 
Fold construction for cross validation 
We divide the SCAN-B dataset into three equal folds, ensuring the balance between 
chemotherapy and no chemotherapy is the same in each fold. Moreover, we ensure the 
HR between the treatment arms does not differ more than /./[ between the folds. The 






Figure 1. Summary of the training procedure for GESTURE in breast cancer 
(GESTURE-BC). First prototypes are identified and optimal parameters for the 
classifier are determined per gene set. The performance of the gene set is then 
defined on hold-out data by comparing the b’s found in class ‘benefit’ and ‘no 
benefit’. The gene sets are then ranked by mean rank over 8 repeats. The rank for 
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Age (years)    









Size (mm)    
Mean (SD) .-.' (-..,) -).[ (--.+) -'.' (-..\) 
Median [Min, 
Max] 
././ [/, -.[] -[./ [-.//, -.,] -(./ [/, -.,] 
Missing .( (..\%) [ (/.\%) \. (-.-%) 
Positive nodes    
No [++ (+[.(%) -.[+ ((-.\%) -)-, (,-..%) 
Yes ,-. ([-.+%) +[/ (.[.,%) -/,+ (\[.)%) 
Missing \+ (..'%) [[ (\.-%) )' (\./%) 
ER    
Negative -,( (-+./%) +- (..\%) .-+ ((..%) 
Positive ))[ ((+.+%) -,(\ ('[.-%) .[,' (),.[%) 
Missing -\) (--.,%) +[ (..,%) -), (,.\%) 
HER*    
Negative )+/ ((/.,%) -,\\ ('..)%) .+'/ ()\.'%) 
Positive \/' (.,./%) ,( (\.)%) \() (-..(%) 
Missing +- (\.+%) [' (\.+%) -/- (\.+%) 
PGR    
Negative .-( (-)..%) -.+ ((./%) \+( (--.(%) 
Positive ()[ (,,./%) -[-+ (),.-%) .\-/ (((.)%) 
















Matching patients between treatment arms  
We calculate a propensity score for receiving chemotherapy for each patient using 
logistic regression with 𝑐ℎ𝑒𝑚𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦	 ∼ 𝑎𝑔𝑒	 + 	𝑛𝑜𝑑𝑒	𝑠𝑡𝑎𝑡𝑢𝑠	 + 	𝑡𝑢𝑚𝑜𝑟	𝑠𝑖𝑧𝑒. All 
patients with missing values for one of these variables are excluded. We also exclude all 
patients older than )., as there are no older patients in the chemotherapy arm. Based 
on the propensity score, we match each chemotherapy treated patient to one untreated 
patient. These pairs are chosen so total distance between all the pairs is minimized. This 
is implemented in the R matchIt package, using the “optimal” setting (Ho et al. ./--)  
 
Construction of gene sets 
We only use genes measured in both the SCAN-B and the METABRIC dataset, which 
results in -,,()' unique genes. We define GO sets with the R package goSTAG (Bennett 
and Bushel ./-() and keep all sets which included more than one and less than a 
thousand genes, which results in ',[() gene sets. We use the FPKM values for SCAN-B 
and the log. normalized data from METABRIC. We then perform a batch correction 
with ComBat (Johnson, Li, and Rabinovic .//(), with METABRIC and SCAN-B as the 
batches. We then perform a quantile normalization, so measurements from both 




Cross-validation on SCAN-B leads to a significant HR in class benefit 
We perform \-fold cross validation on the SCAN-B dataset. In the dataset as a whole an 
HR of /.+[ (p = ,*-/-&) in favor of chemotherapy is found (Figure *a). When we classify 
the population with the GESTURE-BC classifier we find a class ‘benefit’ comprising 
(/..% of the dataset with an HR of /.\- (p = ,*-/-') in favor of chemotherapy (Figure 
*b). The HR in class ‘no benefit’ (n =,)[) is /.)' (p = /.,(). This performance is fairly 
stable across the three cross validation folds. In Fold - (+.\% of the patients are classified 
as ‘benefit’, which results in an HR of /.\- (p = /.///[) in class ‘benefit’ and an HR of 
-.+, (p = /.[/) in class ‘no benefit’. The classifier validated on Fold ., classifies [[..% of 
the patients as ‘benefit’, which results in an HR of /..( (p = /.//() in class ‘benefit’ and 
an HR of /.(+ (p = /.+[) in class ‘no benefit’. The Fold \ classifier classifies )-./% of 
patients as ‘benefit’, which results in an HR of /.\. (p = /./-) in class ‘benefit’ and an 
HR of /.(+ (p = /.[+) in class ‘no benefit’. The Kaplan Meiers of these classifications are 











shown in Supplementary Figure *. The classifiers validated on Fold -, Fold . and Fold 
\ use -/, \- and ,+ gene sets respectively.  
 
The ensemble classifier is formed by classifying all patients with each gene set 
separately. The benefit score of a patient is then defined by the number of gene sets that 
classify the patient as ‘benefit’. To define the final class ‘benefit’ a threshold t is set, 
where a patient is classified as class ‘benefit’ when their benefit score is above the 
threshold. This threshold t is optimized by the difference in β between the classes, with 
the constraint that both classes contain at least ./% of the patients and the HR in class 
‘benefit’ is significant at p < /./[. There is a trade-off between class size and HR in 
setting t.  
 
When we vary the threshold determining class ‘benefit’ we find that a smaller class 
‘benefit’ is associated with a lower HR (Figure *c), since a higher threshold requires the 
classifier to be more confident about the classification (i.e. more individual gene sets 
need to classify the patient as ‘benefit’). This shows the performance is not dependent 
on one specific threshold, but a high score also means more benefit.  
 
GESTURE-BC classification is not characterized by known chemotherapy predictors  
There are already many factors known to influence chemotherapy benefit. We first 
compare our classification with that of the MammaPrint. It has been shown that 
patients who are predicted to have a good prognosis by the MammaPrint can safely 
forego chemotherapy, i.e. see no benefit from it. The MammaPrint signature included 
(/ probes that code for [, unique genes, which we can all match to a gene measured in 
the SCAN-B dataset. When we apply the MammaPrint to the SCAN-B dataset we do 
find a prognostic effect (HR poor prognosis = -.,(, '[% CI -.-\ - ..+,, p = /./-), but we 
do not see a predictive effect (Supplementary Figure *). This could be due to the fact 
that the population in SCAN-B was in part already treated in accordance with this risk 
classification: +..)% of the poor prognosis group received chemotherapy, versus just 
-[.[% of the good prognosis group. For only ,[.\% patients the classification of our 
classifier and MammaPrint overlap, which is according to statistical expectation given 
a class ‘benefit’ comprising (/.-% of the patients. Our classifier clearly identifies a 




















































































































Chemo, benefit (n = 60)
Chemo, no benefit (n = 36)
No chemo, benefit (n = 473)
No Chemo, no benefit (n = 234)
HR class benefit = 0.32, p = 0.05
HR class no benefit = 0.66, p = 0.42


























Chemo, benefit (n = 73)
Chemo, no benefit (n = 23)
No chemo, benefit (n = 515)
No Chemo, no benefit (n = 192)
HR class benefit = 0.28, p = 0.03
HR class no benefit = 0.85, p = 0.75
a.
b. c.
Figure 3. a. Overview of the difference in patient characteristics between the two 
treatment groups, in all data and in the matched dataset. b. Kaplan Meier of the 
performance of the classifiers trained on all data on the SCAN-B hold out data. c. 
Kaplan Meier of the performance of the classifier trained on matched data on the 
SCAN-B hold out data.  
 






























HR  = 0.88, p = 0.4
Chemo (n = 850)
No Chemo(n = 1446)






























Chemo, benefit (n = 629)
Chemo, no benefit (n = 221)
No chemo, benefit (n = 982)
No Chemo, no benefit (n = 464)
HR class benefit = 0.31, p = 6*10
HR class no benefit = 0.89, p = 0.67



























Figure 2. a. Kaplan Meier of the SCAN-B dataset, only including ER positive and 
ER treated patients. b. Kaplan Meier of the cross-validated performance of the 
GESTURE classifiers. c. Performance of the GESTURE classifiers using varying 
thresholds to define class ‘benefit’. The dotted line represents the HR found in the 
dataset as a whole.  
 











chemotherapy benefit rather than prognosis and the fact that most patients were 
already treated according to their MammaPrint classification.  
 
Tumor characteristics like tumor grade, tumor size and lymph node status are also 
included in treatment guidelines. Tumor grade information is not available for the 
SCAN-B dataset, but tumor size and lymph node status is included. While tumor size is 
significantly greater in the chemotherapy treated group (p = +*-/-'), this is not the case 
between class ‘benefit’ and ‘no benefit’ (p = /.'().  
 
The same holds true for lymph node status, with the percentage of lymph node positive 
patients similar in class ‘benefit’ and ‘no benefit’ (+/.)% versus \,.[%). This shows our 
classifier does not identify patients according to known risk factors and adds new 
information that can be used clinically.  
 
Classifier on matched data results in a better performance in unseen data  
As seen in Table 4, patient characteristics vary between the treated and untreated 
patients, which may impede GESTURE-BC from finding the right predictive signal for 
predicting treatment benefit. To mitigate this issue, we created a matched population 
where the difference between the treatment arms is minimized. To this end, we 
calculate a propensity score per patient that describes the probability of receiving 
chemotherapy given the age, tumor size and node status of the patient. We then match 
each treated patient to an untreated patient minimizing the difference in this score over 
all patients pairs. Figure +a shows the distribution of the characteristics in the data 
before and after matching. It can be observed that the difference in tumor 
characteristics cannot be fully equalized with the matching procedure. However, the 
difference in likelihood of receiving chemotherapy is much smaller in between the two 
matched groups. The HR in favor of chemotherapy in the matched dataset is /.)[ (p = 
/.+'), which is much higher than in the dataset as whole. In total )/\ patients are not 
included in the matched dataset. These patient samples are used to compare the 
performance of the cross validated classifiers and the matched classifier. These )/\ 
patients are not matched on patient characteristics and thus represent a better test case 
for performance in a clinical setting, where treatment is non-randomized. While the 
classifiers trained on all data do find a class ‘benefit’ with a larger benefit from 














matched classifier performs better (Figure +c), particularly in identifying a class ‘no 
benefit’. This shows matching a population to simulate a more randomized setting 
could improve performance, even when validating in a non-matched setting.  
 
GESTURE-BC classifier cannot identify a class ‘benefit’ in METABRIC data  
We next assess the performance of the classifier trained on the matched dataset in the 
ER positive en ER treated patients included in the METABRIC data. Most patients in 
this dataset were diagnosed before ./// and thus represent a different clinical reality. 
Moreover, only -../% of patients received chemotherapy and we find an HR of -.[( ('[ 
% CI -.-, - ..-\, p= /.//\) against giving chemotherapy. When we classify these patients 
with the GESTURE classifier, we find an opposite effect, where class ‘no benefit’ in fact 
sees a greater benefit than the population as a whole (Figure ,a). Since there are only 
.- patients in the no benefit class who received chemotherapy this HR is, however, not 
significant and could therefore be due to chance. Interestingly, when we train a classifier 
on METABRIC - matched in a similar manner as with SCAN-B - we see the same effect, 
with a lower HR in class ‘no benefit’ (Figure ,b). Unfortunately, the METABRIC dataset 
does not include enough chemotherapy patients to perform a cross validation. It is clear 
however that the SCAN-B classifier does not validate in the METABRIC dataset. While 
this could be due to overfitting on the SCAN-B dataset, cross validation did show some 
signal was captured in the classifier. It could also be that the METABRIC dataset, where 
an HR not in favor of chemotherapy is found, represents a different population in part 
due to the fact that these patients were included when clinical practise was different.  
 
HAND2 is present in all classifiers  
Finally, we investigate which genes are included in all four classifiers trained on the 
SCAN-B (three classifiers from cross validation and one trained on the matched data). 
Of the selected GO categories none are selected in all four classifiers. Also, there is little 
overlap among the genes within the GO categories selected (Figure ,c). The only gene 
present in all three classifiers trained in cross validation and the classifier trained on the 
matched data is HAND.. HAND. is also present in the classifier trained on the 
METABRIC data. This gene plays an important role in limb development and is 
associated with progression in endometrial cancer (Jones et al. ./-\), but has not been 
associated with breast cancer. It should be noted that the classifier validated on Fold - 
in the cross validation only included -/ gene sets and \[ genes in total, making overlap 










 less likely. The other three classifiers include .. overlapping genes (including HAND-), 
which are shown in Figure ,d. The network was generated by GeneMania, which links 
genes based on the interaction described in literature (Warde-Farley et al. ./-/). The 
network is highly enriched for the GO categories “RNA polymerase II core promoter 
sequence-specific DNA binding transcription factor activity” and “sequence specific 
DNA binding”, both important for the regulation of gene expression. Multiple of these 
.. genes have also already been implicated in disease progression and chemotherapy 
resistance in breast cancer. For example, overexpression of the transcription factor KLFZ 
has been shown to be predictive of complete remission in response to neoadjuvant 
chemotherapy (Dong et al. ./-+). Gas, overexpression has been described to contribute 
Figure 4. a. Kaplan Meier of the performance of the classifier trained on matched 
SCAN-B in the METABRIC dataset. b. Kaplan Meier of the performance of the 
classifier trained on the matched METABRIC dataset on the SCAN-B dataset. c. 
Overlap of genes between the four classifiers trained on the SCAN-B dataset. d. 
The overlapping genes in 3 out of 4 classifiers. The edges are inferred by 
GeneMania. A purple edge indicates co-expression, a green edge a genetic 
interaction, a light-blue edge a shared pathway, a dark-blue co-localization, a red 


















































Chemo, benefit (n = 108)
Chemo, no benefit (n = 21)
No chemo, benefit (n = 794)
No Chemo, no benefit (n = 155)
HR class benefit = 1.83, p = 2*10














































Chemo, benefit (n = 530)
Chemo, no benefit (n = 301)
No chemo, benefit (n = 1074)
No Chemo, no benefit (n = 368)
HR class benefit = 0.56, p = 0.01















to chemoresistance (Wang et al. ./-,). SOX+ and SOX-- are both related to disease 
progression in breast cancer (Zhang et al. ./-.; Shepherd et al. ./-,). While these .. 
genes are not essential for performance - as they were not included in the classifier 




In this work, we show that the GESTURE approach, which we originally developed in 
the context of MM in which survival rates are poor, can successfully be adapted to breast 
cancer, which is characterized by much better survival rates. Our classifiers, which in 
total are based on -/- gene sets containing \,) unique genes, can predict chemotherapy 
benefit with an HR of /.\- (p = ,*-/-') in class ‘benefit’. The classifier represents a 
different signal than known markers. We also show that though treatment is not 
randomized in the SCAN-B dataset, the performance of the classifier in non-
randomized data can be improved by matching patients between the treatment arms in 
the training data.  
 
We find that when applied to an external dataset, the METABRIC dataset, the classifier 
does not show the same predictive behavior. However, it should be noted that the fact 
that there is no HR in favor of chemotherapy in this dataset already indicates it does 
not represent the same patient population and clinical setting. More specifically, the 
patients included in the METABRIC dataset were diagnosed roughly -[ years before the 
SCAN-B dataset and thus do not represent the same clinical practice. It may therefore 
not be surprising that a classifier trained on one of the two datasets does not validate 
on the other. This does highlight the necessity of training and validating in datasets that 
accurately reflect the patient population for which the classifier is intended. It 
represents a fundamental challenge in training these models; while the older dataset 
has longer follow-up, more events and thus more statistical power, the newer data most 
likely represents the intended use population better. The development of these models 
is further hampered by the limited number of datasets with all necessary annotations 
that are made available publicly.  
 
While further validation in a representative test set is necessary, the cross validation 
and validation of the classifier trained on matched data does indicate that GESTURE 











can be successfully adapted to breast cancer data and predict benefit to chemotherapy. 
GESTURE is thus more widely applicable than the setting it was developed in and can 
be adapted to different diseases. It could be an important tool in making personalized 




















































































Chemo, benefit (n = 83)
Chemo, no benefit (n = 201)
No chemo, benefit (n = 199)
No Chemo, no benefit (n = 282)
HR class benefit = 0.28, p = 0.23
HR class no benefit = 0.43, p = 0.01
Supplementary figure 1. Performance of the unadapted GESTURE algorithm in 
Fold 1.  













































Chemo, poor prognosis (n = 774)
Chemo, good prognosis (n = 76)
No chemo,poor prognosis (n = 1031)
No Chemo, good prognosis (n = 415)
HR poor prognosis = 0.43, p = 0
HR class good prognosis = 0, p = 1
Supplementary figure 2. Classification of the SCAN-B dataset with the 
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RAINFOREST: A random forest approach to predict 

















When phase III clinical drug trials fail their end-point, enormous resources are wasted. 
Moreover, even if a clinical trial demonstrates a significant benefit, the observed effects 
are often rather small and may not outweigh the side effects of the drug. Therefore, 
there is a great clinical need for methods to identify genetic markers that can identify 
subgroups of patients which are likely to benefit from treatment as this may i) rescue 
failed clinical trials and/or ii) identify subgroups of patients which benefit more than 
the population as a whole. When single genetic biomarkers cannot be found, machine 
learning approaches that find multivariate signatures are required. In the context of 
SNP profiles this is extremely challenging owing to the high dimensionality of the data. 
Here we introduce RAINFOREST (tReAtment benefIt prediction using raNdom 
FOREST), an adaptation of the random forest that can predict treatment benefit from 
patient SNP profiles obtained in a clinical trial setting. 
 
We demonstrate the performance of RAINFOREST on the CAIRO. dataset, a phase III 
clinical trial which tested the benefit of cetuximab treatment for metastatic colorectal 
cancer. While this trial concluded there was no benefit, we find that RAINFOREST is 
able to identify a subgroup comprising .(.(% of the patients that significantly benefit 
from treatment with a hazard ratio of /.,' (p = /./+) in favor of cetuximab. The method 
is not specific to colorectal cancer and could aid in reanalysis of phase III clinical trial 
data and provide a more personalized approach to cancer treatment, also for drugs 
where there is no clear link between a single variant and treatment benefit. 
  













Novel drugs are tested for efficacy in phase \ clinical trials. Despite enormous 
investments in the development and research prior to the trial, approximately [+% of 
the phase \ clinical trials still fail, most often due to a lack of efficacy of the drug tested 
(Hwang et al. ./-,). Trials testing anti-cancer drugs have a higher failure rate than non-
cancer drug trials. It was found that trials which adopt a biomarker strategy, i.e. attempt 
to identify a subset of patients most likely to benefit, have a significantly lower failure 
rate (Jardim et al. ./-(). This is also true for trials evaluating targeted drugs. It is thus 
clear that even if a clinical trial does not reach its predefined endpoint, there could still 
be a subset of patients that do see benefit from the drug. Moreover, even if a clinical 
trial does indicate statistically significant benefit, this benefit may in fact be quite 
modest and driven by a subset of patients that have a larger benefit from the drug. For 
this reason, the benefit for all patients may be insufficient to warrant prescription of a 
drug with very serious side effects. In such cases, it is important to establish which 
subset of patients benefit more than the population as a whole and develop tools that 
can predict such treatment benefit at the moment of diagnosis.  
 
It has become clear that the genetic background of both tumor and patient can 
influence drug response and several germline variants have been linked to the 
effectiveness of a number of drugs (anti-cancer and other). SNP panels enabling the use 
of these variants for personalized medicine are under active development (van der 
Wouden et al. ./-'). For instance, for several chemotherapies, its sensitivity or toxicity 
has been linked to specific single nucleotide polymorphisms (SNPs) (Panczyk ./-+; 
Sullivan et al. ./-+; Yin et al. ./-.). Despite this initial progress, for many drugs there 
is no clear relationship between response and a single variant or other simple molecular 
biomarker and more complex machine learning models are needed.  
A major challenge is that genome wide germline variation datasets are very high 
dimensional, often including -//- to -///-fold more features (SNPs) than samples 
(patients). As a result, machine learning models have a high risk of overtraining 
(Szymczak et al. .//'). One class of models, which has shown great promise in 
preventing overtraining in such situations, are Random Forests (RFs). Outside the 
cancer field, RFs have successfully been used to predict drug response using germline 














classifiers combining multiple decision trees. RFs are explicitly designed to prevent 
overtraining by using only a subset of the available training samples and randomly 
sampling a subset of the features at each split. Since the algorithm only has access to 
part of the dataset at a time, it is less likely to overtrain on the dataset as a whole, while 
predictive performance remains high due to the fact that many trees are combined in 
an ensemble. For instance, RFs have been successfully employed to predict optimal 
warfarin dose using genome wide germline variation data and shown to outperform 
alternative models (Cosgun, Limdi, and Duarte ./--).  
 
Traditional machine learning methods like RFs enable the discovery of models that 
predict sensitivity for one specific treatment, i.e. distinguish between poor and good 
responders within one homogeneous treatment group. However, owing to recent 
progress in drug development for most cancers there are different treatment options 
available. A clinically more relevant question is thus whether an individual patient will 
benefit more from one treatment than another. In this work, we therefore define 
treatment benefit as having a better survival outcome on the treatment of interest than 
an alternative treatment. The difference between these treatments, often expressed in 
terms of hazard ratio (HR), should furthermore be greater than the difference observed 
in the population as a whole.  
 
RFs have also been applied to survival analysis and used to identify (non-linear) 
prognostic factors in several cancer types, with modest success (Akai et al. ./-); 
Manilich et al. ./--). In essence, these random survival forests are similar to traditional 
RFs and also construct an ensemble classifier from individual decision trees, but the 
optimal split in these trees maximizes the survival difference between the two daughter 
nodes (Ishwaran et al. .//)). 
 
In order to predict treatment benefit as we have defined it, traditional machine learning 
methods are unsuitable. Traditional class labels required for training machine learning 
models are not available. After all, we cannot know how a patient would have responded 
to a treatment they did not receive, and therefore we cannot know a priori (and thus 
label) a patient as class ‘benefit’ or class ‘no benefit’. More specifically, a patient 
responding well to a certain treatment could have had an even better response on an 
alternative treatment. Conversely, a poor response does not necessarily mean the 











patient did not see any benefit from the treatment. This lack of training labels renders 
most regular machine learning approaches unsuitable. Likewise, survival analysis using 
random survival forests also does not solve the problem of a lack of training labels, as 
they simply aim to predict survival outcome instead of benefit to a certain treatment. 
An overview of the different aims of traditional machine learning, survival analysis and 
benefit prediction is provided in Figure 4a.  
 
The machine learning method we propose can directly derive a benefit prediction model 
from germline genetic data gathered in a clinical trial in which patients were randomly 
assigned to one of two different treatment arms. To this end we propose an alternative 
formulation of the traditional RF classifier, called RAINFOREST (tReAtment benefIt 
prediction using raNdom FOREST). RAINFOREST implements the SurvDiff measure as 
an alternative to the Gini impurity, to decide on the best possible split in each decision 
tree. SurvDiff captures the survival difference between the treatment arms within a 
node. The SurvDiff measure enables training predictive decision trees by providing a 
split criterion which results in a ‘benefit’ and ‘no benefit’ branch in the tree. An overview 
of RAINFOREST and the SurvDiff measure is provided in Figure 4b.  
 
We apply RAINFOREST to the CAIRO.-trial, a randomized phase III clinical trial 
designed to test whether patients with metastatic colorectal cancer benefit from 
addition of the EGFR inhibitor cetuximab to standard first-line treatment. This trial 
showed that the addition of cetuximab to a regimen of chemotherapy and bevacizumab 
results in a significantly shorter progression free survival (Tol et al, .//'). However, it 
is known that cetuximab response varies widely between patients. Previously, several 
somatic mutations in the tumor that influence cetuximab response have been identified 
(Salvatore et al. ./-/; Khan et al. ./-(). Moreover, in the context of the CAIRO. trial a 
germline SNP was identified with the potential capability to predict treatment benefit 
(Pander et al. ./-[), although this variant was not validated.  
 
In this paper we demonstrate the capability of RAINFOREST on the CAIRO. trial. We 
show that RAINFOREST can identify a subset of patients with significant benefit from 
cetuximab and that this approach outperforms both univariate analysis and a random 

















Overview of RAINFOREST 
A random forest model is an ensemble classifier consisting of individual decision trees 
trained on different subsets of the training data. More specifically, each tree in the forest 
only has access to a subset of the samples (sampled with replacement) and for each split 
in the tree a random subset of the features is sampled.  
The optimization of each tree, i.e. choosing the optimal split for a node in the tree, is 
most often achieved by minimizing the Gini impurity. The Gini impurity is a measure 
of the probability that a sample would be incorrectly labeled in this split and is / when 
a node contains only samples with the same label. Problematically, in the context of 
predicting treatment benefit no predefined training labels are available, as we cannot 
know if a patient survived longer (or shorter) from treatment than on standard of care 
or some other treatment. We can therefore not use the Gini impurity for RF 
construction.  
 
Treatment effect is most often determined through a Cox proportional hazards model 
(see next section for more details), based on which a hazard ratio (HR) is calculated. 
The HR associated with a treatment provides an estimate of the hazard of experiencing 
progression of disease relative to the hazard when another treatment would be given. A 
HR below - indicates benefit from receiving the treatment. In the absence of training 
labels that can be used to calculate accuracy, we use the HR as performance measure 
when validating the RAINFOREST model in cross validation.  
Problematically, estimating a Cox model is too computationally expensive to be used in 
a splitting criterion when training thousands of decision trees. We therefore propose 
RAINFOREST, a random forest approach in which we introduce a novel splitting 
criterion that can be optimized to directly predict treatment benefit. For each sample, 
RAINFOREST requires treatment arm data, survival data and SNP data. Each decision 
tree should define a class ‘benefit’ and ‘no benefit’ which maximizes the difference 
between treatment effect. We define this difference through the splitting criterion 
SurvDiff: 
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Figure 1. a. An overview of the difference between traditional machine learning, 
survival analysis and benefit prediction. b. An overview of the RAINFOREST 
algorithm. The survival curves show examples of what a class ‘benefit’ and ‘no 
benefit’ should look like. We train 10,000 of these individual decision trees to form 
the RAINFOREST model, which is validated on ⅓ of the data that acts as test data 















where 𝑠𝑢𝑟𝑣𝐴.MMMMMMMMMM and 𝑠𝑢𝑟𝑣𝐵.MMMMMMMMMM are the mean survival data for treatment arm A and B in the 
left node of the split, respectively. Similarly, 𝑠𝑢𝑟𝑣𝐴/MMMMMMMMMM and 𝑠𝑢𝑟𝑣𝐵/MMMMMMMMMM are the equivalent in 
the right node. Moreover, 𝑛0and 𝑛1 denote the number of samples included in the node 
in treatment arm A and B, respectively. For each SNP under consideration we test two 
thresholds (SNP value >/ or >-) to define the left and right node. 𝑆𝑢𝑟𝑣𝐷𝑖𝑓𝑓thus 
corresponds to calculating the absolute difference between the Welch’s T-test statistics 
found in the left and right node. The best SNP is the one resulting in the maximum 
value of 𝑆𝑢𝑟𝑣𝐷𝑖𝑓𝑓.  
 
Using this criterion we train -/,/// decision trees. We further prevent overtraining by 
restricting every tree to a depth of two. This restricts the tree to a maximum number of 
four leaves (nodes without a child node) and means every tree uses at most three SNPs. 
When building a tree using SNP data, the RF can be biased towards choosing non-
informative SNPs with a high minor allele frequency over informative SNPs with a lower 
minor allele frequency (Boulesteix et al. ./-.). This bias is not very pronounced in the 
beginning of a tree, but can dramatically influence SNP selection lower in the tree, when 
smaller sample sizes are present. We therefore also only split a node further when it 
contains at least [/ patients. These restrictions also reduce computational cost. An 
overview of the construction of the RAINFOREST model is given in Figure 4. 
  
Survival analysis and event imputation 
Survival data is right censored, which means that all patients who did not experience 
progression of disease by the end of follow-up are censored, i.e. no event is recorded. 
Cox models can handle censored data by maximizing the partial log likelihood over 
coefficient 𝛽 through: 
 




where 𝜃! = 	𝑒𝑥𝑝(𝑋! ∗ 𝛽) and 𝑋 represents the explanatory variable, i.e. the treatment 
arm in this situation. When estimating the likelihood of an event occurring for subject 
i at a certain time t the 𝜃!is summed for every subject j that has not yet experienced an 
event at t. In this way censored patients can be included and used for optimization up 











to the time of censoring, instead of being excluded from the dataset all together. The 
HR is defined as the exponent of 𝛽.  
 
The SurvDiff measure does not rely on Cox models. Instead, RAINFOREST deals with 
the censoring problem by imputation. More specifically, for all censored patients an 
event time is imputed based on all patients for whom an event was observed as 
reference. To achieve this, a Weibull distribution is fitted to all uncensored patients 
through maximum likelihood estimation. The Weibull distribution can be used to 
adequately parametrize a survival distribution and can also - akin Cox regression - 
model proportional hazards (Carroll .//\). The cumulative distribution function of a 
Weibull distribution is described by  
 
𝐹(𝑥; 𝑘, 𝜆) = 1 −	𝑒.(8/:0) 
 
where 𝑥 is the time to event, 𝑘 is a shape parameter and 𝜆 is the scale parameter. In our 
dataset we find the maximum likelihood is reached with a value of --.'- for 𝜆 and -.,[ 
for k. Importantly, we find very similar parameters for the distribution when we perform 
a maximum likelihood estimation for each treatment arm separately, justifying an 
estimation over the whole dataset. This is in line with the observation in the original 
trial that there is no significant survival difference between the two treatment arms. For 
each censored patient we now sample an event time greater than the time of censoring 
from the estimated Weibull distribution. 
 
Data  
In this work the survival and genome wide genotype data from patients enrolled in the 
CAIRO. trial are used, which included patients in (' Dutch centers to test the addition 
of cetuximab for the treatment of metastatic colorectal cancers. The data generation 
and processing has been previously described in detail (Pander et al. ./-[). Briefly, we 
use survival data and germline DNA of [[\ patients who received treatment regimen 
CAPOX-B (capecitabine, oxaliplatin and bevacizumab) with cetuximab (n = .(+) or 
without cetuximab (n = .(').  
DNA was isolated from peripheral leukocytes and genome wide genotyping was 
performed with Illumina beadchip arrays. Of all measured variants ,+(,[[/ passed all 














SNPs with a minor allele frequency <[% and SNPs with any missing data, after which 
.[(,//) SNPs remain. Each SNP is coded as /,-, or ., corresponding to the number of 
copies of the alternative allele. We use progression free survival (PFS) as the end point 
in all analyses. 
 
Univariate SNP analysis  
To evaluate the ability of individual SNPs to predict cetuximab benefit, we compute two 
Cox proportional hazard models per SNP. First, we compute an additive model which 
contains the SNP and treatment arm as separate variables. The second model also 
includes an interaction term between the SNP and treatment arm (i.e. treatment 
arm*SNP). For a SNP that influences treatment benefit, this second model should 
provide a better fit. We test whether there is a significant difference in model fit using 
a likelihood ratio test. We rank SNPs on most significant contribution of the interaction 
term to the model, as measured by the likelihood ratio test p-value. With the best SNPs 







Where X is the alternative allele count for a certain SNP i and 𝛽 the Cox regression 
coefficient associated with the interaction term. We perform forward feature selection 
to determine the best SNP combination by ranking the SNPs on p-value and adding the 
top .[/ in order. The SNP combination resulting in the lowest HR in class ‘benefit’ is 
chosen. We validate this model in a three-fold cross validation.  
  
Random forest using survival-derived labels  
We compare the performance of RAINFOREST to the results obtained by a regular RF 
trained on the survival labels directly (which, as discussed previously, is not necessarily 
the best measure for treatment benefit). To obtain a labeled dataset, required for 
training a regular RF, we define the class ‘benefit’ as the patients with the .[% best 
progression free survival from the cetuximab arm combined with the patients with the 
.[% worst progression free survival from the other arm. The other ([% of patients 
comprise class ‘no benefit’. With these labels we define a class benefit that has a 











significantly better survival on cetuximab than the rest of the population, satisfying our 
definition of treatment benefit.  
 
Cross validation fold construction 
To evaluate the performance of univariate SNP selection, the regular RF and the 
RAINFOREST models, we employ \-fold cross validation. To ensure the results are 
directly comparable, we use the same folds for all analyses. To obtain a fair estimation 
of the performance, it is important that the different folds are stratified, i.e. contain a 
similar and representative part of the whole dataset. Here we cannot balance the folds 
using training labels, as these are not available. To ensure the cross validation folds are 
representative, we therefore balance on treatment arm. Furthermore, we require that 
the HR found between the treatment arms does not differ more than /./[ between all 
three folds.  
 
Optimization of mtry parameter  
RFs often use an out-of-bag (OOB) error to optimize model parameters. Since in an RF 
model each tree samples a different subset of the patients, each training sample is not 
used in a number of trees. The OOB error is determined by classifying each training 
sample, using only the trees in which a particular sample was not included. However, 
the OOB error can severely underestimate performance when random sampling is 
performed from unbalanced classes (Mitchell ./--). As we do not know the labels here, 
representative sampling is impossible. Using random sampling we indeed see that the 
OOB performance, defined as the HR between treatment arms in class ‘benefit’, is close 
to random (HR class ‘benefit’ in OOB sample is -.+[ ('[% CI /.'+ - ...,, p =/.-/)).  
 
As we cannot obtain a realistic estimation of the performance from the OOB sample in 
RAINFOREST, we cannot optimize the mtry parameter which defines how many 
features are sampled at every split. However, previous work suggests that the best mtry 
is linked to dataset dimensionality (Goldstein et al. ./-/). The RF trained on survival 
labels uses the same features as RAINFOREST. In training this RF we try several settings 
for mtry (√𝑝, .√𝑝, /.-p and /..p). For training RAINFOREST we use the same mtry 

















T-test in SurvDiff criterion captures survival difference  
We first assess whether the T-test on the imputed survival data, which is used in the 
SurvDiff splitting criterion, captures the same signal as Cox regression would capture, 
to ensure this is a suitable measure to use during training of the RAINFOREST model. 
For each SNP we perform a T-test for both the reference and alternative allele, 
contrasting the difference in imputed survival between the two treatment arms. We 
compare the resulting T-test statistic to the equivalent Cox regression 𝛽 (Figure *a). 
We find these measures to be highly correlated for both the reference allele (Spearman 
correlation coefficient = /.'[, p < .*-/-(&) and the alternative allele (Spearman 
correlation coefficient = /.'+, p < .*-/-(&). Importantly, this approach reduces compute 
time by one order of magnitude (\+.+- minutes for the Cox regression computation 
versus -.)' for the T-test on a single core). Thus, the T-test approach captures a similar 
signal as a full survival analysis while keeping it computationally feasible to train a 
model with thousands of trees.  
 
RAINFOREST can identify patients benefiting from cetuximab 
We next trained RAINFOREST to predict cetuximab benefit on the CAIRO. trial data 
and validate its performance in a three-fold cross validation. Figure *b shows the 
survival curves in the dataset as a whole, without any classification. Here we find an HR 
of -.-- ('[%CI /.'\ – -\\, p = /..[) for cetuximab treatment. Figure *c shows the 
different HRs found in class ‘benefit’ when using different operating points of the 
classifier (i.e. different thresholds on the number of trees classifying a sample as 
‘benefit’). This curve indicates a direct relationship between the operating point and the 
HR found in class ‘benefit’ - we find a lower HR when the threshold is set higher. As no 
sample has a posterior probability higher than /.[, we cannot use a majority vote to 
assign a sample to class ‘benefit’ or ‘no benefit’. The threshold set provides a trade-off 
between the size of class ‘benefit’ and the HR found. Figure *d shows the Kaplan Meier 
plot when the classification threshold that results in the lowest p-value in class ‘benefit’ 
is used. Importantly, all thresholds classifying [/% or less of the patients as ‘benefit’ 
result in an HR below - and would thus provide benefit. We show the combined results 
across the three cross validation folds, i.e. the predictions for each patient is based on 
the two folds in which this patient was not present. In class ‘benefit’ (n = -[\) we find a  
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HR = 1.11, p = 0.25 
HR benefit = 0.69, p = 0.04
HR no benefit = 1.32, p = 0.01
c. d.
Figure 2. a. Scatterplot of the T-test statistic and Cox regression coefficient per 
SNP. We perform this analysis once using the reference allele to define class 
‘benefit’ and once using the alternative allele. b. Kaplan Meier of the CAIRO2 
survival data used, showing no survival benefit for the patients who received 
cetuximab. c. The HR found in class ‘benefit’ when using different threshold on the 
posterior probability to define benefit. The red dashed line shows the HR between 
treatments found in the dataset as a whole, without any classification. d. Kaplan 
Meier of the classification in class ‘benefit’ and ‘no benefit’ using the posterior 
















significant HR of /.,' ('[% CI /.+' - /.'), p = /./+) whereas in class ‘no benefit’ (n = 
+//) an HR of -.\. ('[% CI -./( - -.,., p = /./-) is found. This performance is relatively 
stable in all cross validation folds. More specifically, we find an HR of /.,, (/.\\ - -./\, 
p = /..\) in class ‘benefit’ in Fold -, an HR of /.(. (/.+/ - -.\-, p = /..)) in Fold ., and 
an HR of /.,- (/.++ - -./', p = /.-/) in Fold \. While the original trial concluded addition 
of cetuximab to the standard regimen has no benefit, this result shows RAINFOREST 
can successfully identify a subset of patients, comprising .(.(% of the population, that 
do benefit from cetuximab.  
 
Known and new SNPs are identified in frequently chosen SNPs 
Over the three cross validation folds in total [-,-[+ unique SNPs are used (-','-), -',')., 
and -',)-/ in the models validated on Fold -, . and \ respectively). Figure +b shows the 
number of SNPs overlapping between the three different models. We obtain an 
empirical p-value for this overlap by randomly sampling -/,/// trees for each fold and 
computing the overlap. We find the overlap of ()- SNPs between the three folds to be 
significant (p < -*-/-"). We also train a RAINFOREST model using shuffled treatment 
labels with the same cross validation folds. With shuffled labels the association between 
genomic data and treatment specific outcome is removed and these models can indeed 
not predict benefit in hold-out data (HR class benefit = /.'[, '[% CI /.,+ - -.+-, p = /.)). 
Between the models trained on shuffled labels only \[, SNPs overlap, which is similar 
to mean overlap found in random sampling (mean overlap = \++.(). The overlap found 
in the RAINFOREST model is thus clearly non-random.  
Figure +a shows the number of times each individual SNP is selected across the three 
cross validation folds. Interestingly, the SNP selected most often, rs))[/\,, has been 
reported before to predict cetuximab benefit in a univariate analysis of the CAIRO. trial 
(Pander et al. ./-[). This shows that when univariate signals are present in the data, 
RAINFOREST will also capture these. In addition to rs))[/\,, we also find a cluster of 
frequent SNPs on chromosome [ which have not been reported before. Four of these 
variants (rs.[+'()., rs..)(')), rs-/[,)'\ and rs..[[[+,) are intronic variants within 
the ERAP- gene. A fifth SNP (rs-//,'\,-) is annotated to LNPEP, a paralog of ERAP-. 
These SNPs are in high linkage disequilibrium (coefficient of linkage disequilibrium 
>/.'), where linkage disequilibrium is defined as the squared Pearson correlation 
coefficient. Both ERAP- and LNPEP code for aminopeptidases. ERAP- plays an 
important role in cleaving proteins into peptides that can be presented by MHC class - 












proteins to immune cells (Falk and Rötzschke .//.). Cetuximab is a monoclonal 
antibody and it has been shown that activation of the adaptive of the immune system 
and presence of cytotoxic T-cells are essential for its antitumor effect (Holubec et al. 
./-,; Yang et al. ./-\). A potential explanation of these observations is that these SNPs 
represent genetic variation in the T-cell response that influence cetuximab response.  
 
For all ()- SNPs that are present in all three models we also assessed feature importance 
by shuffling the genotype of the individual SNP and predicting the class labels on the 
validation again. This eliminates the association between the genetic data and 
treatment effect, so we can estimate the importance of each SNP. Without exception, 
shuffling SNPs increases the HR, which means the model performs worse. Figure +c 
shows the difference in HR for the ./ SNPs with the largest effect. Note that since many 
Figure 3. a. Manhattan plot showing the number of times individual SNPs were used 
in a decision tree across all three cross validation folds. b. Venn diagram showing the 
overlap in SNPs used in the three models for the three different cross validation folds. 
c. Barplot showing the 20 SNPs with the greatest influence on validation HR when the 
data is shuffled. Error bars indicate standard deviation. The SNPs indicated in red text 
are in LD > 0.9 with each other and all lie in the same region of chromosome 5. SNPs 















SNPs are only present in a few trees (i.e. the most frequent SNP is only present \- times), 
the effect of shuffling is limited. We thus also do not see large changes in validation HR. 
Despite this limitation, + out of [ SNPs from the chromosome [ cluster as well as 
rs))[/\, are present in the top ./, strengthening their putative role in predicting 
cetuximab benefit.  
 
Lactate dehydrogenase and age do not determine benefit prediction 
High baseline lactate dehydrogenase (LDH) is a known prognostic factor in colorectal 
cancer (Li et al. ./-,), but it does not have a significant interaction with treatment effect 
in survival analysis in our data (HR = /.)-, '[% CI /.[( – -.-(, p = /..,). Patients with 
high LDH are fairly evenly spread between class ‘benefit’ (+[.,%) and class ‘no benefit’ 
(+../%) and in neither class there is a significant interaction between treatment and 
high LDH (HR ‘benefit’ = /.'., '[% CI /.+, – -.)+, p = /.\/ and HR ‘no benefit’ = /.)/, 
'[% CI /.[. – -.... p = /.\/).  
There is also no significant difference in the mean age between the two classes (p = 
/.,,). The difference in treatment benefit is thus not explained by LDH and age, which 
are two common patient characteristics used in clinical decision making (van Eeghen 
et al. ./-[; Li et al. ./-,). 
  
Sex influences treatment benefit  
In the original trial the authors reported that women have a significantly better survival 
when not treated with cetuximab. Indeed, when considering the patients classified as 
‘benefit’, we find an HR of /.,- ('[%CI /.+/ - /.'+, p = /./.) for men and an HR of -./+ 
('[% CI /.[, - -.'+, p = /.'/) for women. While for women the HR in class benefit is 
lower than the overall HR (-.[-, '[% CI -.-+ - ..//, p = /.//\), it is not below - and 
therefore does not signify benefit. Moreover, more men are classified as benefit (\-.'%) 
than women (.../%). In our dataset we find an HR of -.(\ (p = /.//\, '[% CI -../ - 
..+') for the interaction term treatment*sex. We therefore investigate whether the 
interaction between treatment effect and chromosomal sex could also partly explain the 
performance of our model. The interaction term for sex*treatment was similar in both 
classes, giving an HR of -.(- (p = /.-(, '[% CI /.)/ - \.,\) in class ‘benefit’ and an HR of 
-.,( (p = /./., '[% CI -./' - ..[,) in class ‘no benefit’. Together, this indicates 
RAINFOREST discovered a signal independent of the sex effect. 
  












Model incorporating chromosomal sex predicts benefit for men 
Since sex is known to influence the outcome of cetuximab treatment and we see a 
different HR for men and women in our class ‘benefit’, we also train a RAINFOREST 
model that incorporates the sex variable, which we call the sex aware model in the rest 
of this text. The training procedure is the same as before, but in the construction of a 
tree, in addition to a sample of the SNPs, chromosomal sex can be selected as a splitting 
variable. We also construct new cross validation folds, in which the stratification is 
chosen such that, in addition to the overall treatment HR, the interaction term 
sex*treatment is similar in all folds. 
 
For each fold we train -/,/// trees. On average --/' trees use the sex variable for a split 
(-.\. for Fold -, -.,\ for Fold . and )\- for Fold \). The optimal HR found in class 
‘benefit’ (n = -\-) is /.[. ('[% CI /.\[ - /.(,, p = /.///(), while the HR in class ‘no 
benefit’ (n = +..) is -.\[ ('[% CI -.-- - -.,(, p = /.//+). The sex aware model thus 
provides a better performance than the original model that did not include the sex 
variable. However, it should be noted that in this case class ‘benefit’ consists almost 
entirely of men ('[.+%). We therefore evaluate the optimal threshold for men and 
women separately, as well as for the whole dataset (Figure ,). It follows that the sex-
aware model works better than the original model for men for a class ‘benefit’ below 
[/%, but not for women. While the sex aware model has a better performance for 
women in a larger class ‘benefit’, it should be noted that all these HRs are well above - 
and thus do not represent true benefit. 
 












































































Figure 4. Performance for different sized class benefit (as determined with different 
thresholds on the posterior probability) for men and women, and the whole dataset. 















When considering the selected SNP-variables, --/ SNPs are shared between all three 
folds of the original model and all three folds of this new model. This includes rs))[/\, 
and all the SNPs in the cluster on chromosome [ described above, underscoring their 
importance in determining benefit to cetuximab. 
 
When we train a RAINFOREST model in only women, we do find an optimal HR of /.(, 
(p = /.\'), suggesting a model can be obtained with a true predictive performance. 
However, the performance curve (Supplemental Figure -) does not show the linear 
relationship between the size of class benefit (as determined by the threshold on the 
posterior probability) and HR in class benefit. This indicates that a well-defined class 
‘benefit’ cannot be identified by RAINFOREST in this dataset. The sex aware model 
reflects this fact by not including women in class ‘benefit’ when given access to this 
information. This shows RAINFOREST can accommodate this type of known effect and 
fit a model on the rest of the variables, improving the performance of the model. 
 
Univariate SNP selection does not validate in cross validation  
We compare the performance of RAINFOREST to the univariate selection of SNPs (see 
Methods). This analysis reveals no SNPs that are significant at a multiple testing 
corrected p-value less than /./[. We perform forward feature selection by ranking the 
SNPs on likelihood ratio test p-value to find the optimal SNP combination. With this 
approach, the models for fold -, . and \ contain -/-, -'( and -'/ SNPs respectively. In 
line with the earlier univariate study (Pander et al, ./-[), Rs))[/\, (the most 
frequently selected SNP in the RAINFOREST model) is selected in all three folds. With 
the exception of one other SNP (rs-/-,[\),) no other SNPs overlap. Moreover, the 
model does not result in a significant HR, as we find an HR of -.// ('[% CI = /.(/ - -.++, 
p = -) in class ‘benefit’ (n = -\)) and an HR of -.-[ ('[% CI /.'\ - -.+-, p = /.-') in class 
‘no benefit’ (n = +-[). Univariate selection of the SNPs thus does not lead to a model 
that validates on unseen patient data.  
 
Random forest on survival based labels does not validate 
We also train a classical random forest model on the benefit labels derived from the 
survival data (see Methods). The cross validation is performed using the same folds as 
in the univariate and RAINFOREST analysis. Since we do have training labels in this 
case, mtry can be optimized using the OOB error. The default setting often used is the  












square root of all features available, but it has been suggested that in high dimensional 
datasets a higher mtry leads to a better performance (Goldstein et al. ./-/). We 
therefore try several values for mtry and evaluate the OOB error. Figure [a shows that 
the default V𝑝, where p is the total number of features, leads to the lowest error (Figure 
[a).  
 
Using the optimal model we find that no patients are classified into the ‘benefit’ class 
when using majority vote, despite the fact that both classes are sampled equally in the 
training data.  We therefore classify a sample with where more than \/% of trees 
indicate benefit as benefiting, as this leads to a class benefit of approximately .[%. 
Using these settings we train a random forest with -/,/// trees and validate it on the 
test set. In the test set we set a threshold on the posterior probability that results in the 
lowest p-value in class ‘benefit’. We then find an HR of /.)) ('[% CI /.[' - -.\., p = 
/.[+) in class ‘benefit’ (n = -\)) and an HR of -.-) ('[% CI /.'( - -.++, p = /.-/) in class 
‘no benefit’ (n = +-[). The Kaplan Meier curve is shown in Figure [b. While the RF can 
identify a class ‘benefit’ with an HR below -, this is not statistically significant at p < 
/./[. Similar results are obtained when defining benefit as the top [/% and bottom 
[/% of the treatment arms (HR benefit = /.'(, '[% CI /.(/ - -.\,, p = /.))) or when 
Figure 5 a. The OOB error found for the survival based levels when using different 
values for mtry. b. Kaplan Meier of the classification in class ‘benefit’ and ‘no benefit’, 
using the threshold that defines the class ‘benefit’ with the lowest Cox regression p-
value.  
 

























































Cetuximab, benefit n = 69
Cetuximab, no benefit n = 205
no Cetuximab, benefit n = 69
no Cetuximab, no benefit n = 210
a. b.
HR benefit = 0.88, p =  0.54














restricting the RF to a depth of two (HR benefit = /.'., '[% CI /.[/ - -.,(, p = /.((). 
We conclude that predefined benefit labels based on survival outcome are not suitable 




We here demonstrate RAINFOREST, a new approach to predict treatment benefit from 
patient germline variation data. The RAINFOREST model successfully identifies a 
subset of patients that benefits from cetuximab treatment in the CAIRO. trial. It 
outperforms univariate analysis and traditional random forest models. We demonstrate 
its performance through cross validation, as the best estimate of the performance on 
independent validation data. Further validation in a truly independent patient cohort 
should further establish clinical utility of our approach. Moreover, in this model we 
have only considered the influence of germline variation on cetuximab benefit. Several 
tumor characteristics, like KRAS and BRAF mutation status and molecular subtype, 
have also been shown to correlate with cetuximab response (Salvatore et al., ./-/, Trinh 
et al, ./-(). A further analysis could take both tumor and germline variation into 
account to identify benefiting patients even more comprehensively.  
 
The CAIRO. trial represents a good test case for RAINFOREST as previous univariate 
analysis has shown a relation between germline variation and treatment specific 
survival. Reassuringly, we identify rs))[/\,, the variant identified previously, among 
the most frequently used SNPs in the RAINFOREST model. Importantly, RAINFOREST 
identifies a number of previously unknown SNPs, which are not found with a univariate 
approach, that suggest a role for genetic variation in the immune response in 
determining cetuximab benefit.  
 
With the sex aware model we show RAINFOREST can be adapted to incorporate 
characteristics known to be important, such as chromosomal sex. However, as the 
overlap in important SNPs show, the same signal can still be identified, underscoring 
the stability of the method.  
 
The authors of the CAIRO. trial concluded that there was a slight detrimental effect of 
the addition of cetuximab to the CAPOX-B treatment regimen. This is a clear example 











for how RAINFOREST can be applied, as roughly half of all phase \ clinical trials fail to 
reach their predefined endpoints and most fail due to insufficient efficacy of the drug 
(Hwang et al. ./-,). As a result, these drugs do not enter the clinic, while it is very 
possible that a subset of the patient population experiences benefit. RAINFOREST can 
identify patients that do benefit from drugs which failed to show significant benefit in 
the patient population as a whole, and thus play an important role in leveraging valuable 
patient data and find an application for drugs that otherwise would not be introduced 
to the clinic.  
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Code availability  
The R code used to produce the results in this paper is available at 
github.com/UMCUGenetics/RAINFOREST. A more configurable, user-friendly Python 






































































Supplementary figure 1. Performance when RAINFOREST is trained and 
























Personalized medicine has been discussed as the future of cancer treatment for over 
three decades now, since the discovery and potential targeting of mutations in the RAS 
signalling pathway (Reddy et al. -').; Downward .//\). There has been tremendous 
progress, particularly in matching targeted treatment with specific mutations or cell 
surface markers. However, despite the fact that we have known for a long time that both 
germline variation and tumor characteristics influence disease progression and 
treatment response, there are not many DNA or RNA signatures in use in the clinic 
(Fröhlich et al. ./-)). There is in fact a great gap between the great number of papers 
reporting gene expression signatures and the ones that have an impact on clinical care 
(Koscielny ./-/). In this thesis several different approaches for predicting treatment 
benefit are presented. While multiple counterfactual approaches exist, they have so far 
been used mostly in low dimensional settings for causal inference. Here we present 
multiple ways of using this kind of reasoning in high dimensional settings to build 
clinically useful models. These approaches could play an important role in a further 
realization of personalized medicine - the tailoring of treatment to a patient based on 
individual characteristics - in cancer treatment. However, there are still various 
challenges to be faced. We will discuss here what the work in this thesis can contribute 
and which challenges still have to be addressed.  
 
Reproducibility of signatures and different populations  
 
A major concern and hindrance in clinical adaptation is the lack of reproducibility for 
many classifiers (Subramanian and Simon ./-/). For prognostic signatures it has been 
shown that many classifiers in fact do not outperform random classifiers when tested 
on external data (i.e. data the classifier was not trained on) (Tang et al. ./-(). Moreover, 
it was also shown a gene expression classifier with satisfactory internal performance 
could be trained on completely random data. Proper validation is thus crucial.  
 
In absence of truly independent data, many studies use cross validation to estimate the 
expected performance, as we also do in Chapter * and Chapter /. However, it is known 
that cross validation can overestimate performance (Castaldi, Dahabreh, and Ioannidis 
./--). In some cases, the cross validation may not have been properly performed (for 
example, when multiple models are validated and the best is presented), but there are 












performance in independent data. This could be due to the fact that the classifier has 
fitted a signal specific to the population in the original data (i.e. the data the cross 
validation was performed on), with the difference in signal between datasets influenced 
by a true biological difference between the patients or differences in lab procedure or 
clinical practice.  
 
This thesis contains some examples of this: in Chapter * we see that when we train the 
model solely on the Total Therapy dataset the classifier does not validate on the 
Hovon,[ dataset, while we can perform a successful cross validation when the two 
datasets are mixed. With mixed dataset GESTURE has the opportunity to fit the mixed 
signal, where the model is most likely too specific when trained solely on the Total 
Therapy dataset.  In Chapter + of this thesis cross validation was quite predictive of the 
performance in independent data, while this was not the case in Chapter ,, even though 
the set-up of the cross validation was nearly identical. Most likely the difference 
between the breast cancer datasets used in Chapter , is far greater than the multiple 
myeloma datasets in Chapter +, as the clinical reality is very different for both diseases. 
Treatment is less guided by patient characteristics in multiple myeloma than in breast 
cancer; patients in an observational trial are probably more likely to match the 
population from a randomized clinical trial. Training on randomized data is more 
suitable for simulated treatment learning, as there are similar patients in both treatment 
arms by definition. While the strategy of matching patients in the breast cancer dataset 
- to simulate a clinical trial like setting - improved performance on hold out data from 
the same population, this classifier still did not validate on external data. There could 
be trade off in data selection: training within one population leads to better results in 
that specific population, but is less generalizable to a wider population. This conflict 
extends to the follow-up time: longer follow up is often beneficial for the training 
procedure, especially for cancer types with a long median survival. When using a ./-
year-old dataset most relevant events will have been recorded, but the setting in which 
these women were treated is no longer relevant. This meant that the older METABRIC 
dataset in Chapter , was less useful for training, even though it included far more 
events than the SCAN-B dataset. There is no clear solution to this problem, though 
potentially subsetting older datasets to more closely match new datasets could be a 
strategy (to for example conform to current treatment guidelines). There are limits to 














with a hazard ratio in favor of chemotherapy. We should always carefully evaluate 
whether a dataset can still be relevant. The training data used has important 
implications for clinical deployment; the intended use population should match the 
training and validation population.  
 
Finally, for identification of cancer subtypes tumor purity is an important factor. When 
a biopsy of a solid tumor is taken it will always contain both cancer cells and other cells 
(for example cells from the immune system). When gene expression is measured on this 
mixture the outcome will also be influenced by non-cancer cells. It has been shown that 
the variability in tumor purity biases subtype classification and estimating tumor purity 
can improve classification results (Aran, Sirota, and Butte ./-[; Zhang et al. ./-(). 
Multiple myeloma is a non-solid tumor and cells are sorted to a purity of at least )/% 
before gene expression is measured. This could lead to a more consistent measurement, 
less bias and thus a higher chance of successful external validation.  
 
Lack of available data  
 
Absolutely crucial for the training and proper validation of these classifiers is the 
availability of data. Especially for diseases that are not very prevalent, data available 
within one institution will not be sufficient. Moreover, as discussed, validation within 
one dataset or population is no guarantee for predictive availability in another 
population. All considerations about matching populations are only relevant if enough 
data is available. Open science and the sharing of data has received a lot of attention in 
the past few years, but many scientists are still worried that sharing their data will be to 
their disadvantage (Gewin ./-,). While many journals now require a statement on data 
availability and the data needs to be publicly available (Naughton and Kernohan ./-,), 
many publicly available gene expression datasets (for example in the Gene Expression 
Omnibus) do not offer enough patient information to enable the training of predictive 
or even prognostic classifiers on this data. We need systems in place that encourage 
sharing of all useful data, while of course keeping an eye on privacy concerns. Journal 
simply requiring data to be available seems to be insufficient. For example, when the 
British Medical Journal randomly audited -[( research articles in their journal, they 












(Rowhani-Farid and Barnett ./-,). However, as more and more journals adopt a data 
sharing policy and open data is normalized, more data will hopefully be shared. 
Increasingly, funders also require a data sharing plan and publishers start encouraging 
data sharing more actively, with Springer Nature starting a research data helpdesk that 
can facilitate the sharing process (Jones, Grant, and Hrynaszkiewicz ./-'). Data can 
also be assigned a digital object identifier (DOI), so it can be cited and researchers 
receive credit for the data they made available. Increasingly, researchers are aware of 
the FAIR data principles: data should be Findable, Accessible, Interoperable, Reusable 
(Wilkinson et al. ./-,). This means it should be clear where data is located, how to gain 
access, and it should be in a format that can be read and manipulated by commonly 
used programs. It should be clear which data is included in the file and how it was 
produced. Importantly, accessible does not mean freely accessible. FAIR data can still 
safeguard privacy. For further model development and validation, wide availability of 
data is crucial and the research community should take all possible steps to encourage 
FAIR data sharing.  
 
Integration of different data types  
 
An approach not employed in this thesis is the integration of different data types (i.e. 
DNA and RNA data). In Chapter *, + and , we use tumor gene expression and in 
Chapter / we use germline DNA variation. The truth is that the benefit for each 
treatment is probably influenced both by factors specific to the cancer cells and specific 
to the individual patient. An important distinction to be made here is the integration of 
different data types from the same cell (type) and data representing different systems 
in the body. For the prediction of prognosis in breast cancer it has been shown that 
tumor gene expression captures most of the information and adding different data types 
does not improve performance (Aben et al. ./-)). However, the data considered there 
was all taken from the tumor and thus represented the same system. When we would 
for example combine tumor gene expression and germline DNA data, we are taking data 
from different systems; the tumor cell and the body surrounding it. The impact of a drug 
not being metabolized in the liver could never be captured by tumor gene expression 
for example. In Chapter / we identify SNPs that are predictive of cetuximab benefit. 














predictive of cetuximab response have been identified (Salvatore et al. ./-/; Baker et al. 
./--). Since information is most likely present in all these data types, a logical next step 
would be to analyze them together to form a more complete picture of which patients 
benefit. There are several ways of integrating data; you can pool all data and train a 
single classifier (early integration) or train separate classifiers and then combine the 
classifications (late integration) and forms in between. RAINFOREST in Chapter / 
could easily be adapted to also take tumor gene expression into account, with the values 
discretized to match the SNP format. However, in early integration dimensionality of 
datasets matters a lot; the higher dimensional data type can dominate the signal and 
seem the most important, even though this is not biologically true. Late integration, on 
the other hand, does not offer opportunities to model interactions between the 
germline data and tumor gene expression. Early integration may then be preferable, but 
steps should be taken to bring different data types in the same (dimensional) space.  
 
Interpretability of the classifiers 
 
When a predictive classifier is able to identify which patients benefit from a treatment, 
the logical next step is to investigate why these patients benefit and how the genes 
included in the classifier fit in. It has been shown for prognostic classifiers that many 
classifiers with a similar performance, and yet using completely different genes, can be 
found (Ein-Dor et al. .//[). Since genes function in pathways and expression is often 
very correlated, many genes can encode the same signal and simply interpreting the 
genes included in a classifier may not be useful. In Chapter * and Chapter , we attempt 
to encode biological information using gene ontology (GO) annotations and these gene 
sets do indeed perform better than random sets at predicting treatment benefit. 
However, the GO sets used in different classifiers predicting benefit for the same drug 
show very little overlap and no (obvious) interpretation of these genes could be 
formulated. An additional concern is that especially when a classifier is trained in a non-
linear way like GESTURE is, it is possible the class ‘benefit’ is actually composed of 
multiple subsets; not all benefiting patients benefit for the same reason. We also 
measure gene expression in bulk, while each multiple myeloma patient probably 
harbors multiple different tumor clones (Keats et al. ./-.). We could be measuring an 












clearly enough information present to predict treatment benefit in a meaningful way, it 
could be a barrier to interpretation.  
 
Gene sets defined by biological knowledge may thus not be useful for interpretation. 
Interestingly, when we formed entirely data driven gene sets in Chapter +, the 
individual genes were more crucial for performance than when we used gene sets 
informed by biological annotation. Without the -+ genes included in the original 
signature, no signature with a similar performance could be found. The strategy 
followed in Chapter + (i.e. only selecting genes that the algorithm always ranks highly 
over different repeats) could be beneficial in finding these crucial genes. However, it 
should be noted we could not describe a mechanism that links the -+ genes in this 
classifier and individually they were not differentially expressed between class ‘benefit’ 
and ‘no benefit’. This approach also does not address the concern of measuring several 
clones at the same time.  
 
Once we have an interpretation of the genes, a next step could be to functionally 
validate the findings. The fact that the -+ genes in Chapter + can only be identified 
together and do not show differential expression by themselves could also be a barrier 
to proving their role in a functional assay. We would have to under- or overexpress a 
combination of -+ genes, without the model itself providing a hypothesis on how benefit 
could be achieved (i.e. which genes should be over- or under-expressed). For even more 
complicated models, like GESTURE produces, this would be impossible. It is also 
important to consider what the goal of interpretation could be, beyond providing 
further insight into the disease. When a clear mechanism can be identified that causes 
a patient not to benefit from a drug, this could be used for rational design of a drug that 
could overcome this. It seems clear the models presented in this thesis are far away from 
playing a role in this.  
 
Clinical practice and clinical utility  
 
Finally, the most important part of work like this is the clinical utility: even if the 
classifier is completely accurate, would clinical care be changed based on its prediction? 
In some cases this may be obvious. With the Mammaprint, which can predict which 














should however be noted, that even here the case is not clear cut. Patients can be 
reluctant to forgo available therapy based on a risk assessment, even if statistically we 
would not expect benefit. In the case of the Mammaprint, the Dutch Healthcare 
Institute declined to mandate insurance companies to reimburse the test, citing a 
possible ..+% increase in distant metastases if chemotherapy was not given 
(Zorginstituut Nederland ./-)). This test failed to become the standard, even though a 
prospective clinical trial proved its accuracy. With algorithms and artificial intelligence 
playing a larger role in society, there has been a lot of public debate on when algorithms 
can be trusted to make decisions that will impact lives. Which decisions can be taken 
by non-human systems and where lies the responsibility for the outcome of such a 
decision? Explainability of the decision plays a large role here (Abdollahi and Nasraoui 
./-)). It could very well be unreasonable to expect physicians and patients to stake lives 
on a model for which it cannot be explained why it works. For this purpose identifying 
which genes are crucial - as discussed above - can be already useful, even if it does not 
lead to a new treatment; it can aid in the explainability of the treatment decision. 
Smaller, clearer signatures like the one presented in Chapter + will then be preferable 
over the large, complicated models built by GESTURE.  
 
Of course, what is clinically useful is not static. When a treatment is standard and given 
to all patients, it may make more sense to attempt finding a group that does not benefit: 
for those patients treatment should be changed. However, without a convincing 
alternative treatment, such a classifier does not have a high probability of being 
adapted. The discovery of a new drug could render a classifier useless or useful; for 
example by establishing a new standard treatment or by providing an alternative 
treatment for a no benefit group.  
 
In light of changing clinical practice, it is crucial to shorten the time between biomarker 
discovery and introduction in the clinic. As mentioned before, there are limitations 
here: sufficient follow up is needed. However, adaptive clinical trials could play a role 
here. This is a trial that changes design based on data gathered during the trial (Barker 
et al. .//'; Gallo et al. .//,). The I-SPY trial in breast cancer is an example, where 
inclusion criteria for treatment arms are adapted as the trial goes on to incorporate 
effects discovered during the trial (Barker et al. .//'). The I-SPY trial is mostly designed 












discovery and validation when no obvious candidates are known. Here patients are 
randomized as normal between two treatment arms and then split in a training and 
validation cohort during the trial. The training cohort can be used to continuously build 
a predictive model, while the validation cohort can be used as a prospective trial at the 
same time (Scher et al. ./--). There are obvious ethical considerations here and in 
practice this design will be followed only when there is no evidence for superiority of 
the treatment under investigation in the population as a whole.  
 
There is also the wider context of health care to consider. In most developed countries 
the cost of healthcare is on the rise and discussions on when treatment is no longer 
affordable need to be had (Baltagi et al. ./-(). Personalized medicine can play an 
important role in this problem and reduce overall health care expenditure (Jakka and 
Rossbach ./-\). When we can predict who will benefit from more generic treatments, 
we do not only spare patients who do not benefit unnecessary side effects, we can also 
reduce the cost of treatment. However, in incurable forms of cancer like Multiple 
Myeloma, where a patient will always receive a form of treatment and often will be 
treated until their death, it may be hard to quantify the amount of money saved.  
 
This also relates to the importance of finding a subset of the population that does 
benefit from drugs that fail to show a significant effect in the population as a whole. 
Pharmaceutical companies claim high prices for drugs are needed to offset all the costs 
made in developing drugs that do not reach the market. The more efficient drug 





Personalized medicine and predictive biomarkers will play an important role in the 
health care of the future. However, it is also clear that there are different challenges for 
different diseases and there is not one model to be applied here. Algorithms should be 
combined with clinical trial design and an awareness of clinical reality. For adaptation 
in the clinic, simpler models may be better.  
In this thesis we present three different algorithms to train a model capable of 














topics discussed, they all have different strengths. For the purpose of training an 
interpretable model, STLsig seems to produce the best classifiers; GESTURE models are 
too complicated. However, STLsig is much more sensitive to high censoring rates. When 
a patient does not have suitable neighbours (i.e. no neighbours who experienced an 
event), our main measure for benefit (zPFS) cannot be calculated and this patient then 
drops out of the analysis. This obviously happens more often when there are fewer 
events recorded in the dataset. STLsig uses the whole distribution of zPFS and its 
performance is more impacted by patients dropping out than GESTURE, which just uses 
patients with a high zPFS. For data with fewer events GESTURE(-BC) is thus more 
suitable. Both GESTURE and STLsig need continuous data like gene expression to 
calculate distances between patients. RAINFOREST is more versatile; it can handle the 
discrete values of SNP data, but could also easily be adapted to categorical data like sex. 
It could potentially also handle gene expression data and a mix of different data types. 
It would thus be most suitable to be used for integration of patient characteristics and 
different data types. Together they can hopefully be used to make personalized 
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Many cancer treatments are associated with serious side effects, while it is known not 
all patients who receive them see benefit from the treatment. It has become clear both 
patient and tumor characteristics can influence the response of a cancer patient to a 
specific treatment. There is therefore great interest in personalized medicine: matching 
the right drug with the right patient, based on certain predictive features that can be 
measured. Certain drugs are designed to target a specific mutation in the tumor DNA; 
this drug is only beneficial for patients whose tumor harbors this alteration. But 
personalized medicine can also play a role in more generic treatments. Machine 
learning approaches have been employed to separate poor and good responders on the 
basis of tumor gene expression, among other things. 
 
However, often there is more than one drug available and a choice has to be made 
between them, which is a more challenging problem. Most machine learning 
approaches employed in predicting benefit for a single treatment require labels to train 
a model.  Patients are be labeled as poor or good responders, and the model is optimized 
to distinguish these two classes. These cannot be employed when predicting whether a 
patient will benefit more from a certain treatment than from an alternative. We can 
only observe the response to a treatment the patient actually receives; we cannot know 
if they would have responded more or less favourably to an alternative treatment. A 
patient can thus not be labeled as benefiting or not. New methods need to be developed 
to deal with this problem.  
 
This thesis presents several different algorithms that can train a model capable of 
identifying patients that will benefit more from the treatment of interest than an 
alternative treatment. In Chapter *,+ and , we use the concept of Simulated Treatment 
Learning (STL).  STL relies on the idea that genetically similar patients who received 
different treatments can be used to model the response to an alternative treatment. 
Similarity between patients should be defined by genes relevant to treatment benefit. 
As we do not know beforehand which genes are relevant, the algorithms we build to 
implement STL need to both select relevant genes and use these to build a model that 















In Chapter * we present GESTURE (Gene Expression-based Simulated Treatment 
Using similaRity between patiEnts) and demonstrate its utility in Multiple Myeloma, a 
plasma cell cancer. GESTURE uses predefined gene sets, informed by biological 
annotation, to define similarity between patients. It then tests which of these gene sets 
can be used to identify a class ‘benefit’, i.e. patients who benefit more from the 
treatment than the population as a whole. We show it can do so successfully for two 
major treatments in Multiple Myeloma: bortezomib and lenalidomide.  
 
In Chapter + we implement the concept of STL in the algorithm STLsig, which does not 
need predefined gene sets. While GESTURE could predict in unseen data which patients 
would benefit from bortezomib or lenalidomide, it produced models that contain 
hundreds of gene sets and thousands of genes. These models are complicated to 
interpret. Instead, STLsig builds gene networks specific to the disease and treatment by 
connecting pairs of genes that are synergistic in their ability to predict benefit. With 
STLsig we define a -+-gene model that can predict benefit to proteasome inhibitors (like 
bortezomib) in Multiple Myeloma. These -+ genes present a much simpler model and 
they are moreover unique: a model with similar performance cannot be found when 
they are removed from the dataset.  
 
In Chapter , we adapt GESTURE to predict chemotherapy benefit in breast cancer. 
Breast cancer patients have on average a much better survival than Multiple Myeloma 
patients. This poses a statistical challenge as the majority of the patients included in the 
dataset are still alive at the end of follow-up. When two similar patients from different 
treatment arms are both still alive, we cannot define who benefited more. The adapted 
version, GESTURE-BC, uses a different criterion to define the best classifier better suited 
to a dataset with few recorded deaths. We show that GESTURE-BC can identify which 
patients see benefit from chemotherapy treatment and which patients do not benefit. 
However, this model did not show performance on older data where patients were 
treated along different guidelines. This highlights the importance of matching the 
patient populations in which a model is trained and in which its performance is 
evaluated. 
 
In Chapters *, + and , we use tumor gene expression to predict treatment benefit. 












RAINFOREST (tReAtment benefIt prediction using raNdom FOREST), which predicts 
treatment benefit using germline DNA variation, which is the inherited genetic 
variation and not specific to the tumor. We use RAINFOREST to predict cetuximab 
benefit in metastatic colorectal cancer.  
 
The algorithms presented have different strengths and weaknesses. STLsig provides 
simpler models, but is less adept at dealing with low event rates, which GESTURE-BC 
can deal with. Neither can deal with non-continuous data, which RAINFOREST can do. 
Together, GESTURE, STLsig and RAINFOREST provide a versatile toolbox to predict 
















Veel kankerbehandelingen zijn geassocieerd met ernstige bijwerkingen, terwijl het 
bekend is dat niet alle patiënten die er mee behandeld worden baat hebben bij het 
medicijn. Het is bekend dat zowel patiënt- als tumorkenmerken de respons van een 
kankerpatiënt op een specifieke behandeling kunnen beïnvloeden. Er is dan ook grote 
belangstelling voor gepersonaliseerde geneeskunde: het matchen van het juiste 
medicijn met de juiste patiënt, op basis van bepaalde voorspellende kenmerken die 
kunnen worden gemeten. Sommigemedicijnen zijn gericht op een specifieke mutatie in 
het DNA van de tumor; dit medicijn is alleen nuttig voor patiënten wiens tumor deze 
mutatie herbergt. Maar gepersonaliseerde geneeskunde kan ook een rol spelen bij meer 
generieke behandelingen. In het verleden is machinaal leren (“machine learning”) 
toegepast om patiënten met een slechte en goede respons op een bepaald medicijn van 
elkaar te onderscheiden. Dit is bijvoorbeeld gedaan op basis van genexpressie in de 
tumor.  
 
Vaak is er echter meer dan één medicijn beschikbaar en moet er een keuze worden 
gemaakt welk medicijn het beste is voor de patiënt. Dit is een moeilijker probleem dan 
respons voor één medicijn voorspellen. De meeste methodes voor het voorspellen van 
een goede of slechte respons hebben labels nodig; patiënten worden gelabeld als goede 
of slechte responder en het model wordt geoptimaliseerd om deze groepen van elkaar 
te onderscheiden. Deze methodes kunnen niet worden gebruikt om te voorspellen of 
een patiënt meer baat zal hebben bij een bepaalde behandeling dan bij een alternatief. 
We kunnen alleen kijken naar de respons op een behandeling die de patiënt 
daadwerkelijk krijgt; we kunnen niet weten of die beter of slechter gereageerd zou 
hebben op een alternatieve behandeling. Een patiënt kan dus niet worden gelabeld als 
wel of geen baat hebben. Er moeten nieuwe methoden worden ontwikkeld om dit 
probleem aan te pakken.  
 
Dit proefschrift presenteert verschillende algoritmen die een model kunnen trainen dat 
in staat is om patiënten te identificeren die meer baat hebben bij een bepaalde 
behandeling dan bij een alternatief. In Hoofdstuk *, + en , gebruiken we het concept 
van Simulated Treatment Learning (STL). STL is gebaseerd op het idee dat genetisch 












worden gebruikt om de respons op een alternatieve behandeling te modelleren. 
Genetische gelijkenis tussen patiënten moet worden bepaald door genen die relevant 
zijn voor baat bij de behandeling. We weten niet op voorhand welke genen relevant 
zijn. Daarom moeten de algoritmes zowel relevante genen kunnen selecteren, alsook 
nieuwe patiënten kunnen classificeren met behulp van deze genen.  
 
In Hoofdstuk * presenteren we GESTURE (Gene Expression-based Simulated 
Treatment Using similaRity between patiEnts) en demonstreren we het nut ervan in 
multipel myeloom, een plasmacelkanker. GESTURE maakt gebruik van vooraf 
gedefinieerde verzamelingen van genen (“gene sets”), gevormd aan de hand van 
biologische functie, om de gelijkenis tussen patiënten te definiëren. Vervolgens wordt 
getest welke van deze gene sets kunnen worden gebruikt om een ‘baat’-groep te 
identificeren, d.w.z. patiënten die meer baat hebben bij de behandeling dan de rest van 
de patiëntenpopulatie gemiddeld heeft. We laten zien dat GESTURE in staat is dit te 
doen voor twee veel gebruikte medicijnen in multipel myeloom: bortezomib en 
lenalidomide.  
 
In Hoofdstuk + implementeren we het concept van STL in STLsig, een algoritme 
waarbij het niet nodig is van te voren gene sets  te definiëren. Hoewel GESTURE in staat 
is te voorspellen welke patiënten baat zouden hebben bij bortezomib of lenalidomide, 
gebruikte het hiervoor modellen met honderden gene sets en duizenden genen. Het is 
lastig dit soort modellen te interpreteren. In plaats van vooraf gedefinieerde gene sets 
te gebruiken, maakt STLsig netwerken van genen die specifiek relevant zijn voor de 
ziekte en de behandeling. Om deze netwerken te maken, verbinden we genen die samen 
beter in staat zijn om baat te voorspellen, dan met een ander gen. Met STLsig trainen 
we een model dat baat kan voorspellen voor proteasoomremmers (zoals bortezomib) in 
multipel myeloom. Het model gebruikt slechts -+ genen en vormt Hiermee een veel 
simpeler model. Bovendien zijn deze genen uniek in hun voorspellende waarde: als we 
deze uit de dataset verwijderen kunnen we geen model vinden dat even goed kan 
voorspellen welke patiënten baat hebben.  
 
In Hoofdstuk , passen we GESTURE aan om te voorspellen welke 
borstkankerpatiënten baat hebben bij chemotherapie. Borstkankerpatiënten overleven 














Daardoor was de meerderheid van de patiënten in de dataset aan het einde van de 
follow-up periode nog in leven. Dit maakt het statistisch gezien lastiger om een model 
te trainen. Wanneer twee vergelijkbare patiënten die verschillende medicijnen hebben 
gekregen allebei nog in leven zijn, kunnen we niet bepalen of de ene patiënt meer baat 
heeft gehad dan de andere. De aangepaste versie van GESTURE, GESTURE-BC, 
definieert de beste classificatie met een ander criterium. Dit criterium train op zowel 
baat als geen baat en rangschikt de gene sets op een andere manier, waardoor we een 
beter model kunnen trainen op data met goede overleving. We demonstreren dat 
GESTURE-BC kan voorspellen welke patiënten baat hebben bij behandeling met 
chemotherapie en welke niet. Dit model werkt echter niet goed op een andere, oudere 
dataset, waar de patiënten volgens andere richtlijnen werden behandeld. Dit laat zien 
dat het erg belangrijk is om de patiëntenpopulatie waar het model op getraind wordt, 
te matchen met de populatie waar het in getest wordt.  
 
In Hoofdstuk *, + en , gebruiken we genexpressie van de tumor om baat bij een 
behandeling te voorspellen. Dit is echter niet de enige factor die de respons beïnvloedt. 
In Hoofdstuk / introduceren we RAINFOREST (tReAtment benefIt prediction using 
raNdom FOREST), dat gebruik maakt van verschillen in kiemlijn DNA om baat bij 
behandeling te voorspellen. Kiemlijn DNA is DNA dat overgeërfd kan worden, dit is dus 
anders dan het (gemuteerde) DNA van de tumor. We gebruiken RAINFOREST om te 
voorspellen welke patiënten baat hebben bij behandeling met cetuximab bij uitgezaaide 
darmkanker.  
 
Al deze algoritmen hebben zwakke en sterke kanten. STLsig kan simpelere, beter te 
interpreteren, modellen trainen, maar kan minder goed omgaan met data waar de 
meeste patiënten nog in leven zijn; daar kan GESTURE-BC beter mee omgaan. Allebei 
de algoritmes hebben continue data zoals genexpressie nodig om gelijkenis tussen 
patiënten te definiëren, terwijl RAINFOREST ook om kan gaan met andere soorten data. 
GESTURE, STLsig en RAINFOREST vormen samen een toolbox om baat bij behandeling 
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voor alle avonden waar je mijn gestress aan moest horen en je weer moest zeggen dat 
het wel goed kwam en ik heus mijn PhD wel zou halen. Kijk eens aan, je had gelijk. 
Bedankt!  
 
En tot slot, de grootste support van allemaal, mijn familie. Jullie hebben allemaal 
geweldig met me meegeleefd (en geleden, sorry) de afgelopen jaren en zijn de basis voor 
alles. Pap, op deze mag je trots zijn, want het is zeker ook dankzij jou. Bedankt voor de 
eindeloze steun en interesse de afgelopen jaren, ik vond het altijd erg leuk om samen 
over mijn onderzoek te praten. Mam, bedankt voor elk succes, groot en klein, met me 
vieren. En als de successen even uitbleven en het moeilijk werd, stond je altijd klaar met 
een maaltijd en zo nodig een borrel. Richtje, bedankt voor al het no-nonsense advies 
als ik weer eens een veel te gestrest was over de kleine dingen en had en zo nu en dan 
het nodige duwtje om het gewoon te doen. Myrthe en Robbert, ik denk niet dat dit 
proefschrift er nu was geweest zonder jullie opvang tijdens de lockdown. Zo ontzettend 
bedankt. Ook bedankt aan kleine Kees, die een welkome afleiding en dagelijkse portie 
vrolijkheid was in zware tijden. Myrth, je hebt zonder twijfel dit proefschrift gered in 
de laatste fase, maar je was natuurlijk al ver voor corona een grote steun en altijd 
geïnteresseerd in mijn werk. En laten we niet vergeten dat dit alles begonnen is met 
jouw suggestie Kim eens te bellen! En als laatste Sam, mijn eeuwige steun en 
toeverlaat. Ik denk niet dat ik jou ooit genoeg kan bedanken voor alles wat je voor me 
hebt gedaan de afgelopen jaren. Zoals mijn collega’s al constateerden nadat je weer eens 
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Joske Ubels was born on December -.th -''. in 
Amstelveen, the Netherlands. She grew up in 
Amersfoort, where she attended Corderius college for 
her pre-university education. In .//(/.//) she 
attended the Advanced Academy of the University of 
West Georgia in Carrollton, Georgia, USA. After 
returning to the Netherlands she obtained her high 
school diploma and started the bachelor Biomedical 
Science at the Vrije Universiteit in Amsterdam in .//'. In ./-- she attended Lunds 
Universitet in Lund, Sweden for her minor in Neurobiology. After completing an 
internship in the Oncogenomics lab of the Cancer Center Amsterdam she became 
interested in oncology research and started the research master Oncology at the Vrije 
Universiteit in Amsterdam. She first became acquainted with bioinformatics research 
during an internship at SkylineDx in ./-\ and became so enthusiastic she decided to 
pursue a PhD in the topic. She started her PhD in September ./-[ under the supervision 
of prof. dr. Pieter Sonneveld at Erasmus MC and dr. Jeroen de Ridder, first at the TU 
Delft, and later at UMC Utrecht. She currently works as a postdoctoral researcher in the 
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Courses Year ECTS 
BioSB course Pattern recognition 2015 3 
BioSB course Algorithms for Biological Networks 2016 3 
Presenting – Breaking Science 2018 2 
Research planning and Time management 2018 0.5 
Psychological Flexibility 2018 1 
Scientific Artwork with Photoshop and Illustrator 2019 0.6 
Interpersonal Communication 2019 0.5 
This thing called science 2019 2 
Total  12.6 
 
Cancer, Stem cells & Developmental biology PhD Program Year ECTS 
CSND PhD masterclass 2017 2017 1 
CSND PhD retreat 2018 2018 1 
GSLS PhD Day – Talking science 2018 0.3 
CSND PhD masterclass 2018 1 
GSLS PhD Day – Transparent Science 2019 0.3 
Total  3.6 
 
Conferences Year ECTS 
Bioinformatics & Systems Biology meeting  2016 1 
European Conference on Computational Biology (poster) 2016 1 
Bioinformatics & Systems Biology meeting (talk) 2017 1 
European Hematology Association meeting (E-poster) 2017 1 
Intelligent Systems for Molecular Biology (poster) 2017 1 
Bioinformatics & Systems Biology meeting (poster) 2018 1 
Utrecht Bioinformatics Center symposium (talk) 2018 1 
Bioinformatics & Systems Biology meeting (poster) 2019 1 
Intelligent Systems for Molecular Biology (poster) 2019 1 
Total  9 
 
Teaching  
 Year ECTS 
Daily supervisor literature study MSc 2017 1 
Daily supervisor mini-project MSc 2017 2 
Daily supervisor literature study MSc 2017 1 
Daily supervisor minor internship MSc 2018 3 
Supervision paper discussion CSND introductory course 2018 0.1 
Lecturer CSND course Analytics & Algorithms for Omics Data  2019 2 
Total  9.1 
 
Total ECTS  
  
34.3 
 
